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Zusammenfassung 
Trotz intensiver Forschung zeigen die meisten Krebstherapien weiterhin geringen 
Behandlungserfolg. Keine Ausnahme bildet hier das kolorektale Karzinom: Es ist die 
zweithäufigste Todesursache aller krebsassoziierten Tode weltweit. Insbesondere, die 
Ausbildung von Fernmetastasen stellt eine der größten Herausforderung in der 
Krebstherapie dar. Es fehlen hier weiterhin ausreichend verlässliche und effiziente Biomarker 
zur Prognose des Krankheitsverlaufes oder zur Auswahl bestimmter Patienten für 
spezifische Behandlungsstrategien (Prädiktion).  
Metastasis-associated in colon cancer 1 (MACC1) ist ein inzwischen etablierter, 
prognostischer, prädiktiver und kausaler Biomarker für verschiedene Tumorentitäten. Auf 
molekularer Ebene kann es sowohl verschiedene Zielgene wie z.B. MET, NANOG oder 
SPON2 induzieren als auch unterschiedliche Signalwege wie MEK/ERK und AKT/β-catenin 
beeinflussen. Auf diese Weise fördert es Zellproliferation, -migration und -Koloniebildung 
sowie Tumorprogression und Metastasierung in vivo. Diese Arbeit sollte neue Strategien 
erforschen diese Prozesse durch die Inhibition von MACC1 zu unterbinden. 
Wir haben dafür zwei bestimme Screening-Methoden zugrunde gelegt. Zum einen wollten 
wir neue und stärkere transkriptionelle Inhibitoren für MACC1 identifizieren. Zum anderen 
wollten wir weitere Ebenen des MACC1 Signalnetzwerks und somit neue therapeutische 
Interventionspunkte entdecken. Mithilfe des ersten Verfahrens und anschließender 
Validierung konnten wir nahezu alle klinisch angewendeten Statine als potente 
transkriptionelle Inhibitoren von MACC1 nachweisen. Mit den beiden stärksten Inhibitoren, 
Fluvastatin und Atorvastatin, konnten wir zeigen, dass Statine sowohl die Proliferation und 
Koloniebildung in vitro als auch Tumor Wachstum und Metastasierung in vivo MACC1-
spezifisch reduzieren. Die in vivo Versuche wurden mit einer Statindosis äquivalent zur 
Standardtherapie bei Reduzierung der Blutlipide im Menschen durchgeführt.  
Im zweiten Screening konnten wir phosphotyrosin (pY)-abhängige Interaktionen von MACC1 
mit essentiellen Signalmolekülen identifizieren: SHP2, GRB2, SHC1, PLCG1 und STAT5B. 
Interessanterweise, führte Mutation der Bindungsstellen zu einer verringerten Aktivität des 
MACC1-induzierten ERK Signalwegs sowie reduzierter Zellmigration und -proliferation. 
Unsere Daten weisen zudem darauf hin, dass MACC1 in Abhängigkeit verschiedener 
Rezeptor-Tyrosinkinasen (z.B. MET und EGFR) neue SHP2/SRC/ERK und PKA/SRC/CREB 
Signalkaskaden orchestriert, was zu einem malignen Phänotyp führt. Gezielte Intervention 
mit Inhibitoren für MET, MEK, SHP2 und SRC konnte dadurch die MACC1-abhängige 
Koloniebildung von Darmkrebszellen reduzieren. Diese Ergebnisse zeigen somit neue 
therapeutische Interventionspunkte auf und stellen darüber hinaus eine hervorragende Basis 
für weitere Untersuchungen dar. Diese sollten sich am besten mit Kombinations-
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behandlungen mit weiteren zielgerichteten Inhibitoren (z.B. gegen GRB2 oder PKA), 
potentiellen MACC1 pY-Antikörpern oder den Statinen befassen. 
Die zusätzliche Erforschung der spatiotemporalen Organisation des MACC1 Signalosoms 
und der assoziierten Signalkaskaden, insbesondere in vivo, wird voraussichtlich das volle 
Potential von MACC1 als therapeutisches Target ausschöpfen können. Wir empfehlen 
zudem Statine bereits in der Krebstherapie bzw. -prävention, besonders bei MACC1-
stratifzierten Patienten, auch als Monotherapie anzuwenden. 
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Abstract 
Despite intensive research, many cancer treatment strategies present unsuccessful. This is 
reflected in colorectal cancer (CRC) as the second leading cause of cancer associated 
deaths worldwide. Here, the development of distant metastasis represents a major challenge 
in therapy. In addition, reliable and efficient biomarkers for early prognosis of disease course 
or selection of patients for specific treatment (prediction) remain scarce.  
Metastasis-associated in colon cancer 1 (MACC1) has been established as prognostic, 
predictive and causal biomarker for several tumor entities. It has been found to induce 
different target genes such as MET, NANOG and SPON2 and affect several signaling 
pathways including MEK/ERK and AKT/β-catenin. Thus, it promotes cell proliferation, 
migration and colony formation as well as tumor progression and metastasis formation in 
vivo. This study intended to explore new strategies to inhibit these processes by targeting 
MACC1.  
We employed two distinct screening methods to find novel, more potent transcriptional 
inhibitors of MACC1 and illuminate the MACC1 signaling landscape to uncover new drug 
intervention points. With the first screening and subsequent validation, nearly all clinically 
employed statins were revealed as potent MACC1 transcriptional inhibitors. Chosen as 
strongest inhibitors, Fluvastatin and Atorvastatin showed MACC1-specific reduction of 
proliferation and colony formation in vitro as well as restriction of tumor growth and 
metastasis formation in vivo at doses equivalent to human standard lipid reduction therapy.  
Moreover, we identified phosphotyrosine (pY)-dependent interactions of MACC1 with crucial 
signaling molecules: SHP2, GRB2, SHC1, PLCG1 and STAT5B. Mutation of the interaction 
sites abrogated MACC1-dependent ERK signaling as well as cell migration and proliferation. 
Our data further suggest that MACC1 governs SHP2/SRC/ERK and PKA/SRC/CREB axes 
conferring a malignant phenotype in response to different receptor tyrosine kinases such as 
MET and EGFR. Targeted intervention with inhibitors of MET, MEK, SHP2 and SRC 
restricted MACC1-dependent colony formation. These results indicate new drug intervention 
points for MACC1 signaling and provide an excellent baseline for further investigations of 
combinatorial treatments with other targeted inhibitors (e.g. GRB2, PKA), potential MACC1 
pY-antibodies or statins. 
Additional research about the spatiotemporal organization of MACC1 signalosome formation 
and downstream signaling, particularly in vivo, will reveal the entire potential of MACC1 as 
therapeutic target, whereas statins should already be considered for cancer therapy or 
prevention, especially in patients stratified for MACC1 expression. 
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1. Introduction 
1.1 Cancer hallmarks 
Cancer results from a malignant transformation of healthy cells endowing them with specific 
features widely acknowledged as hallmarks of cancer [1,2]: These cells gain the ability to 
evade or circumvent the tightly controlled mechanisms of cell growth (proliferation) and death 
(apoptosis). They develop self-sustaining capabilities including continuous proliferative 
signaling, avoiding and preventing immune attacks as well as rewiring their metabolic 
pathways and angiogenesis. Beyond that, they reach a state of immortality and proceed to 
infiltrate further tissues and organs, processes commonly known as invasion and metastasis. 
Tumor promoting inflammation as well as genomic instability or mutation represent, both, 
prerequisite and self-sustaining features in the multistep and multifactorial process of cancer 
development: pro-inflammatory signals secreted by immune cells (e.g. growth factors, 
proangiogenic factors, etc.) can support the acquisition of hallmark features in chronic 
inflammations and, further, even promote these in neoplastic lesions. Moreover, cells can 
coincidentally acquire growth advantage over others by random mutations whereas tumor 
cells actively fuel this development by disturbing genomic surveillance and maintenance 
[1,2]. The previously described processes appear in different cellular contexts and organs 
giving rise to a broad variety of distinct cancer entities: liquid cancers as leukemia and 
lymphomas or solid cancers of e.g. lung, liver and the gastro-intestinal tract [1,3]. The 
following chapters will shed more light on the cascade of tumor development and metastasis 
with specific regard to colorectal cancer (CRC).  
 
1.2 Tumorigenesis and progression of CRC 
1.2.1 Origin and mutational background 
Mutations demonstrate a key event in the origin and development of cancer and colorectal 
cancer, respectively [1,2,4]. Several factors and mechanisms play a role in the generation of 
these mutations: defects during cell division (mitosis) such as chromosomal missegregation, 
recombination between homologous chromosomes or dysfunction in chromosomal protection 
and damage response mechanisms lead to aberrant chromosome numbers (aneuploidy), 
gene amplifications and monoallelic (loss of heterozygosity) or biallelic gene deletions, 
respectively. This chromosomal instability is one of the major contributors to the CRC 
mutational landscape [5]. 
Furthermore, inactivation of enzymes involved in DNA repair such as mismatch repair (MMR) 
adenosinetriphosphatases (ATPases) and base excision repair genes lead to the 
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accumulation of DNA errors and mutation of the affected gene. MMR deficiency (dMMR) and 
subsequent mutations occur more frequently in highly repetitive DNA motifs called 
microsatellites. This is, therefore, termed the microsatellite instability (MSI) phenotype. 
Hypermethylation of cytosine residues in gene promoters leads to transcriptional inhibition 
and represents the central mechanism of MMR epigenetic silencing [6,7]. Increasing age, 
injury or chronic inflammation of the colon can elevate promoter methylation [8,9].  
Especially, the methylation of cytosine-guanosine dinucleotides (CpG islands) abundant in 
several gene promoters occurs in a higher frequency. This CpG island methylator phenotype 
(CIMP) defines a subset of CRC [7].  
The acquired mutations mentioned above, mostly arise through sporadic somatic events: In 
about 70% of all CRC cases solely somatic events account for the induction of cancer 
development, whereas in 10-30% somatic mutations in addition to a familial predisposition 
initiate this process. Only 5-7% of all CRCs represent hereditary diseases: most of them 
belong to the hereditary nonpolyposis colorectal cancer (HNPCC or Lynch-syndrome) or the 
familial adenomatous polyposis (FAP) syndrome [10]. Generally, the mutational processes 
can be facilitated by endogenous or exogenous mutagenic stimuli continuously challenging 
the DNA, such as reactive oxygen species (ROS), ultraviolet B (UVB) radiation as well as 
heterocyclic amines from tobacco smoke or processed meat [11-13]. 
Only mutations affecting critical genes disturb the regulation of cellular growth and death 
leading to uncontrolled proliferation and spread [1,2]. Among our approximately 20,000 
genes, 138 putative driver genes were identified by now: The 64 oncogenes gain their 
function by mutations rendering them permanently active or overexpressed. Loss-of-function 
mutations in the tumor suppressor genes (74 genes) diminish or terminate their cellular 
gatekeeping abilities [3]. Only three mutated driver genes can suffice to initiate tumorigenesis 
and progression of CRC, but individual CRCs, usually, harbor up to 15 driver gene mutations 
[3,14-16]. Fearon & Vogelstein firstly described this in a model as a series of sequential 
mutational events in specific genes [4].  
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Fig. 1: Adenoma-carcinoma sequence: CRC is a multistep process dependent on the mutational aberration of several crucial 
genes involved in the control of cell growth. Dysfunctional cell division leads to chromosomal instability (CIN) or epigenetic 
silencing through methylation of certain gene promoters followed by (in)activation of these genes and an accumulation of 
mutations. This figure depicts an overview of this process and involved key factors, which is further explained in the text. 
APC - adenomatous polyposis coli; Wnt – wingless/integrated; KRAS - Kirsten rat sarcoma viral oncogene homolog; BRAF - v-
Raf murine sarcoma viral oncogene homolog B; 18q – q-arm of chromosome 18; SMAD4 - SMA & MAD homolog 4; CDC4 - 
cell division control protein 4; TGFBR2 - transforming growth factor beta receptor 2; TP53 - tumor suppressor P53; BAX - 
Bcl-2-associated X protein; IGF2R - insulin-like growth factor 2 receptor; MMR - mismatch repair [17]. 
 
Widely recognized as CRC initiating step, a functional loss of the adenomatous polyposis coli 
(APC) gene is found in about 70% of all sporadic cancers whereas the germline mutation 
characterizes the FAP syndrome. Although most FAP syndrome patients show secondary 
mutations of the remaining wild-type allele, it is not essential for diminished APC function 
since it displays an autosomal-dominant phenotype. The APC protein mainly works in a 
multiprotein complex determining β-catenin for degradation and, consequently, retaining it 
from its oncogenic functions. The FAP syndrome confers a life-time risk of 80-100% for CRC 
and patients undergo prophylactic resection of the colon [18]. APC represents a prominent 
example to highlight the effects genetic mutations inflict on cellular signaling (see further 
1.2.2). 
Further initial steps in the cancer cascade constitute the inactivation of MMR genes such as 
MutL homolog 1 (MLH1), MutS protein homolog 2 (MSH2) or MutY homolog (MYH). 15-25% 
of sporadic CRCs display epigenetic silencing of MMR genes and germline mutations in 
these characterize the HNPCC [6,7]. Additional mutations in key oncogenes such as Kirsten 
rat sarcoma viral oncogene homolog (KRAS) or v-Raf murine sarcoma viral oncogene 
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homolog B (BRAF) as well as tumor suppressors such as tumor suppressor p53 (P53) or 
phosphatase and tensin homolog (PTEN) further contribute to CRC progression [4,6,17]. 
The majority (50-60%) of CRCs follow the adenoma-carcinoma sequence whereas the 
serrated neoplasia pathway and colitis-associated CRC development represent alternative, 
more recently acknowledged routes of CRC progression. On the one hand, serrated polyps 
usually endowed with BRAF mutations and increasing CIMP grow into malignant carcinomas 
[19]. On the other hand, chronic inflammation confers a continuous proliferative, anti-
apoptotic and mutagenic environment leading to CRC development under additional tumor 
suppressor inactivation (e.g. P53) or oncogene (e.g. KRAS) activation [2,20-22]. 
 
1.2.2 Deregulated molecular signaling 
All genetic alterations in cancer are reflected in aberrant cellular signaling pathways [23].  
Gene mutation and expression profiles alone are insufficient to explain particular phenotypes 
in the multistep and multilayer process of cancer development [24,25]. In fact, the number of 
genetic mutations exceeds the number of signaling pathways. Therefore, mutations of 
different genes in individual signaling cascades usually share the same outcome: 
deregulation of a determined cellular process such as proliferation or apoptosis. So far, 9 
different pathways have emerged as central nodes in cancer signaling. In addition to the 
multiple layers of each individual pathway, several crossing points allow for inter-pathway 
regulation and feedback (Fig. 2) [26]. 
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Fig. 2: Central cancer signaling pathways: Schematic representation of 9 crucial pathways (colored boxes) deregulated in 
cancer development. Genetic alteration of genes involved in these pathways leads to aberrant signaling and subsequent 
phenotypic changes such as increased cell proliferation or motility. Some of these pathways share common factors enabling 
significant crosstalk among them. Crossing-points and some of their mediators are indicated with arrows. P53 - tumor 
suppressor P53, Rb - retinoblastoma protein, p14
ARF
 - ARF tumor suppressor, GLI - glioma-associated oncogene, TCF4 - 
Transcription factor 4, APC - adenomatous polyposis coli, Wnt - Wingless/Integrated, HIF1 – hypoxia inducible factor 1, GFs 
– growth factors, RTK – receptor tyrosine kinase,  SMAD4 - SMA & MAD homolog, ERK - extracellular signal–regulated 
kinase, PI3K - phosphatidylinositol 3-kinase, RAS:GTP – active/GTP-bound form of small GTPase RAS, BAD - Bcl-2-associated 
death promoter (BAD) protein, BAX - Bcl-2-associated X protein. Modified from [26]. 
 
 
The progressing tumor continuously interacts with its microenvironment integrating this 
information mainly via surface receptors and their downstream signaling [2]. A prominent and 
important class of receptors are receptor tyrosine kinases (RTKs) comprising different growth 
factor receptors such as epidermal growth factor receptor (EGFR), fibroblast growth factor 
receptor (FGFR) or MET receptor tyrosine kinase [27]. The proto-oncogene MET encodes a 
transmembrane tyrosine kinase, which serves as receptor for hepatocyte growth 
factor/scatter factor (HGF/SF). Therefore, it is also called the hepatocyte growth factor 
receptor (HGFR) [28,29]. MET activation plays a pivotal role in general epithelial-cell motility 
as well as growth and survival of epithelial cells and migration of myogenic precursor cells in 
embryonal development [30-37]. Consequently, overexpression or mutations of MET leading 
to aberrant, constantly activated signaling profoundly contribute to tumorigenesis [38-42]. 
Next to a characteristic domain structure with a β-propeller fold accountable for ligand 
binding, the MET protein contains a distinct binding motif on its intracellular tail: This docking 
site consists of tyrosine sites Y1349 and Y1356 and surrounding amino acids [43,44]. 
Phosphorylation of these tyrosine residues upon receptor activation leads to the recruitment 
of different substrates such as growth-factor-receptor-bound protein 2 (GRB2)-associated 
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binder 1 (GAB1), GRB2 and phosphatidylinositol 3-kinase (PI3K) with GAB1 as central signal 
mediator [44-47]. GAB1 provides several tyrosine sites which upon phosphorylation bind 
further signaling molecules: e.g. Src Homology 2 (SH2) domain-containing protein tyrosine 
phosphatase 2 (SHP2), SH2 domain containing transforming protein (SHC1), phospholipase 
C gamma (PLCG), and signal transducer and activator of transcription (STATs). SHP2, for 
instance, can activate RAS thereby inducing the extracellular signal–regulated kinase (ERK) 
pathway, one of the central MET downstream signaling cascades [48-56].  
RAS activation is usually catalyzed by the guanine nucleotide exchange factor (GEF) son of 
sevenless (SOS) [57]. Activated RAS recruits RAF kinases such as BRAF to the plasma 
membrane leading to their phosphorylation which results in activation. The RAF kinases 
transduce the activating signals by phosphorylating MAPK/ERK kinases (MEKs) at serine 
residues in their activation loop (e.g. S218 and S222 for MEK1). MEKs can now 
phosphorylate ERKs (ERK1 – 44 kDa, ERK2 – 42 kDa) at their activating sites threonine (T) 
202 and tyrosine (Y) 204. Upon stimulation ERK can translocate to the nucleus and induce 
several transcription factors such as c-FOS, P53 and c-JUN by phosphorylation. This leads 
to the expression of target genes crucial for the regulation of proliferation, survival and other 
important cellular processes. ERK can, additionally, stimulate other downstream effectors 
such as 90 kDa ribosomal S6 kinases (RSKs) leading to their nuclear translocation and 
subsequent activation of target genes. Inactivation of the ERK cascade is conferred by 
different phosphatases such as protein phosphatase 2 (PP2A), receptor-type tyrosine-protein 
phosphatase R (PTP-SL) and MAPK phosphatases (MKP) or negative feedback via 
inhibitory phosphorylation of SOS, RAFs or MEKs by ERK [58]. 
PI3K is another important effector of RTK signal transduction. It consists of a regulatory (p85) 
and a catalytic (p110α) subunit. Upon recruitment to activated phosphorylation sites of RTKs 
or adaptor proteins, p85 releases p110α from autoinhibition which can then catalyze the 
phosphorylation of phospholipids in the plasma membrane generating phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) [59,60]. PIP3s serve as platform for the binding of further 
adaptor and signaling molecules such as insulin receptor substrate (IRS), GAB1, PLCγ, 3-
phosphoinositide-dependent protein kinase-1 (PDK1) and AKT [61-65]. Stimulation of the 
central signal mediator AKT via phosphorylation at S473 and T308 leads to its dissociation 
from the plasma membrane and subsequent activation of several downstream targets in the 
cytoplasm or nucleus. These target genes are involved in controlling cell proliferation, 
apoptosis, DNA repair, etc. [59,66-69]. ERK and PI3K signaling share a fair amount of 
crosstalk on different layers of the pathways resulting in dependencies and redundancies for 
the control of crucial cellular phenotypes (see Fig. 3) [23,70].  
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Fig. 3: Overview of crucial signal transduction pathways. Extracellular stimuli are transduced via a variety of signal 
mediators, mainly transmembrane receptors and respective downstream signaling. This scheme shows the most essential 
signal transduction pathways with particular respect to ERK and PI3K signaling. It demonstrates the high level of crosstalk 
and redundancy in cellular signaling. Yellow circles indicate oncogenic proteins while dashed outlines mark tumor 
suppressors. RTKs – receptor tyrosine kinases; PDGF(R) - platelet-derived growth factor (receptor); TGFβ(R) - transforming 
growth factor beta (receptor); EGF(R) - epidermal growth factor (receptor); FGF(R) - fibroblast growth factor (receptor); 
VEGF(R) -  vascular endothelial growth factor (receptor); CSF1(R) - colony stimulating factor 1 (receptor); IL6(R) – interleukin 
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6 (receptor); TNF(R) – tumor necrosis factor (receptor); CXCL12 - C-X-C motif chemokine 12; ECM – extracellular matrix; 
MMPs – matrix metalloproteases; GPCR - G protein-coupled receptor; PTEN - phosphatase and tensin homolog; P53 - tumor 
suppressor P53; Rb - retinoblastoma protein; APC - adenomatous polyposis coli;  HIF1 – hypoxia inducible factor 1; 
SMAD2/3 - SMA & MAD homolog 2/3; ERK - extracellular signal–regulated kinase, PI3K - phosphatidylinositol 3-kinase; NF-1 
- Neurofibromin 1; RAS - rat sarcoma viral oncogene homolog; RAF - v-Raf murine sarcoma viral oncogene homolog; ERK - 
extracellular signal–regulated kinase; STAT3 - signal transducer and activator of transcription 3; PI3K - phosphoinositide 3-
kinases; AKT – protein kinase B; APC - adenomatous polyposis coli; SRC - non-receptor tyrosine kinase SRC; TSC1/2 - 
tuberous sclerosis 1/2; mTORC1 - mammalian target of rapamycin complex 1; VHL - von Hippel–Lindau tumor suppressor; 
BCL2 - B-cell lymphoma 2; NF-κB - nuclear factor kappa-light-chain-enhancer of activated B cells; CDK4/6 - cyclin-dependent 
kinase 4/6; CKIs - cyclin-dependent kinase inhibitors; CHK1/2 - checkpoint kinase 1/2; SNAIL - zinc finger protein SNAI1; ER – 
estrogen receptor [23]. 
 
ERK and PI3K are both able to induce β-catenin signaling via different routes demonstrating 
the complex hierarchy and substitutability of molecular pathways [71-77]. Wnt/β-catenin 
signaling plays a crucial role in embryonal development, cell differentiation and stem cell 
maintenance, which includes the activation of various target genes [78,79]. A destruction 
complex of β-catenin represents the main hub of downstream signaling. It involves the APC 
protein and two continuously active serine/threonine kinases (casein kinase 1 alpha/delta 
(CK1α/δ) and glycogen synthase kinase 3 beta (GSK3β)) scaffolded by Axin. The kinases 
phosphorylate β-catenin on distinct serine and threonine sites which leads to the recruitment 
of β-TrCP, part of an E3 ubiquitin ligase complex, determining it for proteasomal degradation 
[80,81]. Inactivation of the destruction complex through ligand binding to the Wnt receptor 
frizzled or inhibition (e.g. GSK3β) as well as mutation (e.g. APC) of single components leads 
to accumulation and nuclear translocation of β-catenin. Here, it engages T-cell 
factor/lymphoid enhancer-binding factor (TCF/LEF) and further transcription factors for the 
expression of target genes involved in many processes such as proliferation, cell cycle and 
migration [18,78,81-84]. 
1.2.3 Invasion & Metastasis 
During tumorigenesis and carcinoma development, cells acquire additional features enabling 
them to disseminate from the primary tumor site and spread to distant tissues and organs. 
This process of metastasis formation was assumed to occur late in the adenoma-carcinoma 
sequence, but emerging evidence points to the additional possibility of early dissemination 
[85,86]. The formation of metastatic colonies requires overcoming several barriers during this 
invasion-metastasis cascade [87-89]: certain genes and genetic alterations equip the 
affected cells with motility and invasive abilities allowing them to invade surrounding tissue 
and intravasate to the circulating blood system. Here, further characteristics ensure survival 
of immune attacks or sheer stress and permit adhesion as well as extravasation to the 
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distant site where the cells usually reside in a quiescent state of dormancy. Only those cells 
with the ability to persist, switch back to a proliferative state, and reinitiate tumor growth, will 
form metastasis. These cancer stem cells (CSCs) display genetic and epigenetic 
characteristics comparable to common stem cells [86,90].  
In addition, secreted factors from the primary tumor can reach distant sites and prepare a 
suitable microenvironment for disseminating cells: the pre-metastatic niche [91]. The 
aforementioned aspects support the “seed and soil” hypothesis suggested by Paget already 
at the end of the 19th century: only certain cancer cells (“seed”) show matching compatibility 
and adaptive programs with the microenvironment of specific target sites (“soil”) [87]. This 
theory partially applies to CRC: even though CRC cells would not show high adaptive 
potential for liver tissue, the overwhelming number of tumor cells reaching this site via the 
colon clearing portal vein determine the liver as predominant metastatic site [88]. Further 
following the blood flow, the lung was found as secondary dissemination site [92]. Over the 
last years, an increasing number of cases with peritoneal metastasis, cancerous outgrowth in 
different tissues of the bowel cavity, e.g. omentum, mesentery or diaphragm, have been 
documented. The rising diagnoses are most likely due to improved preoperative imaging 
techniques and subsequently higher attention for this topic. Recent studies show an 
approximate incidence of 8% for peritoneal metastasis from CRC [93,94]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Invasion-metastasis cascade. Dissemination and colonization of distant tissues involves different molecular 
mechanisms. Tumor cells need to invade surrounding tissue and further penetrate the circulatory system (intravasation). 
Here, they have to circumvent sheer stress and immune destruction to adapt and infiltrate the distant site (extravasation). 
Metastasis can form out of persistent (dormant) cells with growth initiating ability. Secreted factors by the primary tumor 
can already provide a suitable microenvironment for the disseminated cells at the distant site (pre-metastatic niche). ECM – 
extracellular matrix [95]. 
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Still, there are several molecular mechanisms determining CRC metastasis: The epithelial-to-
mesenchymal transition (EMT) plays a central role in equipping cells with a migratory 
phenotype [90]. During EMT, cells dissolve their cell-cell contacts, individualize and 
rearrange their cytoskeleton as well as cellular polarity thereby establishing motility 
characteristics. These processes can be triggered through different stimuli: i.a. transforming 
growth factor β (TGFβ)-, RTK-, integrin and Wnt signaling regulate EMT-governing 
transcription factors (TFs) such as zinc finger protein SNAI1 (SNAIL), zinc finger protein 
SNAI2 (SLUG), Twist basic helix-loop-helix transcription factor 1 (TWIST1) and zinc finger E-
box binding homeobox 1 (ZEB) [96]. 
The EMT program also induces the expression of extracellular matrix degrading proteases 
such as matrix metalloproteinase (MMP) -2 and -9 [96]. MMPs support the metastatic 
process by degrading physical barriers and proteolytic activation or inactivation of several 
essential factors such as TGFβ, vascular endothelial growth factor (VEGF), E-Cadherin or 
MET [97]. MET is found to be overexpressed or continuously activated in different cancer 
entities including CRC [40,98]. Downstream signaling of MET induces central mitogenic, anti-
apoptotic and pro-migratory pathways such as ERK and PI3K (see 1.2.2) [99]. Moreover, 
MET is a transcriptional target of the metastasis inducer metastasis associated in colon 
cancer 1 (MACC1) which will be elucidated in detail later (1.3.2) [100].  
Further pacemakers of CRC metastasis belong to the S100 protein family: S100A4, identified 
as target of β-catenin signaling, can induce migration in vitro and liver metastasis in vivo, 
whereas S100A8 contributes to establishing the pre-metastatic niche in the liver [101-103].   
Over 50% of patients with CRC develop distant metastasis which drastically affects patient 
survival (see 1.2.4) [104-108]. This highlights the necessity for new and improved therapy. 
The following chapters will discuss treatment strategies for CRC and CRC metastasis, 
respectively.  
1.2.4 Current state of therapeutic intervention 
The previously described molecular mechanisms exert distinct histopathological patterns. 
These classify disease stage and thereof treatment strategy. Stage I and II CRC is locally 
confined thereby partially invading the colon tissue layers, whereas stage III and IV include 
the invasion to surrounding tissues and lymph nodes (III) as well as metastasis to distant 
sites (IV) [109]. Tumor stage at the time of diagnosis strongly determines overall survival 
[110,111]: The 5-year survival rate for patients with early stage CRC (stage I) is around 85%, 
but decreases drastically with tumor progression. It declines to 50% for patients with 
progressed CRC which show tumor invasion to the lymph nodes at time of diagnosis (stage 
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III) and drops to approximately 10% with the development of distant metastasis (stage IV) 
[104,112]. 
 
 
 
 
Fig. 5: Tumor staging and associated survival. The multistep process of CRC progression is reflected in a histopathological 
classification associated with patient survival rates. A) In the early stages the tumor invades locally through mucosa, 
submucosa and muscularis propria (stage I) to the outermost layers of the colon (stage II) whereas the following stages 
show invasion of local lymph nodes (stage III) and metastasis to distant sites (stage IV) [113]. B) Patients in stage I and II 
demonstrate an average 5-year survival of approximately 85% and 70%, respectively. This drastically drops with stage 
progression to about 50% in stage III and below 10% in stage IV. CRC - colorectal cancer [104]. 
 
First line of therapy represents resection of tumor and metastases. In stage IV 
multidisciplinary discussion is warranted to evaluate resection of metastasis. Here, systemic 
chemotherapy can reduce the metastatic burden to alleviate metastasis resection [114,115]. 
Stage III and high risk stage II (perforation of outermost layers of colon or rectum, 
lymphovascular invasion (LVI), perineural invasion (PNI)) patients can also benefit from 
adjuvant chemotherapy [116,117]. Present treatment regimens comprise combinations of 
cytotoxic (irinotecan, oxaliplatin) and cytostatic (capecitabin/5-fluoruracil (5-FU), trifluridin) 
drugs and additional supporting agents (leucovorin, tipiracil): FOLFOX regimen (leucovorin, 
5-FU and oxaliplatin), the FOLFIRI regimen (leucovorin, 5-FU and irinotecan), and the 
XELOX regimen (oxaliplatin and capecitabine) [118-123]. Some cases, predominantly rectal 
cancer, require neoadjuvant (previous) chemo-/radiotherapy to decrease tumor or metastasis 
size rendering them manageable for resection [124,125]. 
During stage progression, tumor cells acquire an increasing amount of mutations. Across 
several tumor entities, individual tumors can harbor up to 15 different driver gene mutations, 
but also a lot of additional “passenger mutations” shaping (epi)genetically unique cancers: 
Most entities, including CRC (microsatellite stable, MSS), show between 25 and 75 non-
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synonymous mutations per tumor, whereas lung cancer or melanoma display even higher 
numbers around 150 mutations per tumor, reflecting the strong influence of potent mutagens 
(UVB and tobacco smoke, respectively) in these entities. Consequently, CRC with MSI 
exhibit an extraordinarily high mutation frequency between 500 and 1500 mutations per 
tumor. Considering that each single tumor develops its individual mutation pattern, these 
facts demonstrate the huge genetic heterogeneity between different tumor entities, but 
especially, within each entity itself (intertumoral heterogeneity) [3,16,126].  
Moreover, the widely acknowledged and established concept of intratumoral heterogeneity 
reflects the clonal divergence within each individual tumor: cancer cells divide and 
accumulate further mutations thereby continuously differentiating from the originating cell 
[127-130]. Here, CSCs, primarily identified by their tumor initiating abilities, might represent a 
common denominator and determinator of intratumoral heterogeneity: their self-renewing 
potential and production of differentiated progeny leads to high subclonal diversity [131,132]. 
Furthermore, CSCs display insensitivity to chemotherapy as well as targeted approaches, 
probably fueled by their increased expression of antiapoptotic and multidrug transporter 
proteins. Consequently, tumor heterogeneity and, specifically, CSCs contribute to cancer 
therapy resistance [132-138]. Accumulating evidence indicates dynamic flexibility of tumor 
heterogeneity: subclonal diversity can increase under chemotherapeutic pressure and tumor 
cells might undergo reversible states of drug-tolerance [139,140]. 
Considering the huge heterogeneity across CRCs, the adverse side effects of systemic 
chemotherapy and increasingly detailed knowledge about cancer signaling pathways, 
molecular targeted therapy has emerged over the last years [141-145]. Currently, different 
antibodies are employed subsequent or in addition to conventional chemotherapy which 
inhibit downstream function of growth factors or growth factor receptors: bevacizumab 
(VEGF antibody), cetuximab or panitumumab (EGFR antibodies) show benefits for 
previously treated patients [119-122,146-149]. Further, aflibercept (a decoy receptor for 
VEGF‑A, VEGF‑B and PGF (placental growth factor)) and ramucirumab (an antibody 
against VEGFR‑2) are combined with chemotherapy [150,151]. Regorafenib (a multikinase 
inhibitor) is used in patients displaying or developing treatment resistance [152].  
Additional kinase or receptor kinase inhibitors, such as trametinib (against MEK), dabrafenib 
(against BRAF) and trastuzumab or lapatinib (against human epidermal growth factor 
receptor 2, HER2) show promising potential in combinatorial treatment based on different 
therapy resistance mechanisms [153-156]. The recently emerging immune checkpoint 
inhibitors, such as pembrolizumab, provide new possibilities for therapy, particularly for CRC 
with MSI. MSI tumors show – probably facilitated through their high mutational load – a high 
infiltration and adaption to the immune system: The microenvironment of MSI tumors 
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presents an unusually high expression of immune checkpoint ligands, including programmed 
cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) which explains a 
stronger susceptibility to checkpoint inhibitors [157].  
More inhibitors remain under preclinical or clinical evaluation: nintedanib and famitinib target 
angiogenesis via fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), 
VEGF, FMS-like tyrosine kinase 3 (FLT-3) and rearranged during transfection receptor 
tyrosine kinase (RET) signaling [158,159]. The alkylating drug temozolomide and the 
monoclonal antibody MABp1 against interleukin 1α might become interesting in the nearer 
future [160,161]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: CRC treatment strategies. The usually employed treatment regimens for CRC (FOLFOX, FOLFIRI, XELOX) can be 
adjusted with respect to currently established, predictive biomarkers. Patients with RAS mutation will not respond to EGFR 
antibody therapy, but RAS wild-type patients with either MSI, BRAF mutation or HER2 overexpression might benefit from 
selective inhibitor treatment (e.g. PD-1 antibody for MSI). RASwt - wild-type rat sarcoma viral oncogene homolog; RASmut - 
mutated rat sarcoma viral oncogene homolog; HER2+ - human epidermal growth factor receptor 2 positive; MSI - 
microsatellite instability; BRAFmut -  mutated v-Raf murine sarcoma viral oncogene homolog B; EGFR - EGFR - epidermal 
growth factor receptor; PD1 - programmed cell death protein 1; MEK - MAPK/ERK kinases; FOLFOXIRI - folinic acid + 
fluorouracil + oxaliplatin + irinotecan [162]. 
 
Despite all the efforts, cancer cells demonstrate therapy resistance due to their highly 
sophisticated and complex signaling networks. On the one hand, there is a high level of 
redundancy between signaling pathways controlling proliferation and survival as well as 
crosstalk among them. On the other hand, cellular signaling is rewired upon therapeutic 
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intervention: lacking feedback inhibition can reactivate targeted pathways or stress response 
pathways are induced [26,163-165]. Alternatively, extracellular stimuli from the tumor 
microenvironment can trigger cellular responses circumventing the inhibited pathway. Clonal 
divergence might have already led to cell clones in the tumor with growth signals 
independent of the targeted pathway or expressing drug-resistant target proteins. Cancer 
cells also might adapt to treatment by accidental or epigenetic activation of crucial 
pathways [166-168]. 
CRC remains the second leading cause of cancer-associated deaths worldwide. It accounts 
for approximately 10% (~900,000 deaths/year) of all cancer-related deaths by a yearly 
incidence of about 1.8 million people [169]. Especially, the development of distant metastasis 
represents a major challenge in CRC therapy: the 5-year survival of about 10% could not be 
significantly improved over the last decades [106-108,170].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Survival of CRC patients over time and disease stage. While overall survival could be strongly increased for CRC 
patients of stage I-III (red, green, blue) over the last 30 to 40 years, stage IV (brown) patients still show very low survival 
rates [170]. 
 
Many therapeutic agents show only partial effectiveness while exerting tremendous side 
effects due to their cytotoxic properties. Molecular targeted therapy only affects a subset of 
patients. More importantly, both treatment strategies struggle with therapy resistance 
[143,144,166-168]. In addition, reliable and efficient biomarkers for early prognosis of 
disease course or selection of patients for specific treatment (prediction) remain scarce. The 
most commonly employed prognostic and/or predictive biomarkers are MMR status (MSI vs 
MSS) and mutations of RAS as well as BRAF [121,171-175]. For instance, stage II CRC 
patients with MSI have a favorable prognosis compared to MSS patients and present no 
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benefits from 5-FU treatment [171,176,177]. Newer revelations indicate prognostic or 
predictive potential for expression of HER2, epiregulin (EREG) or amphiregulin (AREG) as 
well as different microRNAs (miRNAs) [178-182]. Recently, combining of different biomarkers 
and molecular features resulted in consensus molecular subtypes (CMS), which should 
enhance patient stratification and targeted therapy [183]. This approach underlines the 
necessity for the establishment and application of new biomarkers for cancer treatment. 
These biomarkers optimally fulfil all of the following criteria: 1) it is a driver of CRC and CRC 
metastasis (causal biomarker); 2) it identifies the population at high risk for patient 
stratification and potential prevention of the imminent disease (prognostic biomarker); 3) it 
determines therapy response (predictive biomarker) to specify clinical research and design 
personalized treatment strategies; and 4) it could serve as promising drug target [3,162].  
 
1.3 A novel prognostic, predictive and causal biomarker: MACC1  
1.3.1 Prognosis & Prediction 
In 2009, our group analyzed tissue samples of normal colon mucosa, primary tumors and 
their metastases. Interestingly, the primary tumor tissue of non-metastasized patients which 
developed metastases later on showed an overexpression of an unknown gene. This newly 
identified gene was named metastasis-associated in colon cancer 1 (MACC1). The analyses 
revealed a significantly higher expression of MACC1 in malignant tissue compared to normal 
tissue. Most importantly, metachronously metastasizing tumors showed remarkably higher 
levels of MACC1 messenger RNA (mRNA) in the primary tumors than those without the 
development of metachronous and synchronous metastases. High MACC1 mRNA levels are 
also associated with significantly reduced metastasis-free survival, and the 5-year overall 
survival dramatically differs between patients with low and high MACC1 levels in the primary 
tumor: 80% and 15%, respectively [100]. Several follow-up studies corroborated our findings 
of the prognostic characteristics of MACC1 for metastasis and patient survival in more than 
20 solid tumor entities [90,112,184-206]. Also, MACC1 transcript or protein levels in liquid 
biopsies (e.g. patient blood) can be employed for prognosis of tumor progression, metastasis 
formation and patient survival in different solid tumor entities such as pancreatic, gastric, lung 
and breast cancer [207-212]. In addition, high MACC1 expression is able to predict e.g. 
disease recurrence after resection of lung adenocarcinoma, CRC liver metastases or 
hepatocellular carcinoma (HCC) dependent liver transplantation [186,213,214]. 
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Fig. 8: The prognostic value of MACC1. A) The analysis of primary tumor tissues displayed a higher MACC1 expression in 
metastasizing tumors compared to those without metachronous metastases. This difference in MACC1 expression could 
also predict the metastasis-free survival of the respective patients [100]. B) This prognostic value of MACC1 was confirmed 
in CRC and over 20 further tumor entities. HCC - hepatocellular carcinoma; CRC – colorectal cancer; MACC1 – metastasis 
associated in colon cancer 1 [215]. 
 
Furthermore, MACC1 serves as predictive biomarker for different therapeutic drugs 
(cisplatin, oxaliplatin, 5-FU, gemcitabine) in several entities such as tongue squamous cell 
cancer, glioblastoma multiforme (GBM), ovarian cancer, gastric cancer, lung cancer, 
pancreatic cancer and CRC [208,216-224]. It further predicts treatment response for 
temozolomide/Endothelial-Monocyte-Activating Polypeptide–II (EMAP-II) in GBM [225]. 
Moreover, high MACC1 expression was predictive for poor outcome after neoadjuvant 
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chemo-radiotherapy for rectal cancer and after cryoablation therapy for advanced HCC 
[226,227]. 
The role of MACC1 as prognostic and predictive biomarker already indicates its critical 
function in tumor progression and metastasis. Beyond that, MACC1 expression was found to 
increase during adenoma to carcinoma progression and particularly accumulate at the 
invasive front in tumor buds or in circulating tumor cells (CTCs), disseminated by the primary 
tumor. These features combined with its motility inducing function designate MACC1 as 
causal driver of invasion and metastasis [100,212,228-232].  
1.3.2 Signaling landscape and functional impact of MACC1 
MACC1 promotes and participates in several cancer hallmark processes: Most importantly, 
MACC1 induces proliferation, migration, invasion, and colony formation in several solid 
cancer entities and promotes tumor growth and liver metastasis in different mouse models 
[100,208,221,225,233-242]. MACC1 is a transcriptional activator of MET, thereby triggering 
downstream MEK/ERK and PI3K/AKT signaling [99,100]. 
Overexpression of MACC1 led to an upregulation of MET and resulted in increased cell 
motility, invasion, wound healing and metastasis. Reciprocally, the knock down of MACC1 
reduced MET expression, cell motility and proliferation. MACC1 activates MET expression by 
binding to its promoter, which was abrogated by mutating the Src homology 3 (SH3) domain 
or PxxP motif on MACC1. Additionally, the MACC1-hyperactivated ERK pathway, in turn, 
increased MACC1 levels resulting in a potential positive feedback loop [100,191,243,244]. 
MACC1 governed signaling promotes EMT and stem cell characteristics which represent 
crucial features of cancer progression and dissemination (see 1.2.3) underlining its important 
role in these processes [195,223,235,236,245,246]. As discussed above (1.2.3), certain 
transcription factors control the expression of crucial genes for EMT. In fact, TWIST1/2 
expression and downstream targets were shown to depend on MACC1. ZEB2-inhibited EMT, 
including target gene expression, was rescued by MACC1 [247-249]. MACC1 further 
regulates the expression of several genes involved in EMT such as E-Cadherin, N-Cadherin, 
and MMPs, mainly through AKT signaling [228,235,237,250-252]. Concomitantly, MACC1-
activated AKT can inhibit GSK3β thereby stabilizing β-catenin and leading to increased 
expression of target genes such as MYC, Cyclin D1/E and MMPs [237,250].  
The MACC1/AKT/β-catenin axis also confers chemoresistance and stemness characteristics 
such as sphere formation by activating EMT [219,221,223,225,253]. Moreover, MACC1 
directly enhances stemness by regulating the pluripotency markers NANOG and octamer-
binding transcription factor 4 (OCT4) [239]. The expression of additional stem cell genes 
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shows correlations with MACC1 in several tumor entities, characterized by higher invasive 
potential and poor prognosis [254-257]. 
 
 
 
Fig. 9: The molecular functions of MACC1. MACC1 acts as driver of tumor progression and metastasis through different 
mechanisms. It induces the expression of crucial target genes such as MET, NANOG and SPON2, thereby ultimately 
promoting proliferation, migration, invasion, stemness and metastasis. In this context, MACC1 influences several pathways 
including MEK/ERK, AKT/β-catenin and STAT/MCL-1. MACC1 – metastasis associated in colon cancer 1; MET - MET receptor 
tyrosine kinase; HGF – hepatocyte growth factor; GRB2 - growth factor receptor-bound protein 2; SOS - son of sevenless; 
RAS - rat sarcoma viral oncogene homolog; RAF - v-Raf murine sarcoma viral oncogene homolog; MEK - MAPK/ERK kinases; 
ERK - extracellular signal–regulated kinase; AP1 - activator protein 1; SP1 - specificity protein 1; STAT1/3/5 - signal 
transducer and activator of transcription 1/3/5; GAB1 - GRB2-associated-binding protein 1; SHC1 - SHC-transforming 
protein 1; SHP2 - SH2 domain-containing phosphatase 2; PI3K - phosphoinositide 3-kinases; MCL-1 - induced myeloid 
leukemia cell differentiation protein; NANOG - homeobox protein NANOG; SPON2 - spondin 2; AKT – protein kinase B; 
GSK3β - glycogen synthase kinase 3 beta; Dvl - dishevelled protein; APC - adenomatous polyposis coli; CK1α - casein kinase I 
alpha; LRP - lipoprotein receptor-related protein; RAGE - receptor for advanced glycation endproducts; S100A4 - S100 
calcium-binding protein A4. 
 
MACC1 contributes to metabolic rewiring of tumor cells mainly by enhancing the Warburg 
effect associated with augmented tumor progression, poor prognosis or increased resistance 
to apoptosis as well as drug treatment [242,258-261]. It supports tumor growth by generation 
and reorganization of blood and lymphatic vessels inducing angiogenesis, vascular mimicry 
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and lymphogenesis through the elevated expression of several involved key factors such as 
TWIST1 and VEGF A/C/D [245,247,248,256,262].  
Chronic inflammation can establish a malignant microenvironment fostering neoplasia and 
cancer development [2]. Recently, MACC1 was associated with inflammatory bowel disease 
associated dysplasia, a risk factor for CRC, and might contribute to a tumor promoting 
environment through macrophage recruitment via TWIST1/2 activation [189,247,263-266]. 
Otherwise, MACC1 confers protective features to cancer cells, thereby avoiding apoptosis or 
immune destruction. Through activation of different pathways (PI3K/AKT, MEK/ERK and 
STAT), it modulates the expression or activity of several proteins involved in apoptosis or 
immune protection such as FAS ligand (FASL), tumor necrosis factor related apoptosis 
inducing ligand (TRAIL), induced myeloid leukemia cell differentiation protein (MCL-1), 
BAX/BAD, BCL2 and caspase 8/9/3/7 as well as PARP [208,233,241,250,267-270]. Besides 
apoptosis, MACC1 is able to control further tightly monitored mechanisms such as the cell 
cycle: Mainly through regulation of PTEN/AKT with subsequent expression of crucial target 
genes (cyclin B, D1, D2, E, MYC and SPON2), MACC1 governs G0/S-phase transition and 
cell cycle progression thereby initiating cell growth [221,236,237,241,250,251,267,271-273].  
The previous discussion demonstrates the pivotal role of MACC1 in the initiation and 
advancement of several cancer hallmark features, including different signaling mechanisms. 
This highlights the enormous potential for targeted intervention of MACC1 and downstream 
signaling, which will be further discussed in the following chapter.  
    
1.3.3 Structural features and inhibitory potential of MACC1 
The MACC1 cDNA consists of 2559 base pairs which encode for an 852 amino acid protein 
with a molecular weight of 97 kDa. In the genome it is localized on locus 7p21.1. This region 
(7p21) harbors further genes involved in tumorigenesis or metastasis such as TWIST1 or 
integrin beta 8 (ITGB8) [191]. The MACC1 promoter (-992 until -18 bp upstream of the 
transcription start site, TSS) drives transcription under the control of transcription factors AP-
1, SP1 and C/EBP which individually contribute to MACC1 expression [238]. Based on these 
findings, our group aimed to identify transcriptional inhibitors of MACC1. By high-throughput 
drug screening (HTS) we could determine Lovastatin and Rottlerin as effectors of MACC1 
promoter activity and subsequent expression. Both inhibitors could restrict MACC1-
dependent cell migration in vitro as well as metastasis formation in xenografted mice [274]. 
Additionally reported expression regulation via the transcription factor YB1 (in lung cancer) or 
intracellular calcium signaling (in gastric cancer) indicates tissue dependent specificities 
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[246,275]. Further investigations should lead to a better understanding of the spatiotemporal 
expression of MACC1.  
On the posttranscriptional level, the long non-coding RNA (lncRNA) MACC1-AS1 leads to 
increased MACC1 expression through MACC1 mRNA stabilization [259]. Contrary, zinc 
finger protein 36 homolog (ZFP36), an RNA destabilizing protein, and many different 
miRNAs, such as miR-200a, miR-218 or miR-338-3p, negatively regulate MACC1 expression 
and concomitant functions [234,249,262,276-289]. Moreover, successful RNA interference 
(RNAi) of MACC1 expression and associated functions via small interfering RNA (siRNA) or 
small hairpin RNA (shRNA) in vitro an in vivo further reinforces the promising role of MACC1 
as valuable target for cancer therapy [100,219,222,225,233,237,240,250]. 
The translated MACC1 protein expresses a distinct structural architecture with five predicted 
domains: At the N-terminus two domains resemble known structures of zonula occludens 1 
and uncoordinated protein 5 (ZU5), or of uncoordinated protein 5 (Unc5), p53-induced death 
domain protein 1 and ankyrins (UPA) [146]. Further to the C-terminal side, MACC1 harbors a 
SH3 domain as well as a tandem of death domains (DD) [100,290,291]. All these domains 
demonstrate functional abilities involved in protein-protein interaction or protein recruitment 
[292-295]. In this regard, MACC1 contains more protein interaction motifs, such as the 
clathrin box, NPF and DPF tripeptides as well as proline-rich sequences (PxPxP, KxxPxxP) 
and several serine (Ser, S), threonine (Thr, T) or tyrosine (Tyr, Y) sites accessible for 
phosphorylation [100].  
 
 
 
Fig. 10: MACC1 domain architecture. MACC1 contains several distinct, predicted domains characterizing it as potential 
interactor in different processes. The ZU5, UPA, SH3 and death domains are known to play important roles in in protein-
protein interaction or protein recruitment. Further structural motifs such as the Clathrin box, NPF and DPF tripeptides, 
proline-rich sequences or several potential phosphorylation sites (S, T, Y), additionally, indicate its role as signaling and 
adapter molecule. The most crucial proline-rich sequence and previously identified, important Y-sites (Y673, Y695, Y793) 
are depicted in this figure. ZU5 - zonula occludens 1 and uncoordinated protein 5 resembling domain; uncoordinated 
protein 5 (Unc5), p53-induced death domain protein 1 and ankyrins resembling domain; SH3 - Src homology 3 domain. 
 
Especially, tyrosine phosphorylation represents a crucial mechanistic switch in signal 
transduction. Phosphorylation of specific Y-sites mostly leads to an activation of the 
respective protein. Phosphorylated tyrosines (pY), additionally, serve as docking sites for 
SH2 domain containing proteins, thereby fostering downstream signaling [296-299]. Mutation 
of the SH3 domain and the proline rich motif (PxxP) or distinct tyrosine sites interfered with 
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MACC1 function in vitro and in vivo, further indicating the encouraging potential of MACC1 
as therapeutic target in cancer and cancer metastasis, respectively [100,300].  
1.4 Aims of the thesis 
Over the last years MACC1 has emerged as prominent prognostic marker for metastasis 
formation and metastasis free survival in many different solid tumor entities. Moreover, its 
role in prediction of therapy response has become evident. Most importantly, MACC1 has 
been proven to be a driver of tumor progression and metastasis thereby representing a 
promising target for targeted intervention. The reduction of MACC1 levels via RNAi or 
transcriptional inhibition could restrict tumor growth and metastasis formation in vivo. So far, 
only two MACC1 transcriptional inhibitors have been identified highlighting the necessity for 
additional, possibly more potent treatment strategies. Unfortunately, the revelation of the 
precise MACC1 protein structure remains elusive which could facilitate the generation of 
potential MACC1 protein inhibitors. Additionally, the MACC1 phospho-interactome as well as 
signaling pathways associated with MACC1 functionality have to be further elucidated. This 
current background determines the main objectives of this study as follows: 
 Identification of novel MACC1 transcriptional inhibitors from the European 
Molecular Biology Laboratory (EMBL) library to reveal additional, possibly 
more potent inhibitors. This included the evaluation of these inhibitors in vitro 
for the reduction of MACC1 expression and MACC1 associated functions as 
well as in vivo validation for their ability to restrict MACC1-induced tumor 
progression and metastasis formation in a xenografted mouse model. 
 Identification and characterization of tyrosine phosphorylated MACC1 protein-
protein interactions and associated molecular pathways. This comprised the 
validation and functional investigation of identified bindings including their 
respective interaction sites and, additionally, illumination of the MACC1 
involvement in cellular signaling cascades to reveal potential intervention 
points for targeted treatment. 
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2. Material & Methods 
2.1 Cell lines and growth conditions 
All human cancer cell lines used in this study were either purchased from American Type 
Culture Collection (ATCC, Manassas, VA, USA) or German Collection of Microorganisms 
and Cell culture (Leibnitz Institute DSMZ, Braunschweig, Germany) (summarized in table 1). 
They were cultivated in DMEM or RPMI1640 medium (Thermo Fisher Scientific, Waltham, 
Massachusetts) supplemented with 10% fetal bovine serum (FBS; Bio & Sell, Feucht, 
Germany). Plastic consumables from TPP (Trasadingen, Switzerland), BD Biosciences 
(Heidelberg, Germany) or Greiner BioOne (Kremsmünster, Austria) were used for cell 
maintenance and experiments. Cells were kept at 37°C in a humidified incubator with 5% 
CO2. The MycoAlert Mycoplasma detection kit (Lonza, Basel, Switzerland) was regularly 
used to test the cell lines for mycoplasma.  
 
Table 1: Summary of used human cancer cell lines 
Cell line Medium Characteristics 
 
CRC cell lines: 
  
      SW480  
      
RPMI + 10% FBS adherent, colon, colorectal adenocarcinoma 
      SW620 
      
DMEM + 10% FBS adherent, colon, colorectal adenocarcinoma, 
derived from metastatic site: lymph node 
 
      HCT116  
      
RPMI + 10% FBS adherent, colon, colorectal carcinoma 
      SW48  
      
RPMI + 10% FBS adherent, colon, colorectal adenocarcinoma  
 
      HT-29  
    
DMEM + 10% FBS adherent, colon, colorectal adenocarcinoma 
 
Gastric and pancreatic 
cancer cell lines: 
  
     MKN45 
 
     BxPC3  
DMEM + 10% FBS 
 
RPMI + 10% FBS 
adherent, stomach, gastric adenocarcinoma 
 
adherent, pancreas, pancreas adenocarcinoma 
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2.2 Virus production and generation of stably modified cell lines 
For transfection, 1.5 × 107 HEK cells were seeded. After 24 h, cells were transfected using 
2.85 ml serum-free medium, mixed with 90 μg of polyethylenimine and kept at room 
temperature for 5 min. 30 μg of lentiviral plasmids with packing vectors (20 μg psPax2, 
10 μg pMD2.G) were mixed and incubated at room temperature for 20 min and added to the 
respective plates. After 48 h of incubation, the supernatant was collected and filtered 
(0.45 μm filter). The filtered supernatant was loaded on a 20% sucrose cushion and 
centrifuged at 4°C for 4 h at 28,000 rpm. The viral particles were dissolved in 500 μl sterile 
PBS and stored at -80 °C. Cells were transduced in 6-well plates with a multiplicity of 
infection (MOI) less than 10 for each respective well. After 24 h of incubation, virus-
containing medium was replaced with the regular medium and the GFP expressing cells 
were sorted using FACS.  
The plasmid RC224774L2 (Origene, Rockville, Maryland) was employed to create 
cytomegalovirus (CMV) promoter-driven overexpression of MACC1-GFP and GFP control 
cells (HCT116/MACC1-GFP and HCT116/GFP). Tyrosine mutant cell lines were generated 
by site-directed mutagenesis (SDM) of the same plasmid using the QuikChange Lightning 
Multi Site-Directed Mutagenesis Kit (Agilent, Santa Clara, California) following 
manufacturer´s instructions. The employed primers are indicated in table 2. HCT116 cells 
were transfected with the plasmid pGL4.17 (Promega, Fitchburg, Wisconsin) containing the 
luciferase reporter gene under control of the human MACC1 promoter sequence (-992 to -
18 bp upstream of the TSS) to generate HCT116/MACC1p-Luc cells [238]. A CMV promoter-
driven luciferase reporter expressing HCT116 cell line (HCT116/CMVp-Luc) was created as 
described previously [301]. HCT116/MACC1 was generated with the tetracycline inducible 
vector pCW-GW-rtTA/MACC1-P2A-nLuc for the inducible overexpression of MACC1 with a 
nanoLuciferase tag separated by a P2A self-cleaving peptide. MACC1 expression, here, is 
controlled by a tetracycline responsive promoter, PTight, consisting of seven tetracycline 
operator sequences just upstream of the minimal CMV promoter (lacking the CMV 
enhancer). The vector was produced by gateway cloning with the entry vector for MACC1 
(Y2776; GeneCopoeia Inc., Rockville, Maryland) and the destination vector pCW-GW-rtTA-
P2A-nLuc (kindly provided by Dr. Nikolas Gunkel, DKFZ, Heidelberg) using the Gateway™ 
LR Clonase™ II Enzyme Mix (Invitrogen, Carlsbad, California) according to manufacturer´s 
instructions. Cells were lentivirally transduced and selected with Blasticidin. 
HCT116/MACC1 -/- were generated according to the protocol by Ran et al. with the vector 
pSpCas9(BB)-2A-GFP (Addgene, Watertown, Massachusetts) and the single guide RNAs: 
sgMACC1 fwd – GTT TGA AGA GTA CCC GGG TTT GG and sgMACC1 rev – ACA TGC 
CTT GCT CCG TAT GCA GG (Biotez, Berlin, Germany) [302]. 
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SW480/ev and SW480/MACC1 cells with stable overexpression of MACC1 including a V5-
Histidin tag were obtained by transfection of pcDNA3.1-V5-His and pcDNA3.1-MACC1-V5-
His (Thermo Fisher Scientific, Waltham, Massachusetts) in SW480 cells. Neomycin 
treatment selected positive clones. Stable overexpression was monitored via regular 
detection of MACC1 mRNA levels by quantitative real-time polymerase chain reaction (qRT-
PCR; see 2.3).  
2.3 RNA extraction and qRT-PCR 
qRT-PCR was employed to investigate mRNA or DNA expression of different genes. To 
isolate total RNA, we used the Universal RNA Purification Kit (Roboklon, Berlin, Germany) 
according to manufacturer´s instructions. RNA samples were eluted with nuclease-free water 
and quantified using a NanoDrop 1000 Spectrophotometer (Peqlab, Erlangen, Germany). 
50 ng RNA were applied to reverse transcription (RT) with random hexamers in a reaction 
mix (5 mM MgCl2, 1x RT-buffer, 4 mM pooled dNTPs, 1 U/µl RNAse inhibitor and 2.5 U/µL 
Moloney Murine Leukemia Virus reverse transcriptase; Thermo Fisher Scientific) at 23°C for 
15 min, 42°C for 45 min and 99°C for 5 min with subsequent cooling at 4°C for 5 min.  
Complementary DNA (cDNA) was amplified in a quantitative polymerase chain reaction 
(qPCR) employing the LightCycler® 480 (Roche Diagnostics, Risch, Switzerland) with 
GoTaq® dye (Promega, Fitchburg, Wisconsin) chemistry under following conditions: 95°C for 
2 min followed by 45 cycles of 95°C for 7 s, 60°C for 10 s and 72°C for 5 s. Primers were 
synthesized and HPLC purified by BioTeZ Berlin Buch GmbH (see table 2). Data was 
analyzed with the LightCycler® 480 Software release 1.5.0SP3 (Roche Diagnostics, Risch, 
Switzerland). Unspecific amplification products or primer dimers could be identified by the 
melting curve measured with a continuous temperature increase from 65°C to 95°C with a 
rate of 0.1°C/s. Duplicate qRT-PCR reaction values were averaged and each mean value of 
the expressed gene was normalized to the respective controls (e.g. solvent). Glucose-6-
phosphat-dehydrogenase (G6PD) and ribosomal protein L32 (RPL32) were used as 
housekeeping genes to calculate relative gene expression. 
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Table 2: List of employed primers for qRT-PCR and SDM 
Gene Primer Sequence 5´- 3´ 
qRT-PCR-primer   
MACC1 MACC1 fwd TTC TTT TGA TTC CTC CGG TGA 
 MACC1 rev ACT CTG ATG GGC ATG TGC TG 
G6PDH 
 
G6PDH fwd 
G6PDH rev 
ATC GAC CAC TAC CTG GGC AA 
TTC TGC ATC ACG TCC CGG A 
RPL32 RPL32 fwd TAA GCG TAA CTG GCG GAA AC 
 RPL32 rev TAA CCA ATG TTG GGC ATC AA 
SDM-primer   
Y379F Y379F fwd GGAATTTATGGACCCAAATTTATCCATCCCAGTTTTACTG 
Y789F Y789F fwd ATGATGTGGAAACCTGCCTTTGATTTTCTGTATACCTGGA 
 
2.4 Protein extraction and standard & digital Western blotting (WB) 
WB was performed to analyze protein expression. For protein extraction cells were scraped 
off in ice-cold RIPA buffer (50 mM Tris, 150 mM NaCl and 1% NP-40, pH 7.5 supplemented 
with complete protease inhibitor tablets; Roche Diagnostics, Risch, Switzerland, and 
phosphatase inhibitor tablets; Roche Diagnostics, Risch, Switzerland), lysed for 30 min on 
ice with intermediate vortexing, and centrifuged for 45 min at maximum speed. After 
determination of protein concentration using Bicinchoninic Acid Protein Assays Reagent 
(Thermo Fisher Scientific, Waltham, Massachusetts) according to manufacturer´s 
instructions, denatured proteins were applied to sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and, subsequently, standard WB or digital WB (DigiWest). For 
standard WB 30 µg of protein were separated by SDS-PAGE with 10% Tris-HCl gels in 
Tris/glycine/SDS buffer and blotted to PVDF membranes (Bio-Rad Laboratories Inc., 
Hercules, California) at 2.5 A, and 25 V for 7 min employing the TransBlot® TurboTM system 
(Bio-Rad Laboratories Inc., Hercules, California). Membranes were blocked for 1 h at room 
temperature with 5% bovine serum albumin (BSA) in TBST buffer (10 mM Tris-HCl, 0.1% 
Tween20 and 150 mM NaCl, pH 7.5). Incubation of membranes with respective primary 
antibodies (table 3) in 5% BSA TBST solution at 4°C overnight was followed by incubation 
with horseradish peroxidase (HRP)-conjugated secondary antibodies (table 3) in TBST for 
1 h at room temperature. Antibody-protein complexes were visualized with WesternBright 
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ECL HRP substrate (Advansta, Menlo Park, California) and subsequent exposure to CL-
Xposure Films (Thermo Fisher Scientific, Waltham, Massachusetts). WB for β-actin and 
vinculin served as protein loading control. Spot densitometry was performed using ImageJ 
(version 1.51j8, National Institutes of Health, USA). Signal intensities were normalized to 
loading controls. Additionally, intensities measured for phosphorylated proteins were 
normalized to those of total proteins. For reprobing, membranes were stripped according to 
the mild stripping protocol provided by abcam® (Cambridge, United Kingdom), blocked and 
again incubated with respective primary and secondary antibodies [303]. 
 
For the DigiWest, performed in cooperation with NMI TT Pharmaservies (Reutlingen, 
Germany), 10 µg of protein were separated by SDS-PAGE with NuPAGE® Novex® 4-12% 
Bis-Tris protein gels and blotted to PVDF membranes (Merck-Millipore, Burlington, 
Massachusetts) at 30 V for 75 min. Before cutting each lane in 96 fractions (0.5 mm x 6 mm), 
proteins were biotinylated on the membrane at room temperature for 1 h in the dark. The 
proteins of each individual strip are eluted in 96-well plates followed by loading on color-
coded streptavidin-coated Luminex® beads (NMI TT Pharmaservices, Reutlingen, 
Germany). The beads of four initial WB lanes are pooled and aliquoted again in 96-well 
plates using 384 distinct bead populations. Each bead pool is then subjected to antibody-
based immunoassay (1 Ab/well). For this, the bead aliquots (200 beads/well) were washed 
with PBS + 0.1% Tween20 (PBS-T) incubated with diluted antibody in assay buffer (Blocking 
Reagent for ELISA; Roche, Basel, Switzerland) supplemented with 0.2% milk powder, 0.05% 
Tween-20 and 0.02% sodium azide) at 15°C overnight with 750 rpm on a Thermomixer 
comfort (Eppendorf, Hamburg, Germany). Most important antibodies used in the assay are 
listed in table 3. Species-specific phycoerythrin (PE)-labelled secondary antibodies (Jackson 
Dianova, Hamburg, Germany) were added after two PBS-T washing steps and incubated for 
1 h at 23°C with 750 rpm. This was followed by two additional washing steps with 
subsequent read-out in a Luminex® FlexMAP 3D reader (Luminex, Austin, Texas). The 
respective signals are integrated for quantification. Protein size was determined referring to a 
set of proteins of known molecular weight. Data was normalized to total protein loaded 
(streptavidin - phycoerythrin measurement) [304]. 
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Fig. 11: Digital Western blot principle. Standard Western blot procedure is followed by on-membrane-
biotinylation of the proteins. Membranes are then cut in 96 fractions (0.5 mm x 6 mm), distributed to 96-well 
plates where the proteins are stripped and coupled to color-coded neutravidin-coated Luminex® beads. The 
beads are pooled and redistributed to 96-well plates to incubate them with primary and secondary antbiodies 
in an immunoassay and subsequent read-out in a Luminex® reader to evaluate protein expression [304]. 
 
 Table 3: List of antibodies used in standard and digital Western blotting 
Analyte dilution 
 
antibody 
 
product number/company 
Standard WB    
MACC1 1 : 10,000 rabbit, polyclonal HPA020081 / Sigma-Aldrich 
ERK 1 : 1,000 rabbit, polyclonal #9102 / Cell Signaling 
pERK (T202/Y204) 1 : 1,000 rabbit, polyclonal #9101 / Cell Signaling 
MET 1 : 1,000 rabbit, monoclonal #8198 / Cell Signaling 
pMET (Y1234/1235) 1 : 1,000 rabbit, monoclonal #3077 / Cell Signaling 
CREB 1 : 1,000 rabbit, monoclonal #9197 / Cell Signaling 
pCREB (S133) 1 : 1,000 rabbit, monoclonal #9198 / Cell Signaling 
SRC 1 : 2,000 rabbit, monoclonal #2109 / Cell Signaling 
pSRC (Y416) 1 : 1,000 rabbit, polyclonal #2101 / Cell Signaling 
β-actin 1 : 25,000 mouse, monoclonal A1978 / Sigma-Aldrich 
vinculin 1 : 2,000 mouse, monoclonal V9131 /  Sigma-Aldrich 
35 
 
PLCG1 1 : 2,000 rabbit, polyclonal sc-81 / Santa Cruz Biotech 
STAT5B 1 : 1,000 mouse, monoclonal sc-1656 / Santa Cruz Biotech 
SHP2 1 : 1,000 rabbit, polyclonal sc-280 / Santa Cruz Biotech 
SHC 1 : 1,000 rabbit, polyclonal sc-1695 / Santa Cruz Biotech 
GRB2 1 : 1,000 rabbit, polyclonal sc-255 / Santa Cruz Biotech 
    
Anti-rabbit-HRP 1 : 20,000 goat, polyclonal W4011 / Promega 
Anti-mouse-HRP 1 : 20,000 goat, polyclonal # 31430 / Thermo Fisher 
    
DigiWest    
β-catenin   1 : 200 rabbit, polyclonal 06-734 / Merck-Millipore 
pβ-catenin (S552)  1 : 200 rabbit, polyclonal #9566 / Cell Signaling 
BRAF  1 : 200 rabbit, polyclonal 07-583 / Merck-Millipore 
pBRAF (S445) 1 : 100 rabbit, polyclonal #2696 / Cell Signaling 
CREB   1 : 200 rabbit, monoclonal #9197 / Cell Signaling 
pCREB (S133)  1 : 1,000 rabbit, monoclonal #9198 / Cell Signaling 
Cyclin A   1 : 1,000 rabbit, polyclonal ab53054 / abcam 
Cyclin B1   1 : 100 mouse, monoclonal #4135 / Cell Signaling 
Cyclin D1   1 : 200 mouse, monoclonal #2926 / Cell Signaling 
ERK1/2  1 : 200 rabbit, monoclonal #4695 / Cell Signaling 
pERK1/2 ( T202/Y204)  1 : 2,000 rabbit, monoclonal #4370 / Cell Signaling 
FAK   1 : 200 rabbit, monoclonal 2146-1 / Epitomics 
pFAK (Y397)  1 : 200 rabbit, monoclonal ab81298 / abcam 
pFAK (Y576/Y577)  1 : 200 rabbit, monoclonal 2183-1 / Epitomics 
pFAK (Y925)  1 : 200 rabbit, polyclonal ab38512 / abcam 
GSK3β 1 : 200 rabbit, monoclonal #9315 / Cell Signaling 
pGSK3β (S9)  1 : 200 rabbit, polyclonal #9336 / Cell Signaling 
MACC1   1 : 200 rabbit, polyclonal HPA020081 / Sigma-Aldrich 
MEK1   1 : 200 rabbit, polyclonal #9124 / Cell Signaling 
pMEK1/2 (S217/S221)  1 : 200 rabbit, monoclonal #9154 / Cell Signaling 
RSK1   1 : 200 rabbit, polyclonal 06-668 / Merck-Millipore 
pRSK1 (T573)  1 : 200 rabbit, monoclonal ab62324 / abcam 
SRC   1 : 200 rabbit, monoclonal #2109 / Cell Signaling 
pSRC (Y416)  1 : 200 rabbit, monoclonal #6943 / Cell Signaling 
TCF4   1 : 200 rabbit, monoclonal #2565 / Cell Signaling 
VASP   1 : 200 rabbit, monoclonal #3132 / Cell Signaling 
pVASP (S157)  1 : 200 rabbit, polyclonal #3111 / Cell Signaling 
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2.5 Co-Immunoprecipitation (Co-IP) 
To identify or confirm molecular interactions of proteins, Co-IP experiments were conducted. 
We seeded 5x106 cells per 10 cm dish and let the cells accommodate for 24 h. Cells were 
washed once with 1x PBS and scratched off in 500 µl ice-cold IP-lysis buffer (20 mM Tris-
HCl, pH = 7.5, 150 mM NaCl, 0.1% NP40, 1 mM EDTA, 1% Triton X supplemented with 
complete protease inhibitor cocktail and phosphatase inhbitors; Roche Diagnostics, Risch, 
Switzerland). Cell lysis for 30 min with intermediate vortexing was followed by centrifuging for 
45 min at 14,000 rpm and 4°C. Supernatants were collected and divided in 2 mg protein 
containing samples. Proteins were pulled-down with 2 µg of the respective target antibody 
overnight at 4°C on a rotational shaker. The protein-antibody complexes were incubated and 
bound with 20 µl of G-agarose beads (Alpha Diagnostic International Inc., San Antonio, 
Texas) for 4 h at 4°C on a rotational shaker. After five washing steps with 200 µl lysis buffer 
at 2500 rpm for 5 min at 4°C, we eluted the protein-complexes with 30 µl of LDS-buffer 
(Thermo Fisher Scientific, Waltham, Massachusetts) including DTT (1:10; AppliChem GmbH, 
Darmstadt, Germany) at 99°C for 10 min. Following another spin at 2500 rpm for 5 min at 
4°C, 20 µl of supernatant were applied to SDS-PAGE and Western blotting (2.4). 
2.6 Proliferation and cell viability assay 
Cell viability and proliferation was assessed using the IncuCyte® ZOOM System (Essen 
BioScience, Ann Arbor, Michigan). 4x103 cells/well were seeded in 96-well plates and 
allowed to accommodate for 24 h. After respective treatments, plates were placed into the 
IncuCyte® for 72 h – 144 h at 37°C in a humidified incubator with 5% CO2. The IncuCyte® 
ZOOM automatically recorded four pictures of each well every two hours which allowed a 
detailed analysis of the area covered by proliferating cells over time. For data analysis and 
export the IncuCyte ZOOM software 2016B was used.  
2.7 Clonogenic assay 
The clonogenic assay was performed to investigate the reproductive viability. In principle, 
every individual cell is challenged for its ability to divide limitlessly which is judged by their 
colony forming potential [305-307]. HCT116/GFP and HCT116/MACC1-GFP were seeded in 
6-well dishes (400 cells/well) or 24-well dishes (200 cells/well) and allowed to attach for 24 h. 
After drug treatment, plates were placed into a humidified incubator at 37°C with 5% CO2 for 
7 days. For analysis, medium was removed and the colonies were fixed and stained with a 
solution of PBS containing 1% Formaldehyde and 0.1% crystal violet. The colony covered 
area was determined with the colony area plug in and colony number with the particle 
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analyzing function of ImageJ (version 1.51j8, National Institutes of Health, USA). Results are 
expressed as area percent normalized to solvent-treated controls.  
2.8 Migration assay  
The Boyden-chamber assay was performed for evaluation of the migratory potential of cells. 
Here, the ability of cells to migrate along a chemotactic gradient through the pores of a trans-
well membrane was assessed. Previous to seeding, cells were serum starved overnight. 
Afterwards, 2.5x105 cells (24-well format) or 5x104 cells (96-well format) were seeded in 2% 
FBS containing medium onto the membrane of a trans-well insert. This was placed in a well 
containing 10% FBS medium. Plates were incubated in a humidified incubator at 37°C with 
5% CO2 for 24 h. For analysis, cells of the bottom well and the bottom side of the membrane 
were trypsinized and centrifuged for 5 min at 5,000 rpm. The amount of living cell content 
was determined using CellTiter-Glo® solution (Promega, Madison, Wisconsin) and 
subsequent luminescence measurement with the Infinite Pro multiplate reader (TECAN, 
Männedorf, Switzerland).  
2.9 Assessment of growth factor signaling  
For illumination of the influence of MACC1 on growth factor mediated downstream signaling, 
we seeded cells in 6-well dishes at a density of 3x105 cells/well. Cells could accommodate 
for 24 h in a humidified incubator at 37°C with 5% CO2. After serum starvation for 18 h, cells 
were treated with 20 ng/ml of respective growth factors (HGF; kindly provided by Prof. Dr. 
Walter Birchmeier and EGF; Sigma-Aldrich, St. Louis, Missouri) for 0, 1, 8 and 90 min. The 
treatment was terminated by removing the media and application of ice-cold PBS. Cells were 
immediately scraped off in ice cold RIPA buffer and then further processed according to WB 
procedure (2.4).   
2.10 High-throughput drug screening (HTS) and in vitro validation 
For identification of MACC1 transcriptional inhibitors, an HTS was conducted in collaboration 
with the European Molecular Biology Laboratory [308]. Here, HCT116-MACC1p-Luc CRC 
cells were seeded in 384-well plates (Perkin Elmer, Waltham, Massachusetts) at 
4,000 cells/well. The 4241 compounds were previously distributed on these plates in two 
different concentrations: 5 µg/ml and 0.5 µg/ml of Prestwick library compounds, and 1 µM 
and 0.1 µM of NIH and Microsource library compounds, respectively. Incubation of cells with 
compounds for 24 h at 37°C in a humidified incubator with 5% CO2 was followed by the 
assessment of the luminescent signal. For this, plates were treated with 25 µl luminescent 
reagent for 5 min (BriteLite plus; Perkin Elmer, Waltham, Massachusetts) and measured in 
an Envision Reader with ultrasensitive luminescence detector (Perkin Elmer, Waltham, 
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Massachusetts). The most promising compounds were chosen based on the largest ratio 
between luminescence reduction and cytotoxicity for 72 h assessed by ATP measurement 
with ATPlite solution (Perkin Elmer, Waltham, Massachusetts). 
Statins were purchased from Selleckchem (Houston, Texas) (Atorvastatin, Pravastatin and 
Pitavastatin) or Thermo Fisher Scientific (Waltham, Massachusetts) (Fluvastatin, 
Simvastatin, Rosuvastatin, Lovastatin) and stored at -20°C. The 20 mM stock solutions were 
prepared fresh for every application in dimethylsulfoxide (DMSO). Control cells were always 
treated with equal amounts of solvent to rule out adverse effects caused by DMSO. 
2.11 PamChip® assay 
In cooperation with PamGene International B.V. (BJ 's-Hertogenbosch, Netherlands) we 
conducted the PamChip® kinase microarray assay to evaluate the influence of MACC1 on 
kinase activity in CRC cells. The array chip contains 144 unique peptide sequences each for 
Y and S/T kinases immobilized onto a porous membrane. These 15-amino acid sequences 
correspond to a putative endogenous phosphorylation site and serve as phosphorylation 
substrate for kinases in the cell lysate (see [309,310]). In presence of ATP and fluorescein-
labeled anti-phospho-Y (PY20) or anti-phospho-S/T antibodies plus fluorescein-tagged 
secondary antibody (STK antibody mix), the phosphorylation was measured in the 
PamStation®12.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11: PamChip® assay principle. Immobilized peptides are phosphorylated by active kinases in whole cell 
lysates. Phosphorylation is detected by anti-phosphotyrosine or –serine/threonine antibodies with fluorescein-
tag or fluorescein-tagged secondary antibody. Measurement is processed in a PamStation®12 [311,312]. 
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For this, we generated lysates of untreated CRC cells modulated in MACC1 expression 
(SW480/ev & SW480/MACC1, HCT116/GFP & HCT116/MACC1-GFP) with Mammalian 
Protein Extraction Reagent (M-PERTM; Thermo Fisher Scientific, Waltham, Massachusetts) 
containing phosphatase and protease inhibitors (Thermo Fisher Scientific, Waltham, 
Massachusetts). A reaction mix with 5 µg (Y kinase assay) / 0.5 µg (S/T kinase assay) of 
protein lysate, NEBuffer™ for protein kinases (New England Biolabs, Ipswich, 
Massachusetts), ATP (400 μM; Sigma-Aldrich, St. Louis, Missouri), 20 μg/mL PY20 (Exalpha 
Biologicals, Inc., Shirley, Massachusetts) or STK antibody mix (PamGene, BJ 's-
Hertogenbosch, Netherlands) was applied to pre-blocked (2% BSA in PBS) array chips. The 
chips were incubated for 60 min using the PamStation®12 pumping the reaction mixture 
through the membranes every minute. This was followed by washing and fluorescence 
measurement. 
2.12 Mass spectrometry (MS) screen 
For the identification of interactors of tyrosine-phosphorylated MACC1, we conducted a mass 
spectrometry (MS) screen in collaboration with the lab of Prof. Bernhard Küster (Technical 
University Munich). Here, we used bead-coupled peptides representing all putative 
phosphotyrosine (pY) sites of MACC1 as affinity tools to pull down potential binding partners 
from whole cell lysates. 
For this, synthesized peptides (Integrated DNA Technologies, Coralville, Iowa) were linked to 
NHS-Sepharose beads (Amersham Biosciences, Little Chalfont, United Kingdom) as 
described previously [313]. Sequences of the most important peptides are summarized in 
table 6. SW480 and SW620 cells were lysed in IP buffer containing 0.8% NP40, 50 mM Tris-
HCl pH 7.5, 5% glycerol, 1.5 mM MgCl2, 150 mM NaCl, 1 mM Na3VO4, 25 mM NaF, 1 mM 
DTT supplemented with protease inhibitors (Sigma-Aldrich, St. Louis, Missouri) and 
phosphatase inhibitors (Sigma-Aldrich, St. Louis, Missouri). Adjusted cell lysates (5 mg/ml) 
were incubated with the bead-coupled peptides for 30 min at 4°C with subsequent 
centrifugation. After washing with IP buffer with successively reduced amounts of NP40 
(0.4% and 0.2%, respectively), pulled-down proteins were eluted with LDS sample buffer 
(Invitrogen, Carlsbad, California) containing 50 mM DTT for 30 min at 50°C. Eluates were 
alkylated with chloroacetamide (55 mM) and applied to a short SDS-PAGE (approximately 
1 cm) in a 4-12% NuPAGE gel (Invitrogen, Carlsbad, California). Here, the proteins were 
desalted and concentrated for following in gel digestion with trypsin. 
Derived peptides were analyzed using an Eksigent nanoLC-Ultra 1D+ (Eksigent, Dublin, 
California) coupled to an LTQ-Orbitrap XL ETD (Thermo Fisher Scientific, Waltham, 
Massachusetts). For this, peptides were trapped in a column (100 μm × 2 cm) with self-
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packed Reprosil-Pur C18-AQ 5 µm resin (Dr. Maisch GmbH, Ammerbuch-Entringen, 
Germany) and 0.1% formic acid in HPLC grade water at a flow rate of 5 µL/min. Separation 
was achieved on an analytical column (75 µm × 40 cm, self-packed with Reprosil-Pur C18-
AQ, 3 µm resin; Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) with a 110 min 
gradient of a buffer containing 0.1% formic acid and 5% DMSO in water differing in 
acetonitrile concentration (gradient: 4-32%) at 300 nL/min flow rate. MS spectra were yielded 
at a resolution of 30,000 (m/z 400) after accumulation to a target value of 1,000,000.  
MaxQuant (version 1.5.3.30.) software was used for peptide identification and quantification. 
Here, MS/MS data is compared to all canonical protein sequences as annotated in the 
Swissprot reference database [314,315]. Analysis criteria comprised trypsin as proteolytic 
enzyme, two missed cleavage sites allowed variance and precursor and fragment ion 
tolerances of 10 parts per million (ppm) and 20 ppm, respectively. Further, the minimum 
recognized peptide length was set to seven amino acids as well as the peptide false 
discovery rate to 1% including common contaminants and reverse identifications. 
 
 Table 4: List of crucial MACC1 pY-peptides used in the MS screen 
pY-site  Aminod Acid Sequence 5´- 3´ 
Y365  ATIWD(p)YIHKTT 
Y379  IYGPK(p)YIHPSF 
Y789  MWKPA(p)YDFLYT 
 
2.13 In vivo validation of transcriptional inhibitors 
To investigate the effect of identified MACC1 transcriptional inhibitors, drugs were applied to 
xenografted SCID-beige mice (Charles River, Wilmington, Massachusetts) and tumor growth 
as well as metastasis formation was measured. Animal experiments were conducted 
according to the United Kingdom Coordinating Committee of Cancer Research (UKCCCR) 
guidelines and in cooperation with Experimentelle Pharmakologie & Onkologie Berlin-Buch 
GmbH (EPO, Berlin, Germany). The State Office of Health and Social Affairs (Landesamt für 
Gesundheit und Soziales, LaGeSo, Berlin, Germany) granted the animal experiments under 
the permit Reg0010/19. 
2.13.1 Intrasplenal tumor transplantation 
3x105 of HCT116/CMVp-Luc cells were intrasplenically transplanted into 6-week-old female 
SCID-beige mice (Charles River, Wilmington, Massachusetts) with a 27-gauge needle. For 
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this, 35 mg/kg Hypnomidate® (Janssen Pharmaceutica, Beerse, Belgium) was applied to the 
mice for anesthetization and the skin and peritoneum were laterally incised to exteriorize the 
spleen. During surgery HCT116/CMVp-Luc cells, resuspended in PBS, were kept on ice. 
After repositioning of the spleen, the peritoneum was closed with Surgicryl® absorbable 
suture and the skin was clamped twice. 
2.13.2 In vivo drug application 
Intrasplenically transplanted SCID-beige mice were randomly assigned to 3 groups of 10 
animals each. Oral application with daily doses of either solvent (10% Kolliphor in 0.9% 
NaCl) or 13 mg/kg body weight of Fluvastatin or Atorvastatin (in 0.9% NaCl) was started 24 h 
after transplantation. This dose agrees with a human equivalent dose of approximately 
1 mg/kg body weight which is commonly applied in standard blood lipid lowering therapy 
[316,317]. Due to ethical reasons mice were sacrificed at day 28.  
2.13.3 In vivo bioluminescence imaging 
For monitoring of tumor growth and metastasis formation the bioluminescence imaging 
system NightOWL LB 981 (Berthold Technologies, Bad Wildbad, Germany) was used. Here, 
150 mg/kg D-luciferin (Biosynth, Staad, Switzerland) was intraperitoneally applied to 
anesthetized (isoflurane gas) mice. Tumor growth as well as metastasis formation were 
imaged and quantified by WinLight (Berthold Technologies) and ImageJ (version 1.51j8, 
National Institutes of Health, USA). After termination of the experiment, spleen (as the 
transplantation site) and liver (as a metastasis target organ) were removed and shock frozen 
in liquid nitrogen for preparation of cryosections and further analysis (2.13.4 and 2.13.5). 
2.13.4 MACC1 expression in xenograft tissue 
The frozen tumor tissue was grinded to powder under liquid nitrogen. After adding of RL 
buffer and 10 pulse sonications at 40% for proper cell lysis, RNA isolation and qRT-PCR was 
carried out as previously described (2.3).  
2.15 Statistical analysis 
Microsoft Excel 2010 and GraphPad PRISM version 6.0 were used to perform calculations 
and statistical analysis. The comparison of two different groups was done by t-test whereas 
three or more different groups were compared by One-way or Two-way analysis of variance 
(ANOVA) and Dunnett, Turkey´s or Sidak´s post multiple comparison test. All significance 
tests were two sided with a confidence interval of 95% (* = p < 0.05, ** = p < 0.01, *** = p < 
0.001, **** = p < 0.0001). 
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3. Results 
In this study we aimed to elucidate new strategies to intervene in tumor progression and 
metastasis formation via the novel target MACC1. On the one hand, we made use of the 
previously determined MACC1 promoter to identify new and possibly more potent 
transcriptional inhibitors. Therefore, we employed high-throughput drug screening and 
validated the identified inhibitors in vitro and in vivo for their effect and specificity on MACC1 
expression and function (3.1). On the other hand, we wanted to illuminate the MACC1 
signaling landscape to reveal additional drug intervention points. For this, we used a mass-
spectrometry based approach to find interactors of tyrosine-phosphorylated MACC1. We 
further evaluated these for their functional impact on MACC1 signaling using a variety of cell-
based assays (3.2). 
 3.1 Transcriptional inhibition of MACC1 
3.1.1 HTS identifies statins as most potent inhibitors of MACC1 expression 
Previously, our group identified the MACC1 promoter and, subsequently, Lovastatin as the 
first transcriptional inhibitor of MACC1 [238,274]. Now, we intended to reveal novel and 
possibly more potent transcriptional inhibitors of MACC1 by using an additional, independent 
HTS including different compound libraries: The Microsource, NIH and Prestwick libraries 
comprise 4241 compounds. The HTS was performed in cooperation with European 
Molecular Biology Laboratory (EMBL) and German Cancer Research Center (DKFZ), 
respectively. We used HCT116 cells expressing the luciferase reporter gene under control of 
the MACC1 promoter (HCT116/MACC1p-Luc) which is schematically represented in figure 
12A. In the primary screen two doses (1 µM and 0.1 µM for NIH and Microsource library; 5 
µg/ml and 0.5 µg/ml for Prestwick library) were applied to the cells and promoter activity was 
measured via luciferase expression and resulting luminescence intensity after addition of 
substrate. This process yielded 35 compounds able to reduce luciferase activity. These 
compounds were assessed in a counter selectivity screen using HCT116/CMVp-Luc cells to 
eliminate non-specific luciferase inhibitors. Additionally, we determined cytotoxicity of these 
compounds by MTT and ATP measurements for 24 h and 72 h, respectively. Based on the 
largest ratio between 72 h cytotoxicity and promoter activity reduction, four compounds 
(Fluvastatin, Bosutinib, PD173952, PD161570) were chosen for in vitro validation (Fig. 12C): 
cytotoxicity as well as reduction of MACC1 mRNA and protein expression was assessed in 
HCT116 wild-type cells for these four compounds. Here, we identified Fluvastatin as most 
effective inhibitor of MACC1 expression. The workflow of the HTS is depicted in figure 12B.  
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Fig. 12: HTS identifies statins as most potent transcriptional inhibitors of MACC1. (A) Scheme of construct expressed in 
HCT116/MACC1p-Luc cells used for HTS. The luciferase reporter gene expression is controlled by the MACC1 promoter 
(MACC1p). (B) Overview of stepwise identification of Fluvastatin as transcriptional inhibitor of MACC1 from 4241 Prestwick, 
NIH and Microsource library compounds via HTS and in vitro validation. (C) Dose-response curves and chemical structures 
of the four compounds showing best effects on MACC1 promoter activity: Fluvastatin, Bosutinib, PD173952 and PD161570. 
The four compounds were selected based on the largest ratio between Inhibition of luciferase activity (green) reflecting 
promoter activity after 24 h and cytotoxicity (red) determined by ATP measurement after 72 h of treatment. Luminescence 
intensities of promoter activity and cytotoxicity assay were normalized to respective solvent controls (0.3% DMSO). Results 
represent means + Standard error of the mean (SEM) of three independent experiments. 
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Previously, we identified Lovastatin, another member of the statin family, as transcriptional 
inhibitor of MACC1 [274]. This prompted us to evaluate all clinically employed statins 
(Fluvastatin, Atorvastatin, Lovastatin, Pitavastatin, Simvastatin, Rosuvastatin, Pravastatin) on 
their ability to reduce MACC1 expression. Indeed, we showed that most of them reduce 
MACC1 expression on mRNA and protein level in a concentration-dependent manner (1-
10 µM) in HCT116 cells. Fluvastatin (Fig. 13A) treatment at 1 µM reduced MACC1 
expression below 50% compared to the control treated cells whereas Lovastatin (Fig. 13B), 
Atorvastatin (Fig. 13C) and Pitavastatin (Fig. 13D) reached this only at 2.5 µM and 
Simvastatin at 5 µM (Fig. 13E). Fluvastatin, Lovastatin and Atorvastatin treatment showed a 
maximal inhibition of MACC1 at 7.5 µM with approximately 10% remaining expression. 
Comparably, Simvastatin and Pitavastatin reduced MACC1 expression to about 30% and 
40%, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13: Different members of the statin family reduce MACC1 expression. MACC1 showed a dose-dependent (0 -10 µM) 
decrease of mRNA and protein expression upon 24 h treatment with Fluvastatin (A), Lovastatin (B), Atorvastatin (C), 
Simvastatin (D) and Pitavastatin (E). MACC1 mRNA levels were normalized to G6PD mRNA expression and respective 
solvent controls (0.1% DMSO, white bars). Results for mRNA represent means + Standard error of the mean (SEM) of three 
independent experiments and for WB one representative example of at least two independent experiments is shown. In the 
WB, β-actin served as loading control. Significant results were determined by one-way ANOVA and Dunnett’s multiple 
comparison test with a confidence interval of 95% (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001). 
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3.1.2 Statins reduce endogenous MACC1 expression in different cancer entities 
In order to further validate our previous findings, we examined the statins in additional CRC 
and other cancer entity wild-type cell lines. We have chosen Fluvastatin and Atorvastatin as 
most effective statins for representative verification.  
Both statins were able to reduce MACC1 expression on mRNA and protein level in the CRC 
cell lines SW48 and HT29 in a concentration-dependent manner. Compared to solvent 
control, Fluvastatin treatment decreased MACC1 expression to approximately 50% at 5 µM 
in SW48 and 10 µM in HT29, whereas Atorvastatin diminished it to approximately 60% in 
SW48 and 70% in HT29 at 10 µM (Fig. 14A). Furthermore, both statins decreased MACC1 
mRNA and protein expression in a pancreatic (BxPC3) and a gastric cancer cell line 
(MKN45). In BxPC3 cells Fluvastatin treatment reached over 50% reduction at 5 µM and 
about 75% at 10 µM whereas Atorvastatin treatment reduced MACC1 expression under 50% 
at 10 µM (Fig. 14B). Both statins reduced MACC1 expression to about 70% in MKN45 cells 
with the highest concentration tested (10 µM). These results are depicted in figure 14C. 
 
 
 
 
Fig. 14: Statins reduce endogenous MACC1 expression in different cancer entities. (A) Dose-dependent reduction of 
MACC1 mRNA and protein expression by Fluvastatin and Atorvastatin (0 – 10 µM) in further CRC cell lines SW48 and HT29. 
MACC1 mRNA and protein expression was also diminished by Fluvastatin and Atorvastatin in BxPC3 (pancreatic cancer) (B) 
and MKN45 (gastric cancer) cells (C). MACC1 mRNA levels were normalized to G6PD mRNA expression and respective 
solvent controls (0.1% DMSO, white bars). Results for mRNA represent means + SEM of three independent experiments and 
for WB one representative example of three independent experiments is shown. In the WB, β-actin or vinculin served as 
loading control. Significant results were determined by one-way ANOVA and Dunnett’s multiple comparison test with a 
confidence interval of 95% (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001). 
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3.1.3 Statins reduce endogenous MACC1 expression in different CRC cell models 
For later functional and specificity analysis of the statin effect on MACC1, genetically 
modified models of HCT116 were generated. We chose models of HCT116 cells stably 
overexpressing MACC1-GFP, a MACC1-inducible overexpressing cell line and HCT116 with 
MACC1 knock-out (HCT116/MACC1 -/-) (see 2.2). First, it was of importance to evaluate 
statin treatment on MACC1 expression in these models. Figure 15A shows the statin effect 
on HCT116 cells overexpressing either GFP or a MACC1-GFP fusion protein. Both, 
Fluvastatin and Atorvastatin, diminished MACC1 mRNA expression in HCT116/GFP cells. 
The mRNA levels remained stable in HCT116/MACC1-GFP under Fluvastatin treatment and 
were not significantly decreased under Atorvastatin treatment. In more detail, the Western 
blot analysis demonstrates that only the endogenous, MACC1 promoter-driven MACC1 
expression is reduced by statin treatment with a concomitant, strong overexpression of 
MACC1-GFP.  
To induce MACC1 expression in HCT116/MACC1, cells were treated with doxycycline 
(+Dox) or solvent H2O (-Dox) for 48 h. As seen in figure 15B, MACC1 mRNA expression was 
significantly increased (about 30%) in the control cells (0 µM), which was also confirmed in 
the WB. In both, doxycycline treated and untreated cells, statin treatment led to a decrease in 
MACC1 mRNA and protein expression while the +Dox cells retained a higher level compared 
to -Dox cells. For instance, under Fluvastatin treatment +Dox cells showed mRNA 
expression levels of approximately 85% at 1 µM and 70% at 2.5 µM compared to 60% and 
45% in -Dox cells, respectively.  
HCT116/Cas9 also reacted to Fluvastatin treatment: Figure 15C demonstrates a reduction of 
MACC1 mRNA expression to about 70% and 60% at 1 µM and 2.5 µM confirmed by protein 
expression via WB. In HCT116/MACC1 -/- cells, MACC1 expression was not abundant in 
qRT-PCR or WB.  
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Fig. 15: Statins reduce endogenous MACC1 expression in different CRC cell models. Different cell models modulated in 
MACC1 expression were generated and tested for reactivity to statin treatment. (A) HCT116 cells stably overexpressing GFP 
show a reduction of MACC1 mRNA and protein expression upon Fluvastatin and Atorvastatin treatment (1 or 2.5 µM). 
HCT116/MACC1-GFP cells present stable expression of MACC1 mRNA after statin treatment while only endogenous MACC1 
protein levels are diminished by statins. (B) HCT116 cells with doxycycline inducible MACC1 expression are affected by 
statin treatment regardless of MACC1 induction, but induced cells (for 48 h; +Dox) show a generally higher expression of 
MACC1 mRNA or protein than those not induced (-Dox). (C) In HCT116 cells transduced with a Cas9 plasmid serving as 
control cell line, Fluvastatin treatment led to a decrease of MACC1 mRNA and protein expression. For the respective 
MACC1-/- cell line, MACC1 expression was absent in qRT-PCR and WB. MACC1 mRNA levels were normalized to G6PD 
mRNA expression and respective treatment controls (DMSO, H2O; white bars). Results for mRNA represent means + SEM of 
at least two independent experiments and for WB one representative example of two independent experiments is shown. 
In the WB, β-actin served as loading control. Significant results were determined by one-way ANOVA and Dunnet´s or 
Sidak´s multiple comparison test with a confidence interval of 95% (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001). 
48 
 
3.1.4 Statins specifically inhibit MACC1-mediated functions in vitro 
MACC1 is known to induce a variety of cellular functions involved in tumor progression and 
metastasis formation, such as proliferation, colony formation and motility [100]. To evaluate 
the potential of statins for specific inhibition of MACC1-mediated cellular functions, 
proliferation and clonogenic assays were performed. For proliferation assessment, 72 h live 
imaging with subsequent confluence analysis was used on HCT116/MACC1 cells (-
Dox/+Dox) treated with 1 µM Fluvastatin or 2.5 µM Atorvastatin. Figure 16A+B show the 
relative proliferation determined by area under the curve (AUC) of the respective growth 
curves normalized to solvent treated controls (white bars). MACC1 overexpression in +Dox 
cells exerted a proliferative phenotype demonstrated by an approximate 30% increase in cell 
growth compared to -Dox cells. Proliferation was reduced to 40% by Fluvastatin and to 55% 
by Atorvastatin treatment which could be rescued by MACC1 induction to 77% and 93%, 
respectively (Fig. 16A). 
In a similar manner, HCT116/Cas9 and HCT116/MACC1 -/- cells were subjected to the 
proliferation assay. As depicted in figure 16B, MACC1 knock-out led to an over 50% 
decrease in cell growth compared to Cas9 control cells. Interestingly, we found a dose-
dependent reduction in the proliferation of HCT116/Cas9 under Fluvastatin treatment 
whereas the MACC1 knock-out cells remained unaffected.  
 
 
 
Fig. 16: Statins specifically inhibit MACC1-mediated proliferation. Relative proliferation was determined with the 
IncuCyte® live imaging system for 72 h and calculated by the AUC normalized to solvent controls (0.1% DMSO; white bars). 
(A) HCT116 cells with doxycycline induced MACC1 expression (+Dox) demonstrated a 30% increase in proliferation. MACC1-
induced proliferation in +Dox compared to -Dox cells was still observed under statin treatment indicating a MACC1-specific 
rescue of proliferative function. (B) Confirmation of the previous findings with MACC1 knock-out cells (HCT116/MACC1 -/-). 
MACC1 knock-out resulted in an over 50% reduction in proliferation compared to control cells (HCT116/Cas9). Control cell 
proliferation was decreased by Fluvastatin treatment (1 and 2.5 µM) whereas HCT116/MACC1 -/- cells remained 
unaffected. Results represent means + SEM of at least three independent experiments. Significant results were determined 
by two-way ANOVA and Sidak´s multiple comparison test with a confidence interval of 95% (* = p < 0.05, ** = p < 0.01, *** 
= p < 0.001, **** = p < 0.0001). 
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The clonogenic assay was performed to investigate the reproductive viability. In principle, 
every individual cell is challenged for its ability to divide limitlessly which is judged by their 
colony forming potential [305-307]. Here, it was employed to assess MACC1-dependent 
reproductive viability upon statin treatment. This was used to evaluate the specificity of the 
statin effect on MACC1-mediated functions. Low density seeding of HCT116/GFP or 
HCT116/MACC1-GFP cells (400 cells/6-well) was followed by treatment with 1 µM and 
2.5 µM of statin for seven days. The ability to form and grow colonies was determined by 
imaging and analyzing the fixed and stained cells (Fig. 17A). Here, the number of colonies 
(Fig. 17B) and colony covered area (Fig. 17C) were measured with ImageJ (version 1.51j8, 
National Institutes of Health, USA). By normalizing the values of treated cells to solvent 
controls of each respective cell line (HCT116/GFP or HCT116/MACC1-GFP), adjusted 
rescue values were calculated (Fig. 17C). 
In general, solvent treated cells overexpressing MACC1-GFP showed an approximately 1.5 
to 2-fold increase in colony covered area and colony number compared to control cells. Upon 
statin treatment colony formation was reduced in HCT116/GFP cells in a concentration-
dependent manner whereas the overexpression of MACC1-GFP rescued this effect. 
Especially, the treatment with 1 µM of either statin, reducing control cell colony formation, 
hardly affected colony number (Fig. 17B) or colony covered area (Fig. 17C) of MACC1-GFP 
overexpressing cells. When treated with 2.5 µM of statin, MACC1-GFP overexpression still 
partly rescued colony formation. This is also represented by the adjusted rescue values: 
Colony number was rescued by 16% (1 µM) and 14% (2.5 µM) upon Fluvastatin treatment or 
9% (1 µM) and 20% (2.5 µM) upon Atorvastatin treatment. Adjusted values showed a rescue 
of colony covered area by 30% (1 µM) or 9% (2.5 µM) for Fluvastatin and 20% (1 µM) or 
25% (2.5 µM) for Atorvastatin treatment.  
In general, the rescue effects by forced MACC1 overexpression demonstrated in figure 16 
and 17 indicate a specific effect of statins on MACC1 function, particularly clonogenicity and 
proliferation, respectively. 
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Fig. 17: Statins specifically inhibit MACC1-mediated clonogenicity. Clonogenicity of formaldehyde fixed and crystal violet 
stained cells was imaged (A) and assessed by colony number (B) and the colony covered area (C). Stable overexpression of 
MACC1-GFP in HCT116 cells led to a strongly augmented (1.5 to 2-fold) colony formation compared to HCT116/GFP cells. 
Colony formation of control cells was reduced upon treatment with 1 µM of either statin whereas MACC1-GFP 
overexpressing cells remained nearly unaffected indicating a MACC1-specific rescue of clonogenic function. A partial rescue 
was also seen upon treatment with 2.5 µM of either statin. Results represent means + SEM of three independent 
experiments. One representative of nine technical replicates divided in three independent experiments is shown. Significant 
results were determined by two-way ANOVA and Sidak´s multiple comparison test with a confidence interval of 95% (* = p 
< 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001). 
 
 
 
 
 
 
 
51 
 
3.1.5 Statin treatment decreases tumor burden and metastasis formation in vivo 
As shown previously, MACC1 aggravates tumor growth and induces metastasis formation. 
Both were specifically reduced by RNAi or use of previously identified MACC1 inhibitors 
Lovastatin and Rottlerin [100,219,222,225,233,237,240,250,274]. Therefore, we wanted to 
proof this concept for Fluvastatin and Atorvastatin in vivo. In collaboration with the EPO 
Berlin-Buch GmbH, SCID-beige mice were intrasplenically transplanted with 3x105 
HCT116/CMVp-Luc cells and treated orally with either solvent or daily doses of 13 mg/kg 
body weight of the respective statin (10 animals per group). This corresponds to a human 
equivalent dose of approximately 1 mg/kg body weight which is commonly used in statin 
therapy for blood lipid reduction [316,317]. Tumor growth and metastasis formation were 
continuously monitored by bioluminescence imaging over 24 days until the ethical end point 
(cancer burden of control group animals) was reached. One animal had to be sacrificed early 
(day 19) due to this reason.  
Bioluminescent signals of all mice in lateral view at day 24 are presented in figure 18A. The 
lateral view captures the bioluminescent signals emitted by the tumor cells growing in the 
spleen forming the primary tumor. In general, most control animals show larger signal areas 
and stronger signal intensities than statin treated ones judged by the luminescence intensity 
scale. This was confirmed by the integrated luminescence quantification with ImageJ 
(version 1.51j8, National Institutes of Health, USA) shown as means + SEM per group in 
figure 18B. These data demonstrate that treatment with either statin led to a strong restriction 
of tumor growth. Here, significant differences (p = 0.013) in tumor growth were already 
observed between control and Atorvastatin treated animals at day 15. This effect increased 
over time presenting strong differences between control and statin treated animals at day 19 
(Fluvastatin and Atorvastatin: p < 0.0001) and day 24 (Fluvastatin: p < 0.0001, Atorvastatin: 
p = 0.0002). 
For the assessment of health or imminent death, progressive loss of body weight represents 
a major criterion for in vivo studies with mice [318]. In accordance with this, body weight of 
mice was monitored besides the bioluminescent imaging. Until the termination of the 
experiment, neither control group nor statin treated animals displayed significant changes or 
differences between groups in body weight (Fig. 18C). 
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Fig. 18: Statin treatment decreases tumor burden in vivo. (A) Bioluminescent imaging at day 24 of SCID-beige mice from 
lateral view to detect tumor growth in the spleen. One animal in the control group was sacrificed due to ethical reasons 
already on day 19. In general, Fluvastatin and Atorvastatin treated animals show smaller signal areas and weaker signals 
indicating restricted tumor growth. (B) Bioluminescence intensity was quantified via ImageJ and averaged per group and 
day. These data demonstrate a significant restriction of tumor growth through statin treatment. (C) Body weight of the 
mice was regularly monitored as indicator of health or imminent death. None of the animals displayed drastic changes in 
body weight. Results represent means + SEM of 10 animals per group. Significant results were determined by two-way 
ANOVA and Dunnet´s multiple comparison test with a confidence interval of 95% (* = p < 0.05, ** = p < 0.01, *** = p < 
0.001, **** = p < 0.0001). 
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Bioluminescent signals of all mice in ventral view at day 24 are presented in figure 19A. 
Imaging from the ventral view determines the bioluminescent signals emitted by tumor cells 
forming metastasis in the liver. In general, most control animals show larger signal areas and 
stronger signal intensities than statin treated ones judged by the luminescence intensity 
scale. This was confirmed by the integrated luminescence quantification with ImageJ 
(version 1.51j8, National Institutes of Health, USA) shown as means + SEM per group in 
figure 19B. These data demonstrate that treatment with either statin led to a strong restriction 
of metastasis formation. At day 19 and 24 significant differences in metastasis formation 
were observed between control and statin treated animals: day 19 (Fluvastatin:  p < 0.0001, 
Atorvastatin: p = 0.0001) and day 24 (Fluvastatin: p < 0.0001, Atorvastatin: p < 0.0001). 
Moreover, we found reduced amounts of MACC1 transcripts in the livers of statin treated 
mice reflecting their MACC1 specific targeting also in an in vivo setting (Fig. 19C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19: Statin treatment decreases metastasis formation in vivo. (A) Bioluminescent imaging at day 24 of SCID-beige mice 
from ventral view to detect metastasis formation in the liver. One animal in the control group was sacrificed due to ethical 
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reasons already on day 19. In general, Fluvastatin and Atorvastatin treated animals show smaller signal areas and weaker 
signals indicating reduced metastasis formation. (B) Bioluminescence intensity was quantified via ImageJ and averaged per 
group and day. These data demonstrate a significant restriction of metastasis formation through statin treatment. (C) 
Fluvastatin and Atorvastatin treated mice further showed reduced amounts of MACC1 transcripts in the liver compared to 
control animals. Results represent means + SEM of 10 animals per group. Significant results were determined by two-way 
ANOVA and Dunnet´s multiple comparison test with a confidence interval of 95% (* = p < 0.05, ** = p < 0.01, *** = p < 
0.001, **** = p < 0.0001). a – one outlier was identified by the ROUT method (Q=1%) and Grubbs´s test (alpha=0.01) which 
was not considered for the calculation of the mean MACC1 mRNA expression in the livers. 
 
In summary, we identified Fluvastatin as additional transcriptional inhibitor of MACC1 via 
HTS. Together with our previous results, this prompted us to test all clinically employed 
statins for their inhibitory potential on MACC1 expression. Indeed, we demonstrated that 
most statins reduce MACC1 expression on mRNA and protein level in CRC cells. Fluvastatin 
and Atorvastatin, selected as strongest inhibitors, diminished MACC1 mRNA and protein 
expression also in pancreatic and gastric cancer cells. Both statins were further shown to 
specifically inhibit MACC1-dependent cell functions such as proliferation and colony 
formation. We proved this by partially rescuing the inhibitory effect by inducible or stable 
overexpression of MACC1 in CRC cells. Finally, both statins decreased tumor growth and 
metastasis formation as well as MACC1 transcripts in the liver of a xenografted mouse model 
for CRC metastasis.  
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3.2 MACC1 phospho-interactome and signaling landscape 
3.2.1 A MS-based screen identifies interactors of tyrosine phosphorylated MACC1 
The domain architecture of MACC1 comprises several distinct domains such as ZU5, UPA, 
SH3 and two DDs indicating its involvement in protein-protein interaction or protein 
recruitment [100,290-295]. MACC1 also contains further protein interaction motifs such as 
the clathrin box, NPF and DPF tripeptides as well as proline-rich sequences (PxPxP, 
KxxPxxP) and several serine (Ser, S), threonine (Thr, T) or tyrosine (Tyr, Y) sites accessible 
for phosphorylation [100]. Especially tyrosine phosphorylation represents a crucial 
mechanistic switch in signal transduction. Phosphorylation of specific Y-sites mostly leads to 
an activation of the respective protein. Phosphorylated tyrosines (pY), additionally, serve as 
docking sites for SH2 domain containing proteins, thereby fostering downstream signaling 
[296-299]. Therefore, we aimed to identify pY-dependent interactions of MACC1 in CRC. 
In cooperation with the Küster lab at TUM, we performed pull-down experiments in SW480 
and SW620 CRC cells as well as placenta tissue. Placenta tissue is an easily accessible 
human primary tissue expressing a large variety of proteins: 69% of all human proteins were 
found to be expressed in placenta tissue compared to a 44% expression baseline detected in 
most other tissues [319-321]. Therefore, placenta served as control tissue. Pull-downs were 
carried out with bead-coupled peptides representing all potential pY-sites of MACC1. 
Subsequent MS revealed the interaction with several proteins via specific pY-sites on 
MACC1 (Fig. 20A). An overview of pulled-down proteins is given in figure 20B. For further 
analysis, we focused on proteins identified in both cell lines and both conducted screens. 
Most interestingly, some of these were found to be involved in RTK signalosome formation: 
GRB2, SHP2, SHC1, STAT5B and PLCG1 (Fig. 20C) [42].  
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Fig. 20: A phosphoproteomic screen identifies interactors of tyrosine phosphorylated MACC1. (A) Scheme of assay 
workflow. Cell lysates were incubated with bead-coupled MACC1 pY-peptides. After binding and washing steps, the beads 
were removed, and pulled-down proteins trypsin digested. Subsequent MS revealed several potential interactors of pY-
MACC1. (B) Tabular results of identified interactors of pY-MACC1. Pull-downs were performed in SW480 and SW620 CRC 
cells as well as in human placenta lysate as control tissue. The screen was conducted twice revealing overlapping bindings 
of pY-MACC1 with a variety of proteins. (C) Five proposed interactors are known to form signaling complexes below RTKs 
which is schematically represented here (modified from [42]). These five interactions with GRB2, SHP2, STAT5B, SHC1 and 
PLCG1 were subjected to further analysis. MACC1 – metastasis associated in colon cancer 1; MET - MET receptor tyrosine 
kinase; GRB2 - growth factor receptor-bound protein 2; RAS - rat sarcoma viral oncogene homolog; MAPK - mitogen-
activated protein kinase; STAT - signal transducer and activator of transcription; GAB1 - GRB2-associated-binding protein 1; 
SHC - SHC-transforming protein ; SHP2 - SH2 domain-containing phosphatase 2; PI3K - phosphoinositide 3-kinases; p85 - 
p85 regulatory subunit of phosphoinositide 3-kinase; PLCγ – phospholipase C gamma; CRKL - Crk-like protein; SRC - non-
receptor tyrosine kinase SRC; CD44v6 - cluster of differentiation 44 splice variant 6. 
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In order to validate the findings of the MS screen, we selected Co-IP experiments as one of 
the established standard methods for identification and verification of protein-protein 
interaction [322]. We performed pull-downs with specific antibodies for the respective 
interactors or MACC1 in SW480 cells with ectopic MACC1 overexpression (SW480/MACC1) 
(Fig. 21A) and SW620 wild-type cells (Fig. 21B). The interaction of MACC1 with all five 
suggested proteins was confirmed in WB using the antibody of the respective opposing 
interactor. Protein size was referenced either with an input of whole cell lysate or a positive 
control of the pull-down with the respective interactor antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21: Co-Immunoprecipitation (Co-IP) confirms interactions with suggested proteins. Co-IP was performed with cell 
lysates from SW480 CRC cells with ectopic MACC1 overexpression (SW480/MACC1) (A) and SW620 CRC wild-type cells (B). 
All five suggested bindings of MACC1 with GRB2, PLCG1, SHP2, SHC1 and STAT5B were validated in this assay. Reference of 
protein size was achieved with an input of whole cell lysate or a positive control of the pull-down with the respective 
interactor antibody. Results show one representative example of at least two independent experiments.  
 
 
In further pull-down experiments with subsequent MS, we wanted to confirm the specificity of 
the interactions for distinct pY-sites on MACC1. For this reason, we performed separate pull-
downs with unphosphorylated and phosphorylated versions of the previously identified 
peptides. Figure 22 shows that four of the five interactors bind specifically to phosphorylated 
and selectively to one respective site on MACC1: pY365 – STAT5B; pY379 – GRB2 and 
SHP2; pY789 – SHC1. PLCG1 showed a more promiscuous binding pattern but favored the 
binding to pY379 and pY789 over their respective opposing peptide version. The results 
were identical for SW480 and SW620 cells except the binding of PLCG1 to Y365. Here, the 
cell lines demonstrate contradictory results.  
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Fig. 22: Peptide pull-downs reveal selectivity of interactors for distinct pY-sites on MACC1. Phosphorylated or 
unphosphorylated peptides of the identified pY-interaction sites on MACC1 were used to pull-down proteins from lysates of 
SW480 (A) and SW620 wild-type cells (B). Subsequent WB showed the selective binding of SHP2 and GRB2 to the 
phosphorylated Y379 peptide whereas SHC1 and STAT5B interacted with pY789 and pY365, respectively. PLCG1 binding was 
rather unspecific: It showed the strongest interaction with pY379 followed by pY789 and contradictory results for Y365.  
3.2.2 pY-interaction sites are important for MACC1 function 
To assess the functional relevance of the pY-interactions sites on MACC1, we performed 
site-directed mutagenesis. First, we focused on the interaction sites Y379 and Y789 which 
bind the majority of interactors: GRB2, SHP2, SHC1, PLCG1. All of these have been found 
to regulate cellular signaling such as the ERK pathway governing many decisive processes 
such as proliferation or migration [23,42,44-56].  
Figure 23A shows the putative domain structure of MACC1 including mutated tyrosine sites 
as well as an exemplary histogram for the mutation at Y379. By a single nucleotide exchange 
from adenosine to thymidine, the tyrosine is substituted by a structural similar phenylalanine 
(F) which is not accessible for phosphorylation. Next, HCT116 CRC cells transduced either 
with GFP, MACC1-GFP or MACC1-GFP mutated at Y379 and Y789 (Y379F+Y789F) were 
employed in a Boyden chamber migration assay. Overexpression of MACC1-GFP led to a 
more than 2-fold increase in cell migration compared to GFP control cells. Interestingly, the 
cell clones harboring tyrosine-mutated MACC1 showed significantly reduced migratory ability 
compared to wild-type MACC1-GFP transfected clones (Fig. 23B). Figure 23C demonstrates 
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a similar effect on HGF-induced proliferation. After seeding, cells were accommodated for 
24 h in 10% FBS medium and then switched to 0% FBS medium containing 20 ng/ml HGF. 
Via cell confluence assessment, an increased proliferative capacity of HCT116/MACC1-GFP 
cells was observed whereas the Y379F+Y789F expressing cells show proliferation on control 
cell level. In total, this indicates a strong influence of MACC1 phosphorylation status 
(Y379+Y789) and mediated signaling via the associated interactions on cancer cell migration 
and proliferation. 
 
 
 
 
Fig. 23: pY-interaction sites are important for MACC1 function. (A) Schematic domain architecture of MACC1 including 
identified pY-interaction sites and binding partners. Further, a representative example of site-directed mutagenesis 
performed at Y379. The single base substitution from adenosine to thymidine leads to an amino acid switch from tyrosine 
to the structural similar phenylalanine which is not accessible for phosphorylation. (B) HCT116/MACC1-GFP cells 
demonstrate significantly elevated levels of cell migration in the Boyden chamber assay compared to control cells. In 
contrast, mutation of MACC1-GFP at Y379 and Y789 (Y379F+Y789F) reduced migratory potential in HCT116 cells expressing 
this construct almost to control level. (C) Similarly, HGF-induced proliferation assessed by IncuCyte® live imaging was 
increased through MACC1-GFP overexpression whereas mutation at Y379 and Y789 (Y379F+Y789F) led to proliferation on 
control cell level. Results represent means + SEM of three independent experiments. Significant results were determined by 
one-way (Fig. 23B) or two-way (Fig. 23C) ANOVA and Turkey´s or Sidak´s multiple comparison test with a confidence 
interval of 95% (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001). Blue - GFP expressing cells; red - MACC1-GFP 
expressing cells; green - MACC1-GFP (Y379F+Y789F) expressing cells. 
3.2.3 MACC1 facilitates downstream signaling of receptor tyrosine kinases 
MACC1 was shown to exert some of its functions such as induction of proliferation and cell 
scattering in response to HGF stimulation [100]. In this study, we identified and confirmed 
interactors of MACC1 which play important roles in signal transduction of RTKs such as MET 
[23,42,44-56]. Therefore, we aimed to investigate the effect of MACC1 on receptor tyrosine 
kinase signaling by performing stimulation experiments with HGF plus subsequent WB of the 
downstream effector ERK and activating phosphorylation at T202 and Y204. Concomitantly, 
MACC1 expression was determined. Vinculin served as loading control. The WB pictures 
show one representative example whereas bar graphs represent the normalized signal 
strength of three independent experiments analyzed by spot densitometry which correlates to 
the respective protein expression levels. Here, expression of pERK and ERK were 
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normalized to vinculin expression before normalizing pERK to ERK indicating the level of 
active protein. Values for untreated (0 min) HCT116/GFP or SW480/ev cells were set to 1 
resulting in relative expression levels depicted in the respective bar graphs. 
Figure 24 A and B show an increase of ERK phosphorylation upon growth factor treatment 
indicating the activation of the MET signal transduction cascade. Interestingly, the activating 
phosphorylation of ERK demonstrate a stronger amplification in the cell lines overexpressing 
MACC1 compared to the respective empty vector cell lines over the time period of 
stimulation, especially at 1 and 8 min. pERK levels are also higher in MACC1 overexpressing 
cells at the unstimulated start point of the experiment (0 min). After 90 min, ERK activation 
reaches a plateau in control cells whereas MACC1 high cells demonstrate already subsiding 
pERK levels. This indicates an activation loop with increased velocity and signal strength 
through MACC1 overexpression. These findings hold true for both cell models tested. 
 
 
 
 
 
 
 
Fig. 24: MACC1 facilitates downstream signaling of MET. Cells were serum starved and, subsequently, treated with 
20 ng/ml HGF for 0, 1, 8 and 90 min, respectively. As downstream target of RTK signaling the activation of ERK via 
phosphorylation at T202 and Y204 was determined in WB. This experiment was performed in two different CRC cell models 
with modulations in MACC1 expression: (A) HCT116/GFP vs. HCT116/MACC1-GFP and (B) SW480/ev vs. SW480/MACC1. 
Growth factor stimulation led to an increased pERK expression peaking at 8 min in the MACC1 overexpressing cell lines 
whereas control cell lines showed an expression plateau after 8 and 90 min. The pERK activation was augmented by MACC1 
overexpression. Especially at 1 min and 8 min, pERK levels were higher in MACC1 overexpressing cells than control cells. 
Interestingly, the same was also seen in untreated cells (0 min). Results are demonstrated by WB and respective spot 
densitometry analysis. Here, expression of pERK and ERK were normalized to vinculin (loading control) expression before 
normalizing pERK to ERK indicating the level of active protein. Values for untreated (0 min) HCT116/GFP or SW480/ev cells 
were set to 1 resulting in relative expression levels depicted in the respective bar graphs. Results represent means + SEM of 
three independent experiments. Blue - GFP expressing cells; red - MACC1-GFP expressing cells. 
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The identified interactors are not only involved in signalosome formation and regulation of 
downstream signaling of MET, but provide similar functions for further RTKs, e.g. EGFR 
[323-325]. Therefore, we additionally investigated the effect of MACC1 on further receptor 
tyrosine kinase signaling by performing stimulation experiments with EGF. Similar to figure 
24, WB was used to determine the activation of the downstream effector ERK by activating 
phosphorylation at T202 and Y204. We observed according expression patterns for both cell 
models with pERK levels peaking after 8 min of growth factor stimulation. Also upon EGF 
treatment, MACC1 overexpression applied a stronger and faster ERK activation loop to the 
cells (Fig. 25 A+B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25: MACC1 facilitates downstream signaling of EGFR. Cells were serum starved and, subsequently, treated with 
20 ng/ml EGF for 0, 1, 8 and 90 min, respectively. As downstream target of RTK signaling the activation of ERK via 
phosphorylation at T202 and Y204 was determined in WB. This experiment was performed in two different CRC cell models 
with modulations in MACC1 expression: (A) HCT116/GFP vs. HCT116/MACC1-GFP cells and (B) SW480/ev vs. 
SW480/MACC1 cells. Growth factor stimulation led to a pERK activation loop peaking at 8 min in all four cell lines. This 
activation loop was augmented by MACC1 overexpression. Especially at 1 min and 8 min, pERK levels were higher in MACC1 
overexpressing cells than control cells. Interestingly, the same was also seen in untreated cells (0 min). Results are 
demonstrated by WB and respective spot densitometry analysis. Here, expression of pERK and ERK were normalized to 
vinculin (loading control) expression before normalizing pERK to ERK indicating the level of active protein. Values for 
untreated (0 min) HCT116/GFP or SW480/ev cells were set to 1 resulting in relative expression levels depicted in the 
respective bar graphs. Results represent means + SEM of three independent experiments. Blue - GFP expressing cells; red - 
MACC1-GFP expressing cells. 
 
62 
 
3.2.4 MACC1 induced signaling is abrogated by mutation of specific tyrosine sites 
As described previously, the MACC1 interactors GRB2, SHP2, SHC1 and PLCG1 are 
implicated in RTK signal transduction and regulation of cellular signaling like the ERK 
pathway thereby governing many decisive processes such as proliferation or migration 
[23,42,44-56]. 
To examine the role of the identified pY-interaction sites in MACC1-dependent RTK 
downstream signaling, we subjected the previously created tyrosine mutated MACC1 cell line 
(Y379F+Y789F) to HGF treatment and subsequent WB. Results are shown in figure 26. The 
bar graphs depict the results of spot densitometry analysis. Normalization was performed as 
described before in 3.2.3. Due to the lack of a WB signal at 0 min for HCT116/GFP cells in 
one of the experiments, normalization to untreated GFP control cells was not conducted and 
values represent arbitrary units instead of fold changes to control. The results in figure 26 
also demonstrate the MACC1-dependet increase in ERK phosphorylation whereas the 
Y379F+Y789F cells lack this amplification and demonstrate pERK levels similar or below 
control after 1 min and 8 min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 26: The MACC1 signaling effect is abrogated by mutation of specific tyrosine sites. ERK activation (phosphorylation at 
T202/Y204) upon HGF stimulation is reduced in HCT116 cells expressing tyrosine mutated MACC1-GFP (Y379F+Y789F) 
compared to wild-type MACC1-GFP, especially after 8 min. Here, pERK levels are even lower than in GFP control cells. 
Expression of pERK and ERK were normalized to vinculin (loading control) expression before normalizing pERK to ERK 
indicating the level of active protein. Results represent means + SEM of two independent experiments. Blue - GFP 
expressing cells; red - MACC1-GFP expressing cells; green - MACC1-GFP (Y379F+Y789F) expressing cells. 
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3.2.5 MACC1 exerts a hyperactivated signaling phenotype - DigiWest 
Cellular signaling pathways share high levels of crosstalk and redundancy (see 1.2.2) 
[23,26]. Therefore, we wanted to evaluate the effect of MACC1 on the cellular signaling 
landscape using DigiWest. This allowed the protein expression assessment of a large target 
variety from a single standard WB membrane. Proteins on the membrane were stripped and 
labeled via biotinylation and streptavidin-coated colored beads. Bead-pools reconstituting 
different membrane lanes were subjected to antibody-based immunoassays (PE-labeled 
secondary antibodies) with subsequent fluorescent read-out for respective protein 
expressions. We used the HCT116/GFP and MACC1-GFP cell pair plus HFG treatment for 
0, 1, 8 and 90 min, respectively. Figures 27-30 show the protein expression of different 
phosphorylated proteins presented in corresponding normalization to previous experiments 
(3.2.3 and 3.2.4).  
The relative expression of pMEK (S217/S221) (Fig. 27A), pERK1 (T202/Y204), pERK2 
(T185/Y187) (Fig. 27B) and p-p90 ribosomal s6 kinase (pRSK) (T573) (Fig. 27C) indicating 
the activated proteins are depicted in figure 27. Again, we observed an increased 
phosphorylation upon HGF treatment from 0 to 8 min which subsided at 90 min. A stronger 
increase was seen in MACC1 overexpressing cells at 1 and 8 min accompanied by an also 
stronger decrease at 90 min. Untreated MACC1 overexpressing cells showed already higher 
pERK and pRSK levels than controls. This faster and stronger activation loop of ERK 
signaling corroborated previous results (3.2.3) and served as baseline for the following 
findings. 
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Fig. 27: MACC1 exerts hyperactivated ERK signaling. A large set of protein and phospho-protein expression in response to 
HGF treatment (0, 1, 8, 90 min) was assessed by DigiWest. Bar graphs illustrate integrated signal strength of phosphorylated 
proteins normalized to respective total protein expression indicating activated or inactivated protein levels. Stronger 
activation loops are found in MACC1-GFP overexpressing compared to control cells for different members of the ERK 
signaling pathway: (A) pMEK (S217/S221), (B) pERK1 (T202/Y204), pERK2 (T185/Y187) and (C) pRSK (T573). Blue - GFP 
expressing cells; red - MACC1-GFP expressing cells. 
 
Similarly, expression of pGSK3β (S9; inactivated form) (Fig. 28A) and β-catenin (S552; 
activated form) (Fig. 28B) were comparably higher in HCT116/MACC1-GFP than 
HCT116/GFP cells for all time points. The cyclic activation pattern was also observed here 
(Fig. 28 A+B). Further, activating phosphorylation of SRC (Y416) (Fig. 29A) and focal 
adhesion kinase (FAK) (Y397) were strongly augmented in MACC1 overexpressing cells 
compared to respective controls for all time points whereas sequentially active FAK forms 
pFAK (Y576/577) and pFAK (Y925) showed higher expressions at 1 or 8 min, respectively 
(Fig. 29C). In figure 30, the results depict an increased expression for activated cAMP 
response element-binding protein (pCREB) (S133) in MACC1 high expressing cells from 0 to 
8 min followed by a stronger drop at 90 min (Fig. 30A). The expression of active vasodilator-
stimulated phosphoprotein (pVASP) (S157) was similarly higher in MACC1-GFP 
overexpressing cells from 0 to 8 min and lower at 90 min with a concomitant activation 
decline over time (Fig. 30B). 
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Fig. 28: MACC1 exerts hyperactivated β-catenin signaling. A large set of protein and phospho-protein expression in 
response to HGF treatment (0, 1, 8, 90 min) was assessed by DigiWest. Bar graphs illustrate integrated signal strength of 
phosphorylated proteins normalized to respective total protein expression indicating activated or inactivated protein levels. 
(A) The inactivating phosphorylation of GSK3β at S9 and (B) the activating phosphorylation of β-catenin at S552 show an 
earlier and stronger activation in HCT116/MACC1-GFP vs. HCT116/GFP cells. Blue - GFP expressing cells; red - MACC1-GFP 
expressing cells. 
 
 
 
 
 
 
 
 
 
Fig. 29: MACC1 exerts hyperactivated FAK/SRC signaling. A large set of protein and phospho-protein expression in 
response to HGF treatment (0, 1, 8, 90 min) was assessed by DigiWest. Bar graphs illustrate integrated signal strength of 
phosphorylated proteins normalized to respective total protein expression indicating activated or inactivated protein levels. 
(A) Here, a drastic upregulation of SRC phosphorylation (Y416) was observed through MACC1-GFP overexpression. (B) The 
sequential, activating phosphorylations of FAK at Y379, Y576/577 and Y925 were earlier and stronger increased in 
HCT116/MACC1-GFP compared to HCT116/GFP cells. Blue - GFP expressing cells; red - MACC1-GFP expressing cells. 
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Fig. 30: MACC1 exerts hyperactivated cAMP signaling. A large set of protein and phospho-protein expression in response 
to HGF treatment (0, 1, 8, 90 min) was assessed by DigiWest. Bar graphs illustrate integrated signal strength of 
phosphorylated proteins normalized to respective total protein expression indicating activated or inactivated protein levels. 
The downstream effectors of cAMP signaling CREB and VASP were also affected by MACC1-GFP overexpression: (A) The 
phosphorylation of CREB at S133 demonstrated a faster and stronger activation cycle whereas (B) pVASP (S157) levels were 
basally increased and showed a decline over time. Only after 90 min they reached control cell level. Blue - GFP expressing 
cells; red - MACC1-GFP expressing cells. 
 
In general, the results in figure 27-30 demonstrate an activating influence of MACC1 on 
several central signaling molecules involved in different cellular pathways. In most cases, 
MACC1 overexpression leads to faster and/or stronger activation loops with already elevated 
baseline levels. 
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3.2.6 MACC1 exerts a hyperactivated signaling phenotype - PamChip® 
In an additional assessment of the signaling phenotype via the PamChip® assay, kinase 
activity was determined by using immobilized substrate sequences in the presence of whole 
cell lysate, ATP and anti-pY or anti -pS/T antibodies with fluorescent label. In this case 
SW480/ev and two different MACC1 overexpressing cell clones (SW480/MACC1 #10 and 
#43) as well as HCT116/GFP and HCT116/MACC1-GFP cells were compared. Figure 31 
shows the results for the STK activity. In general, MACC1 overexpression led to an elevated 
STK activity indicated by increased phosphorylation of most targets compared to control cells 
(blue dashed line). Interestingly, augmented phosphorylation of CREB (S129/S133) and 
VASP (S157) were observed confirming the DigiWest findings. This was accompanied by 
increased phosphorylation of further members of the cAMP signaling pathway: PKA 
regulatory subunits alpha (S92/S99/T104) and beta (T110/S114), Phosphorylase b 
kinase (S1018/1020/1023) and Aurora kinase A (S283/S284/T287/T288/T292).  
 
 
Fig. 31: MACC1 exerts a hyperactivated signaling phenotype - PamChip®. Kinase activity was determined with the 
PamChip® assay. Phosphorylation of several target proteins in the presence of whole cell lysates was measured with 
fluorescence labeled anti-pY or anti -pS/T antibodies. Results show relative phosphorylation increase of the respective 
target protein in MACC1 overexpressing cells (SW480/MACC1 and HCT116/MACC1-GFP, red lines) compared to control cell 
lines (SW480/ev and HCT116/GFP, blue dashed line). Phosphorylation of most target proteins is elevated through MACC1 
overexpression in the STK assay indicating higher STK activity. A subset of stronger phosphorylated target proteins is 
involved in cAMP dependent signaling (black arrows): CREB, PKA, phosphorylase b kinase, Aurora kinase A and VASP.  
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3.2.7 MACC1 exerts a hyperactivated signaling phenotype – validation 
For validation of DigiWest and PamChip® assays, we chose pSRC (Y416) and pCREB 
(S133) as target proteins in the HGF stimulation assay with subsequent WB. In figure 32 one 
representative WB and averaged spot densitometry bar graphs of two independent 
experiments are shown. pSRC levels are depicted in arbitrary units instead of fold changes 
due to the lack of a control value signal for HCT116/GFP at 0 min in one of the experiments. 
The results clearly illustrate that overexpression of MACC1 leads to a drastic induction of 
pSRC expression upon HGF treatment over time. Also, untreated cells already demonstrate 
higher expression levels than controls. In contrast, HCT116/GFP cells only show a brief and 
low pSRC expression increase with a decline already after 8 min and, further, after 90 min.  
Total as well as phosphorylated CREB levels were increased by MACC1 overexpression. 
More importantly, the ratio of pCREB/CREB, indicating the activated protein levels, was 
higher in HCT116/MACC1-GFP cells for all time points, especially at 0 and 1 min. We 
observed a time-dependent pCREB elevation until 8 min and decline after 90 min upon HGF 
treatment for both cell lines. In total, these results confirm the effects of SRC and CREB 
activation found by DigiWest thereby validating this assay. The activation of CREB as 
downstream effector of PKA/cAMP signaling additionally corroborates the findings of the 
PamChip® assay.  
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Fig. 32: MACC1 exerts a hyperactivated signaling phenotype – validation. To validate previous findings of DigiWest (3.2.5) 
and PamChip® (3.2.6) assay, pSRC (Y416) and pCREB (S133) levels under HGF treatment were determined with standard 
WB. (A) As seen with DigiWest, phosphorylation of SRC (Y416) is drastically increased in HCT116/MACC1-GFP compared to 
HCT116/GFP cells. A low and brief activation loop is observed for pSRC in GFP transduced cells whereas already high 
baseline levels (0 min) are further increased in MACC1-GFP overexpressing cells. (B) Similarly, pCREB shows higher baseline 
levels and stronger activation in HCT116/MACC1-GFP compare to HCT116/GFP cells. Expression of respective proteins 
determined with spot densitometry was normalized to vinculin (loading control) expression before normalizing pSRC to SRC 
and pCREB to CREB, respectively, indicating the level of active protein. Results represent means + SEM of two independent 
experiments. Blue - GFP expressing cells; red - MACC1-GFP expressing cells. 
3.2.8 Intervention in MACC1 signaling reveals new possible treatment strategies 
Currently, conventional cancer treatment strategies are increasingly supplemented or 
expanded with targeted intervention. Mostly, inhibitors of RTK signaling and downstream 
pathways are employed [162,326]. To apply this strategy to our findings, we wanted to 
evaluate the impact of different inhibitors on MACC1 induced signaling and function. For this, 
we conducted clonogenic assays in the presence of DMSO (control) or inhibitors of MET 
(Critzotinib, PHA-665752), SHP2 (GS493), MEK (Cobimetinib) or SRC (Dasatinib, Bosutinib, 
PP2). HCT116/GFP or HCT116/MACC1-GFP cells were seeded in 24-well plates at low 
density (200 cells/well), treated with respective drugs and colony formation was analyzed. 
Figure 33 shows the averaged colony covered area of at least three independent 
experiments with one representative example below. Values were normalized to control 
treated HCT116/GFP cell values (Fig. 33A; blue dashed line).  
MACC1 overexpression led to a significantly increased colony formation compared to control 
cells (Fig. 33A). Targeted intervention of the pathways previously identified to be induced by 
MACC1 (3.2.3 - 3.2.7) managed to abrogate this effect. All employed inhibitors of MET (Fig. 
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33B), SHP2/MEK (Fig. 33C) or SRC (Fig. 33D) reduced the reproductive viability of MACC1-
GFP cells to control cell level. Only Crizotinib, Cobimetinib and PP2 demonstrated minor 
effects on control cell colony formation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 33: Specific intervention in MACC1 signaling reveals new possible treatment strategies. Clonogenic assays in the 
presence of different inhibitors were performed. (A) Solvent (DMSO 0.1%) treated controls demonstrated a significantly 
augmented colony forming potential of HCT116 cells overexpressing MACC1-GFP compared to GFP control cells. (B) 
Treatment with inhibitors of MET (Crizotinib and PHA-665752), (C) SHP2 (GS493), MEK (Cobimetinib) or (D) SRC (Dasatinib, 
Bosutinib, PP2) reduced reproductive viability to control cell level. Colony covered area was normalized to values of solvent 
treated HCT116/GFP cells (blue dashed line) resulting in relative reproductive viability depicted in the dot plots. Results 
represent means of at least three independent experiments with one representative example illustrated below. Significant 
results were determined by t-test or one-way ANOVA and Turkey´s multiple comparison test with a confidence interval of 
95% (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001). 
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In summary, we identified and confirmed interesting interaction partners of MACC1 via a MS-
based screen and Co-IP. The interactors bind selectively to specific pY-sites on MACC1: 
pY365 – STAT5B; pY379 – GRB2 and SHP2; pY789 – SHC1. PLCG1 showed a more 
promiscuous binding pattern but favored the binding to pY379 and pY789 over their 
respective opposing peptide version. Mutation of two sites binding the majority of interactors 
(Y379F+Y789F) reduced MACC1-induced ERK activation, migration and proliferation in CRC 
cells. Furthermore, we demonstrated that MACC1 facilitates ERK signaling upon stimulation 
with HGF and EGF. By employing DigiWest and PamChip® assays, we added new layers to 
the MACC1 signaling landscape. Targeted inhibition of these new signaling axes restricted 
MACC1-promoted colony formation revealing novel intervention points for MACC1 as 
molecular target. 
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4. Discussion 
 
Despite the intensive research of the past decades, many cancer treatment strategies 
present unsuccessful. Lots of chemotherapeutics show only partial effectiveness while 
exerting tremendous side effects due to their cytotoxic properties. Molecular targeted therapy 
only affects a subset of patients [143,144,166-168].  
This is reflected in CRC as the second leading cause of cancer associated deaths worldwide 
[169]. Here, the development of distant metastasis represents a major challenge in therapy: 
the 5-year survival of about 10% could not be significantly improved over the last decades 
[106-108,170]. In addition, reliable and efficient biomarkers for early prognosis of disease 
course or selection of patients for specific treatment (prediction) remain scarce. The most 
commonly employed prognostic and/or predictive biomarkers are MMR status (MSI vs MSS) 
and mutations of RAS or BRAF [121,171-175]. Recently, combining of different biomarkers 
and molecular features resulted in consensus molecular subtypes (CMS), which should 
enhance patient stratification and targeted therapy [183]. This approach underlines the 
necessity for the establishment and application of new biomarkers for cancer treatment. One 
of the emerging biomarkers was identified in our group [100]: MACC1 has been established 
as prognostic, predictive and causal biomarker for several tumor entities [90,100,112,184-
214,216-232]. So far, only two MACC1 transcriptional inhibitors have been determined [274], 
which highlights the necessity for additional, possibly more potent treatment strategies. 
Unfortunately, the revelation of the precise MACC1 protein structure remains elusive which 
could facilitate the generation of potential MACC1 protein inhibitors. Additionally, the MACC1 
phospho-interactome as well as signaling pathways associated with MACC1 functionality 
have to be further elucidated. 
On this basis, this study aimed to find novel, more potent transcriptional inhibitors of MACC1 
and, additionally, illuminate the MACC1 signaling landscape to uncover new drug 
intervention points.  
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4.1 Transcriptional inhibition of MACC1 
4.1.1 HTS identifies statins as most potent inhibitors of MACC1 expression 
This study employed different strategies to identify possibilities of therapeutic intervention in 
high risk CRC patients by targeting MACC1 and MACC1-dependent signaling. Two 
distinguished screening methods built the foundation for these approaches. While the first 
approach demonstrated a rather classical HTS, the second one presented a newly 
developed method. This will be discussed in more detail later (4.2.1). 
HTS developed to be one of the most widely employed methods in drug discovery. Of 
course, technical advances such as new or improved screening and detection systems or 
automated processes furthered this development [327]. In principle, an HTS is designed 
according to target and hypothesis. It should identify compounds from large compound 
libraries that affect the target in the desired manner at optimally low concentrations [328]. To 
identify transcriptional inhibitors, we used a luciferase reporter under control of the target 
(MACC1) promoter - a system already successfully demonstrated by us and others 
[274,329,330]. Usually, so called lead compounds are discovered which will be subjected to 
further drug development processes, because the HTS is not able to assess all compound 
properties necessary for final drug discovery: e.g. bioavailability, pharmacokinetics, toxicity 
and specificity [328]. Therefore, we chose a tiered approach: first, false positives were 
eliminated in a counter screen using the same cell line expressing the luciferase gene 
controlled by a CMV promoter. Cytotoxicity was subsequently assessed to determine the 
most promising compounds. They were selected based on the largest ratio between drug 
effect on promoter activity and cytotoxicity. This therapeutic index is a widely used measure 
of safety and efficacy of potential drugs [331]. Four compounds emerged, all of which were 
initially discovered for different applications: Fluvastatin is a member of the hydroxy-3-
methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor family used for blood lipid 
reduction [332]. Bosutinib and PD173952 are inhibitors of tyrosine kinases of the SRC and 
Abelson murine leukemia viral oncogene homolog 1 (ABL) family whereas PD161570 was 
found to inhibit the FGF-1 RTK [333-336]. The selected compound libraries (NIH, 
Microsource and Prestwick) predominantly consisted of already known and FDA approved 
drugs. Drug repurposing or repositioning recently advanced as strategy to find alternative 
applications of already approved drugs differing from their initially intended use. This 
approach lowers risk, time and costs of drug development mainly by avoiding the preclinical 
testing for drug safety [337]. 
 
In vitro validation confirmed Fluvastatin as most promising effector of MACC1 expression. 
Most interestingly, our previous investigation for transcriptional inhibitors in an independent 
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HTS using the ChemBioNet compound library revealed other members of the statin family 
(Mevastatin, Lovastatin) [274]. This prompted us to evaluate all clinically applied statins for 
their effect on MACC1 expression: The strongest effect on MACC1 mRNA expression was 
found for Fluvastatin (IC50: 0.85 µM) followed by Lovastatin (IC50: 1.53 µM), Atorvastatin 
(IC50: 1.65 µM) and Simvastatin (IC50: 3.1 µM). Pitavastatin showed more varying results 
indicated by larger standard errors but overall reduced MACC1 expression. These results 
were also demonstrated on protein level. Only here, Atorvastatin performed better than 
Lovastatin. Pravastatin and Rosuvastatin hardly showed any effect on MACC1 mRNA and 
protein expression even at high concentrations (data not shown). Interestingly, these findings 
correlate with the hydrophobic/hydrophilic character of the statins: Pravastatin and 
Rosuvastatin present a higher hydrophilicity than the remaining hydrophobic statins [338-
340]. In general, all statins possess the active center with structural similarity to HMG-CoA 
responsible for HMG-CoA reductase (HMGCR) inhibition. Different core structures and 
residues attached to the active center determine the hydrophilicity and thereof metabolism as 
well as tissue distribution of the individual statins [341].  
The metabolism of hydrophobic statins is catalyzed by cytochrome P450 enzyme (CYP) 
isoforms 3A4 (Atorvastatin, Lovastatin, Simvastatin) and 2C9 (Fluvastatin) whereas 
Pravastatin and Rosuvastatin are excreted without major CYP metabolism [342,343]. More 
importantly, hydrophobic statins can penetrate cell membranes by simple diffusion 
processes. This allows a widespread tissue distribution in comparison to hydrophilic statins 
which necessitate active transport via membrane transporters such as organic anion-
transporting polypeptide (OATP1B1). OATP1B1 is only expressed in hepatocytes [342-344]. 
This would explain the differing effects of hydrophobic and hydrophilic statins on MACC1 
expression in vitro. Concomitantly, Menter and colleagues found a variety of cancer cell lines 
nearly unaffected in growth by Pravastatin (hydrophilic) whereas Simvastatin (hydrophobic) 
strongly reduced proliferation of most cell lines. None of the cancer cell lines of entities such 
as colon (i.a. HCT116), pancreas and liver expressed OATP1B1 mRNA or protein [345]. 
Interestingly, the membrane transport of Pitavastatin also partly depends on OATP1B1 [346]. 
This might explain the varying effects of Pitavastatin on MACC1 expression. Pitavastatin also 
undergoes only minor CYP dependent metabolism further supporting the similarities to the 
hydrophilic Pravastatin and Rosuvastatin [342,343]. 
  
As described above, the originally intended use of statins is the inhibition of HMGCR which 
represents the central enzyme in physiological cholesterol synthesis (Fig. 34). In this 
pathway, HMGCR catalyzes the reaction of HMG-CoA to mevalonate, a key precursor of 
cholesterol [347]. The resulting decrease in intracellular cholesterol levels triggers a cascade 
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leading to the increased expression of low-density lipoprotein (LDL) receptors on the cell 
surface. Lipoproteins are responsible for the transport of triglycerides and cholesterol through 
the blood. LDLs shuttle from the liver to distant sites whereas high-density lipoproteins (HDL) 
carry the lipids from the periphery to the liver for recycling and/or excretion. By increasing 
LDL receptors through statin intervention, LDL uptake and degradation is facilitated leading 
to physiological cholesterol levels in the cell and reduced lipid levels in the blood [348]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 34: The mevalonate pathway. Mevalonate is a central precursor of cholesterol, an important component of steroid 
hormones and the cell membrane. Other products of the mevalonate pathway, farnesyl-diphosphate (FPP) and geranyl-
geranyl-diphosphate (GGPP) are used for protein prenylation. These posttranslational modifications are necessary for 
proper protein (membrane-) localization and function. Statins inhibit the HMG-CoA reductase (HMGCR) to block 
mevalonate and subsequent cholesterol production. The resulting decrease in intracellular cholesterol levels triggers a 
cascade leading to increased cholesterol uptake and degradation in the cells [347-353]. 
 
Since the first approval in 1987, statins have been frequently employed in prevention and 
therapy of cardiovascular diseases [317,354,355]. Recently, several alternative applications 
of statins outside the scope of their blood lipid lowering properties have emerged. Statins 
have been found to modulate immune response, anti-inflammatory processes and signaling 
pathways which involve or depend on cholesterol precursors. Therefore, statin use is now 
connected to a variety of diseases such as multiple sclerosis, inflammatory bowel diseases, 
rheumatoid arthritis, systemic lupus erythematosus, HIV and cancer [348,356,357]. Several 
studies already reported the inhibiting effects of statins on tumor cell expansion in vitro and in 
vivo [358-368]. 
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In accordance with this, we demonstrated in this study that statins reduce MACC1-
dependent, malignant, cellular functions such as proliferation or colony formation and restrict 
tumor growth as well as metastasis formation in a xenografted mouse model for CRC. 
Previously, we already documented the effect of Lovastatin on MACC1-dependent migration 
and wound healing in vitro as well as tumor growth and metastasis formation in vivo [274]. 
With this study, we expanded the statin effect on MACC1 expression to nearly all members 
of the statin family and to further MACC1-dependent cellular functions. Most importantly, we 
demonstrated restricted tumor growth and metastasis formation with daily doses of 13 mg/kg 
body weight (compared to 100 mg/kg body weight [274]) which represents a human 
equivalent dose of approximately 1 mg/kg body weight [316]. This dose is commonly 
employed in blood lipid reduction therapy [317]. 
 
4.1.2 Statins specifically inhibit MACC1-dependent functions in vitro and in vivo 
Regarding the mode of action, we previously reported that statins hinder the binding of 
transcription factors AP-1 and SP1 to the MACC1 promoter leading to diminished 
transcriptional activation and MACC1 expression. In silico molecular docking analysis 
additionally showed that statins can competitively bind to the DNA binding pocket (leucine 
zipper) of AP-1 providing more insight into the mechanism of statins acting on MACC1 
expression. To proof the specificity of the inhibiting effect of statins on MACC1-dependent 
cellular functions, we ectopically overexpressed MACC1 under control of a different promoter 
(CMV promoter) which rescued in vitro migration and wound healing [274]. In this study, we 
corroborated these findings for MACC1-dependent proliferation and clonogenicity with the 
overexpression of either MACC1-GFP under control of a CMV promoter or MACC1 under 
control of a tetracycline responsive inducible promoter. Additionally, MACC1 knock-out led to 
strongly reduced proliferation which was not further reduced by statin treatment. In vivo, we 
found decreased amounts of MACC1 transcripts in the liver metastasis of statin treated 
xenografted mice in this as well as the previous study. Also, the mRNA expression of several 
other proposed transcriptional target genes of statins were not significantly modulated by 
statin treatment in vivo. Only Col1A1 expression was significantly reduced whereas HMGCR 
showed strikingly augmented mRNA expression [274]. Statin-induced HMGCR feedback 
induction has already been demonstrated by others as well [369]. Nevertheless, MACC1 
expression appears unaffected by HMGCR upregulation in vitro and in vivo in this and the 
previous study [274]. 
None of the observed effects was absolute and transcriptional inhibition of MACC1 cannot be 
claimed as the only mechanism of statins perturbing tumor development. This notion was 
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further supported by the finding that MACC1 expression in HCT116 cells was partly restored 
by replenishing culture medium with mevalonate (data not shown). Moon and colleagues 
further suggested the dependency of mevalonate pathway activity and subsequent 
vulnerability to statin treatment on P53 status in HCC [366]. This is also reflected in the data 
of this and our previous study [274]: The CRC cell lines with P53 wt (HCT116, SW48) show 
reduction of MACC1 expression at lower concentrations than these with mutated P53 (HT29, 
DLD1, SW620) indicating the potentially higher mevalonate pathway activity in these cell 
lines [366,370-372]. In an oncogene dependent context, the mevalonate pathway was shown 
to induce ERK signaling druggable with statins [373]. Thus, intervening in the mevalonate 
pathway interferes in the proposed MACC1/MET/ERK/MACC1 positive feed-back loop 
providing a potential mechanism for the effect of statins on MACC1 expression independent 
of transcriptional inhibition [215]. 
The mevalonate pathway further provides crucial end-products such as farnesyl-diphosphate 
(FPP) and geranyl-geranyl-diphosphate (GGPP) important for protein isoprenylation. These 
posttranslational modifications are necessary for proper protein (membrane-) localization and 
function [349-352]. Central prenylation targets are members of the RAS and RHO GTPase 
families involved in cancer cell proliferation and invasion [374-378]. Many studies showed 
decreased proliferation and invasiveness of tumor cells from different entities by targeting 
protein prenylation with statins [365,379-389]. We found possible interactions of MACC1 and 
different RHO GTPases such as RHO A, RAC1 and CDC42 by MS (unpublished data). 
These RHO GTPases can form complexes modulating cellular polarity thereby aggravating 
cancer cell migration and invasion at the leading edge of the tumor [390,391]. MACC1 was 
also shown to accumulate at the tumor front and tumor budding cells [230]. This indicates a 
potential association of these proteins to drive tumor invasion at the invasive front. 
Furthermore, in silico prediction of the MACC1 protein structure demonstrated a suggested 
farnesylation site providing an additional possible target for statin interference with MACC1 
function (unpublished data).  
 
The main effect conferred by statins on the molecular level represents cell cycle arrest: 
Statins have been found to regulate cell cycle on several levels via cyclin A, D1, E, Cyclin-
dependent kinases (CDK) 2 and 4, p21, p27, P53, Checkpoint kinase (CHK) 1 and cell 
division cycle (CDC) 25 phosphatase in different tumor entities [360,367,386,392-396]. 
Recently, Wang et al. demonstrated restricted HCC growth through Simvastatin in vitro and 
in vivo. Here, statin treatment reduced phosphorylation of STAT3 leading to a downstream 
cascade which resulted in cell cycle arrest [358]. Another study suggested that statin 
treatment interfered with cell membrane cholesterol composition with subsequent ligand-
78 
 
independent FAS activation and apoptosis [397]. Interestingly, our group showed that 
MACC1 knock-down also reduced phosphorylation of STAT1 and STAT3 leading to 
increased sensitivity of tumor cells to death receptor (i.a. FAS)-mediated apoptosis [268]. 
Beckwitt and colleagues further suggested the involvement of AKT signaling in statin-
mediated restriction of cancer cell growth [398]. MACC1 has already been demonstrated to 
govern cell cycle progression through PI3K/AKT signaling and expression of several target 
genes, such as cyclin B, D1, D2, E, c-MYC, and SPON2 whereas MACC1 silencing - 
independent of interference in the mevalonate pathway - led to cell cycle arrest 
[221,236,237,250,251,267,271,272]. This underlines the specificity of the statin effect on 
MACC1 and mediated functions in vitro and in vivo presented in this study.  
In total, we can observe complex and multilayered mechanisms of statins intervening in 
tumor growth and development. The disturbance of the mevalonate pathway and subsequent 
molecular consequences represents a central process, but the transcriptional inhibition of 
MACC1 is a non-neglectable parallel mode of action. There are also different possible 
intersections or mergers of both functional interventions as described in this chapter. 
However, the striking potential of repurposing statins for therapy or prevention of cancer 
(chemoprevention [399]) is obvious and will be discussed in the following chapter. 
 
4.1.3 Statins for cancer therapy and prevention in the clinics 
Chemoprevention was firstly introduced by Sporn and colleagues in 1976, when they 
investigated vitamin A and synthetic analogs for their cancer preventive potential [400]. It 
describes the continuous application of pharmacologically active substances to inhibit, delay 
or reverse the onset of cancer. Several agents of different categories haven already been 
employed, researched or discussed such as hormonal agents (e.g. tamoxifen), dietary 
agents (e.g. different vitamins or calcium), vaccines (e.g. hepatitis B virus and human 
papilloma virus) or pharmaceuticals (e.g. aspirin or metformin) [399,401].  
The use of statins as chemopreventive agent is controversially discussed in the scientific 
literature: Some meta-analyses report the risk reduction potential of statins for different 
entities [402-405] whereas others observed no such effects [406-409]. Numerous further 
studies provide evidence pro chemopreventive effects of statins: Poynter and colleagues 
found a 47% reduced risk for colorectal cancer with statin use while Voorneveld et al. 
observed a 34% risk reduction [410,411]. Others showed weaker effects for CRC: HR 0.71 
and HR 0.84, respectively [412,413]. The risk for pancreatic cancer was found to be lowered 
through statins by 39%, 34% or not significantly (OR 0.93) [414-416]. Statin effect on gastric 
cancer risk presented contradictory with RR 0.56, HR 0.83 and RR 1.37 [417-419]. 
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Interestingly, statin use decreased the risk of bone metastasis of breast cancer patients (OR 
0.49) and was linked to better overall survival of patients with metastatic pancreatic cancer 
[420,421]. We support these observations with the findings of this study that statins abate 
MACC1 expression in CRC, pancreatic and gastric cancer cells and specifically inhibit 
MACC1-mediated functions in vitro. More importantly, we demonstrated that statins hinder 
tumor growth and metastasis formation in a xenografted mouse model for CRC metastasis at 
concentrations equal to those used for standard statin therapy in humans [316,317]. In 
cooperation with the Preissner group at the Charité, we further applied a real-world evidence 
(RWE) study design to a large transatlantic cohort of 53,113 cancer patients. Here, statins 
presented an overall cancer risk reduction of 50%. We additionally identified strong risk 
reductions for individual cancer entities and metastasis by different statins (Gohlke & Zincke 
et al., submitted). 
Obviously, the results of clinical trials strongly depend on study design including cohort 
population and randomization as well as vulnerability to certain bias [422]. Modern clinical 
trials certainly try to decrease the influence of bias and follow precise protocols to ascertain 
proper data generation and evaluation. By application of these strict criteria, especially for 
patient enrollment, they partially disregard the real-world situation with higher variability in 
patient age, disease severity or comedications and comorbidities. Moreover, present 
expanses for clinical trials are high, with predictions of increase, and they consume a lot of 
time and resources. To account for this, generation of RWE has gained increasing interest. It 
makes use of the expanding electronic health records and administrative data which 
consistently monitor and reflect patient health status and care [423,424]. 
Because of the usually long latency of a treatment effect and the predominant fatality of 
cancer diagnosis, the discovery and employment of biomarkers is inevitable for 
chemoprevention [399]. They help identifying the population at high risk for a certain disease 
course (prognostic biomarker) or can predict responsiveness to treatment (predictive 
biomarker) [425]. In view of the current literature and our present data, we recommend 
chemoprevention with statins in patients stratified for MACC1 expression. This is especially 
sensible because MACC1 serves as direct target of statins. For the evaluation of the 
predictive character of MACC1 upon statin treatment, more clinical research is warranted.  
Here, a combined approach with P53 status might be of interest as Moon and colleagues 
independently suggested P53 status as prognostic and predictive marker for statin therapy 
[366]. 
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4.2 MACC1 phospho-interactome and signaling landscape 
4.2.1 MACC1 interacts with crucial proteins promoting a malignant phenotype 
The second part of this study intended to uncover more details of the MACC1 signaling 
landscape, thereby revealing potential drug intervention points. As previously indicated, it 
was based on an MS screen to identify interactions of tyrosine-phosphorylated MACC1. 
Tyrosine phosphorylation represents a crucial mechanistic switch in signal transduction. 
Phosphorylation of specific Y-sites mostly leads to an activation of the respective protein. 
Phosphorylated tyrosines (pY) additionally serve as docking sites for SH2 domain containing 
proteins, thereby fostering downstream signaling [296-299]. Therefore, we aimed to identify 
pY-dependent interactions of MACC1 in CRC. The MS screen was originally set up and 
employed for kinase inhibitor profiling: It used sepharose-immobilized kinase inhibitors 
(kinobeads) to pull down kinases from kinase inhibitor treated or untreated cell lysates to 
determine binding inhibition and competition [313,426,427]. Here, we applied tyrosine-
phosphorylated peptides, representing all potential pY-sites on MACC1, as affinity tools to 
pull down interactors from whole cell lysates of SW480 and SW620 CRC cells as well as 
human placenta tissue. Placenta tissue is an easily accessible human primary tissue 
expressing a large variety of proteins: 69% of all human proteins were found to be expressed 
in placenta tissue compared to a 44% expression baseline detected in most other tissues 
[319-321]. Therefore, placenta served as control tissue.  
For further analysis, we focused on interactors identified in both screens and all tissues. 
Here, five interactors known to be involved in RTK signalosome formation and downstream 
signaling particularly piqued our interest: GRB2, SHP2, SHC1, STAT5B and PLCG1 [42,44-
56]. In order to biochemically validate the findings of the MS screen, we selected Co-IP 
experiments as one of the established standard methods for identification and verification of 
protein-protein interaction [322]. All five interactions were confirmed in SW480/MACC1 and 
SW620 cells.  
The initial screen already indicated the binding of the interactors to specific pY-sites on 
MACC1. With further pull-down experiments using the respective phosphorylated and 
unphosphorylated pY-peptides, we showed the selective binding of SHP2 and GRB2 to the 
phosphorylated Y379 peptide whereas SHC1 and STAT5B interacted with pY789 and 
pY365, respectively. PLCG1 binding was rather unspecific: It showed the strongest 
interaction with pY379 followed by pY789 and contradicting results for Y365. This prompted 
us to perform SDM at the respective pY-sites to evaluate their functional potential. First, we 
focused on the interaction sites Y379 and Y789 which bind the majority of interactors: GRB2, 
SHP2, SHC1, PLCG1. All of these have been found to regulate cellular signaling like the 
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ERK pathway governing many decisive processes such as proliferation or migration 
[23,42,44-56].  
Indeed, we found impaired migration and proliferation in CRC cells expressing MACC1-GFP 
carrying mutations at Y379 and Y789 (Y379F+Y789F) compared to those expressing wild-
type MACC1-GFP. They showed migration close to and proliferation on control cell level. 
Moreover, we demonstrated that HGF-induced ERK activation was reduced upon mutation of 
these sites. This indicates a strong influence of MACC1 phosphorylation status (Y379+Y789) 
and mediated signaling via the associated interactions on these cellular processes in CRC. 
This is a phenomenon already observed in different studies. For instance, phosphorylation 
and subsequent SHP2 binding of Y627 and Y659 on GAB1 has been shown to be crucial for 
downstream activation of the ERK pathway in response to different stimuli such as HGF, 
EGF, VEGF, Lysophosphatidic acid (LPA) or interleukin-6 (IL-6). GAB1 with mutations at 
these sites failed to mediate corresponding biological functions in vitro and in vivo including 
cell migration, cytoskeletal reorganization or organ development [52,53,428-435]. Bertotti 
and colleagues demonstrated the importance of (by MET) phosphorylated tyrosine sites 
Y1257, Y1440 and Y1494 on β4-integrin for SHP2 binding and downstream signaling. 
Mutation of these sites prevented SHP2 binding thereby reducing anchorage-independent 
growth of breast cancer cells via a SHP2-SRC-GAB1-GRB2-ERK axis [436]. 
Preliminary Co-IP data further showed that the binding of all four interactors to MACC1 is 
abrogated upon mutation of both pY-sites, but more work is needed to finally validate these 
findings. Based on our current results, the most probable route of interaction occurs between 
the pY-site on MACC1 and the SH2 domain occurring in all interactors. SH2 domains present 
approximately 100 amino acid long protein elements that specifically recognize and bind pY-
sites. The surrounding amino acids of the pY-site ranging from -2 to +4 (in some cases even 
-6 to +6) position play a crucial role in the selectivity for the target protein [297,437,438].  
For instance, the SH2 domain of SHC1 preferentially binds pYXXФ motifs, where X 
represents a random and Ф a hydrophobic amino acid, which fits to the MACC1 sequence at 
Y789 (pYDFL) [439]. GRB2 characteristically interacts with motifs such as pY(L/V)N(V/P) 
[438,440]. The corresponding sequence on MACC1 at Y379 (pYIHP) shows close 
similarities: While the proline (P) already fits the motif, valine (V) or leucine (L) could be 
substituted by their close relative isoleucine (I) since they only differ in occurrence or position 
of one methyl group, respectively. GRB2 is also able to bind the pYVNV motif on SHC1 
providing the additional possibility of indirect interaction with MACC1 [441]. STAT5 has been 
shown to predominantly interact with motifs harboring an acidic amino acid (e.g. aspartic 
acid, D) in -1 and aliphatic amino acids such as leucine, isoleucine or valine at +1 and +3 
position of the pY which also presents a strong overlap with the suggested Y365 (DpYIHK) 
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binding site on MACC1 [442]. SHP2 prefers binding to so called immuno-receptor tyrosine-
based inhibitory motifs (ITIMs): (I/V/L)XpYXX(I/V/L) [443]. While this motif is not specifically 
found at Y379 on MACC1, newer findings suggest a binding dependence on aliphatic amino 
acids at +1 and +3 position and a significant involvement of large hydrophobic or positively 
charged amino acids at +4 and/or +5 position [444,445]. This, in contrast, occurs on MACC1 
with an isoleucine at +1 and a phenylalanine (F) at +5 position of Y379 (pYIHPSF) 
supporting the proposed SH2-dependent interaction. Known and potential binding motifs of 
proteins interacting with PLCG1 SH2 domains comprise following sequence: 
pY(I/V/L)X(I/L/V/P) [438]. This also clearly resembles the Y379 site of MACC1. PLCG1 has 
been found to interact with a wide variety of proteins and additionally binds phospholipids via 
its SH2 domains [446-448]. Therefore, motif selectivity and specificity might present rather 
promiscuous which supports our pull-down data.  
In general, none of these motifs provide absolute assurance of specific interaction 
considering the small protein-protein interface. Best physiological binding is also not 
inevitably achieved by the most precise interaction motif. The recurring use of small domains 
and motifs however promoted the development and complexity of cellular functions by 
enhancing protein networking independent of gross changes in proteins or gene number 
[449]. On the other hand, this high level of flexibility and redundancy is one of the major 
issues in cancer and cancer therapy, respectively (see 1.2.2 and 1.2.4).  
Besides the SH2 domain dependent binding of MACC1 pY-sites, there are additional 
potential modes of interaction (Fig. 35): SHC1 contains a phosphotyrosine binding (PTB) 
domain with similar function as the SH2 domain. It preferentially binds to NPXpY motifs, 
which also displays similarities with the Y789 (KPApY) site on MACC1. Additionally, it 
harbors a proline-rich domain which can interact with the SH3 domain in MACC1 [439,450-
452]. PLCG1 and GRB2 respectively possess one and two SH3 domains able to bind to the 
proline-rich domain of MACC1 [453,454]. SHP2 provides an additional catalytic protein 
tyrosine phosphatase (PTP) domain for the execution of its protein dephosphorylating 
functions. This demonstrates substrate specificity for motifs containing one or more acidic 
(and aromatic hydrophobic) amino acids on both sides of the pY-site [455]. While these 
conditions are not met by the Y379 site (IYGPKpYIHPSF), Y365 (ATIWDpYIHKTT) or Y789 
(MWKPApYDFLYT) might serve as substrate for SHP2. Catalytic activity usually 
necessitates the release from the autoinhibitory intramolecular interaction between the PTP 
and the N-terminal SH2 domain [456-458]. Therefore, a SH2 domain dependent binding to 
Y379 with subsequent dephosphorylation of Y365 or Y789 with possible negative regulation 
of MACC1 activity presents a possible model. SHP2, however, is predominantly associated 
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with the activation of several signaling pathways and cellular processes [455,456,459]. This 
will be discussed in more detail later. 
 
 
 
 
 
 
 
 
 
Fig. 35: Possible MACC1 domain interactions. Domain architecture of MACC1 and interactors provide several possibilities 
of interaction. The current results and binding motif sequences suggest binding of SH2 domains to distinct pY-sites on 
MACC1: SHP2, GRB2 and PLCG1 – pY379; SHC1 – pY789; STAT5B – pY365. Further binding opportunities exist between 
respective SH3 domains and proline rich sequences as well as the phosphotyrosine binding (PTB) domain and a pY-site. ZU5 
- zonula occludens 1 and uncoordinated protein 5 resembling domain; uncoordinated protein 5 (Unc5), p53-induced death 
domain protein 1 and ankyrins resembling domain; SH2 - Src homology 2 domain; SH3 - Src homology 3 domain; DD - death 
domain; PH - Pleckstrin homology domain; PRD - proline rich domain; PTP - protein tyrosine phosphatase domain; C2 – C2 
domain; X and Y – catalytic domains; CH1 – CH1 domain 
 
In addition to the example of SHP2, there is a multitude of possibilities how different protein 
domains can cooperate or interfere with each other: Another negative regulation is observed 
in the competition of adjacent binding motifs. For instance, the chromo domain of 
heterochromatin protein-1 (HP1) binds the trimethylation of K9 on histone H3, which 
quenches gene expression. To reactivate this process in cell division, Aurora B kinase 
phosphorylates the juxtaposed S10 of histone H3 leading to the loss of interaction with HP1 
[460,461]. To increase binding affinity and specificity, neighboring domains can attach to 
parallel motifs such as the SH2 domains of ζ-chain (T-cell receptor)-associated protein 
kinase 70 kDa (ZAP-70). One domain can also recognize multiple motifs like cell division 
cycle-4 (CDC4) only interacts with inhibitor of cyclin-dependent protein kinase-1 (SIC1) after 
phosphorylation of at least six S/T residues [462-464]. Cooperative domain interactions can 
also occur in a sequential pattern: Recruitment of the casitas B-lineage lymphoma proto-
oncogene (CBL) to phosphorylated RTKs via its SH2 domain leads to ubiquitination of 
adjacent K residues providing docking sites for proteins involved in subsequent receptor 
endocytosis [465]. One of the most famous examples is the sequential formation of signaling 
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complexes at RTKs usually mediated by the central (multi)adaptor proteins GRB2, SHC1 and 
GAB1 [42,48,466]. 
In total, all these possible module and motif interactions, let alone the fact that five interactors 
potentially compete for three pY-sites, warrants further investigation in the spatiotemporal 
regulation of MACC1 signalosome formation (see 4.3). 
 
All MACC1 interactors have been found to be involved in crucial cellular processes. SHP2 
associates with GAB1 to mediate several functions including cell migration, cytoskeletal 
reorganization or organ development mainly via the activation of RAS/ERK signaling 
[52,53,428-435]. A few studies link SHP2 mutations to the development of different 
leukemias or cancers of colon, breast and skin [467-473]. SHP2 has also been found to 
promote growth and progression of lung and breast cancer as well as glioblastoma in vitro or 
in vivo [54,436,474,475].  
GRB2 is a key adaptor protein linking RTKs to their downstream effector proteins. In most 
scenarios, it is continuously bound to SOS, a GEF catalyzing the RAS activation reaction, via 
its SH3 domain. It promotes signal transduction by linking SOS and RAS to the activated 
RTK (e.g. EGFR, MET, PDGFR) via its SH2 domain [454,476-478]. By recruiting GAB1 to 
RTKs, GRB2 can also mediate further signaling responses through PI3K, PLCG1 or STATs 
[42,47,48,52,466]. Increased GRB2 expression or function have been linked to tumor 
progression and metastasis formation in different entities such as breast, bladder and 
colorectal cancer [479-487].  
In a similar manner, SHC1 mainly functions as adaptor between RTKs and the GRB2-SOS 
or GRB2-GAB1 complex, thereby modulating downstream signaling [466,488,489]. 
Consequently, SHC1 has also been reported to be implicated in oncogenic events, especially 
malignant cell transformation and metastasis, e.g. in breast or colorectal cancer [485,489-
493]. 
Upon receptor stimulation, PLCG1 is recruited directly or indirectly via GAB1 to the receptor 
and its substrate phosphatidylinositol(4,5)bisphosphate (PIP2). By hydrolysis, it generates the 
second messengers inositol(1,4,5)trisphosphate (IP3) and diacylglycerol (DAG) which in turn 
control several distinct cellular processes. Also independent of this enzymatic function, 
PLCG1 has been found to influence functions such as actin cytoskeleton reorganization, 
migration and proliferation [494-503]. Some of these functions are exploited in cancers or 
cancer cells of breast, head and neck or prostate to drive progression and metastasis [504-
508]. 
STATs are usually directly recruited to the activated receptor leading to their 
phosphorylation, dimerization and nuclear translocation with subsequent induction of target 
85 
 
gene transcription [509]. The phosphorylation of STAT5B has been shown to depend on 
GAB1 expression: GAB1 overexpression led to increased SHP2 phosphatase activity 
dephosphorylating its substrate STAT5B [432,510,511]. Besides different physiological 
activities, STAT5B is involved in several tumorigenic processes, e.g. in cancers of the 
hematopoietic system, prostate or head and neck [509,512-515]. 
Interestingly, all MACC1 interactors show spatiotemporal and/or functional association with 
GAB1. The apparent similarities between MACC1 and GAB1 and their possible 
consequences should be investigated in more detail. This will be discussed later (4.3).  
4.2.2 MACC1 rewires cellular signaling networks to exert malignant functions 
In view of the previously iterated literature and our findings that MACC1 overexpression 
facilitates ERK activation in CRC cells, we were interested to further illuminate the MACC1 
signaling landscape. For this, we employed the recently developed methods of DigiWest and 
PamChip® assay. With both methods, we confirmed and extended our knowledge of MACC1 
signaling. We found the phosphorylation of several proteins to be upregulated in MACC1 
overexpressing CRC cells. These proteins are involved in different crucial signaling pathways 
indicating a central role for MACC1 in the control of their activity. 
We demonstrate the hyperactivation of ERK signaling by MACC1 overexpression indicated 
by the increased phosphorylation of activating sites on MEK, ERK1/2 and RSK [58]. MACC1 
has already been shown by us and others to exert some of its tumorigenic effects via ERK 
signaling [100,191,208,233,241,243,244,250,267-270]. Here, we revealed a more precise 
picture including signal strength and duration. Moreover, we demonstrated that MACC1 
facilitates ERK signaling in response to HGF and EGF.  
MACC1 has been shown to induce β-catenin signaling leading to increased expression of 
target genes such as MYC, Cyclin D1/E and MMPs [237,250]. The MACC1/AKT/β-catenin 
axis also confers chemoresistance and stemness characteristics such as sphere formation 
by activating EMT [219,221,223,225,253]. This study corroborated the induction of β-catenin 
via MACC1: The inactivating phosphorylation of GSK3β, a negative regulator of β-catenin, at 
S9 and the activating phosphorylation of β-catenin at S552 were upregulated by MACC1 
overexpression. Both phosphorylations have been shown to be conferred by AKT and PKA 
[75,516-521]. While a MACC1/AKT/β-catenin axis has been established already (see above), 
AKT activity was not increased in the experimental set-up of this study. More interestingly, 
several members of cAMP/PKA signaling including PKA (regulatory subunit alpha - pS99 and 
regulatory subunit beta - pS114) and its downstream effectors CREB (pS133) and VASP 
(pS157) showed elevated activity upon MACC1 overexpression [522-527]. VASP connects 
upstream signaling to cytoskeleton dynamics and, therefore, controls processes such as cell 
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adhesion, polarity and motility [526]. CREB is involved in multiple physiologic and 
homeostatic functions and in vivo knock-out has been shown to be lethal. It can act as 
transcription factor to drive genes implicated in proliferation, survival and migration. 
Consequently, overexpression and increased activity haven been found to enhance tumor 
progression and metastasis [528]. In addition, β-catenin and CREB have recently been found 
to associate in the promotion of lung cancer [529].  
FAK stimulation is usually triggered by integrin clustering, i.e. when cells interact with the 
extracellular matrix. This interaction mediates autophosphorylation of FAK at Y397, a central 
binding site for SRC. Recruitment of SRC leads to its activation via phosphorylation at Y416. 
In turn, SRC catalyzes the phosphorylation of Y576/577 and Y925 on FAK resulting in its full 
activation [530,531]. We found that MACC1 overexpression strongly enhanced the 
phosphorylation of all these five presented sites indicating a clear activation pattern of this 
pathway. Now, PI3K can bind to pY397 whereas GRB2 interacts with pY925 of FAK. 
Together with SRC, these interactions link FAK to a multitude of signaling pathways, such as 
PI3K and ERK, involved in cell survival, invasion and migration. In consequence, FAK and 
SRC have also been shown to drive tumor progression and metastasis [530-533]. With these 
findings, we added several new layers to the MACC1 signaling landscape underlining its 
strong impact on shaping a tumorigenic and metastatic phenotype (Fig. 36). 
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Fig. 36: MACC1 signaling landscape with additional layers. This study revealed several new layers of MACC1 signaling. 
MACC1 interacts with central signaling components (GRB2, SHP2, SHC1, PLCG1, STAT5B) governing different signaling 
cascades involved in the control of proliferation, migration and survival. MACC1 was newly found to facilitate FAK/SRC and 
PKA/CREB/VASP signaling. MACC1 – metastasis associated in colon cancer 1; MET - MET receptor tyrosine kinase; HGF – 
hepatocyte growth factor; GRB2 - growth factor receptor-bound protein 2; SOS - son of sevenless; RAS - rat sarcoma viral 
oncogene homolog; RAF - v-Raf murine sarcoma viral oncogene homolog; MEK - MAPK/ERK kinases; ERK - extracellular 
signal–regulated kinase; AP-1 - activator protein 1; SP1 - specificity protein 1; STAT1/3/5 - signal transducer and activator of 
transcription 1/3/5; SHC1 - SHC-transforming protein 1; SHP2 - SH2 domain-containing phosphatase 2; PI3K - 
phosphoinositide 3-kinases; MCL-1 - induced myeloid leukemia cell differentiation protein; NANOG - homeobox protein 
NANOG; SPON2 - spondin 2; AKT – protein kinase B; GSK3β - glycogen synthase kinase 3 beta; Dvl - dishevelled protein; APC 
- adenomatous polyposis coli; CK1α - casein kinase I alpha; LRP - lipoprotein receptor-related protein; RAGE - receptor for 
advanced glycation endproducts; S100A4 - S100 calcium-binding protein A4; FAK - focal adhesion kinase; SRC - non-receptor 
tyrosine kinase SRC; PKA – protein kinase A; AC - adenylate cyclase; ATP - adenosine triphosphate; GTP - guanosine 
triphosphate; cAMP - cyclic adenosine monophosphate; VASP - vasodilator-stimulated phosphoprotein; CREB - cAMP 
response element-binding protein. 
 
Interestingly, most of the target proteins demonstrate similar phosphorylation patterns 
indicating stringent activation loops. These patterns are typically found in signaling pathways 
and represent their internal negative feedback loops [534,535]. A very prominent example is 
the ERK pathway: Activated ERK confers negative phosphorylations to its upstream 
regulators SOS, RAF and MEK thereby suppressing its own activity [536-539]. As described 
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above (1.2.2), aberrations in these tightly controlled signaling cascades can have detrimental 
consequences. Already minor changes can exert a major impact on cellular function: 
Duration and strength of ERK signaling have been found to strongly determine cell fate by 
altering the downstream transcription machinery and subsequent expression patterns of 
target genes [540-542]. Newer findings show that phosphorylation and recruitment events 
upon receptor stimulation already happen within a timeframe of seconds [543,544]. This 
further emphasizes the influence differences in signal strength or duration within minutes - as 
observed by us and others - can impact on cellular fate [545-547]. Another study showed that 
the closely related ligands FGF-7 and FGF-10 steer cells to distinct functions (proliferation or 
migration) through individual signaling duration routines [548]. In this regard, it is very 
interesting to note that signal duration is determined dependent on the recruitment of SH3 
domain-binding protein 4 (SH3BP4) to FGFR. SH3BP4 presents an almost 50% sequence 
homology to MACC1 [100].  
Besides self-controlling mechanisms, signaling pathways intertwine to compensate or 
congregate with each other, leading to a highly dynamic and precisely adjusted network 
[26,535]. An ideal example for this presents the signal amplifier GAB1. In a basic setting, 
GAB1 recruitment to the plasma membrane depends on generation of PIP3 binding sites in 
the membrane by PI3K and a phosphorylation of GAB1 by ERK on S552 to release the PH 
domain from its inactive state. Membrane-bound GAB1 harbors interaction sites for PI3K and 
the GRB2-SOS-RAS complex which increases downstream signaling of both pathways 
through positive feedback. Upon growth factor binding, GAB1 is predominantly recruited to 
the RTK promoting RAS-ERK signaling with reduced influence of PI3K activity. Continuously 
increasing RAS-ERK signaling negatively feeds back to GAB1 balancing the receptor 
response. The GAB1 amplifying effect has been found to be essential in response to low 
growth factors signals [64,549-551]. Apparently, GAB1 presents a key player in mediating 
downstream signaling below different RTKs. As described above, all RTKs generally involve 
only a certain set of adaptors and mediators, which shares a great overlap among them. The 
signaling response differs depending on recruitment partners and 
patterns [48,449,466,535,543,552]. Our finding that ERK signaling was facilitated by MACC1 
overexpression also in response to EGF supports this notion. It further suggests that MACC1 
can act as malignant signaling mediator below several RTKs. We have preliminary data 
demonstrating MACC1-dependent upregulation of ERK signaling in response to FGF, PDGF, 
IGF and VEGF, but more work has to be done to validate these findings. 
In consideration of the current literature, MACC1 signaling harbors possible key players: 
SHP2, SRC and PKA. SHP2 has already been proven to be a central mediator of RTK 
downstream signaling, governing different cellular responses involved in tumorigenesis and 
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metastasis [52-54,428-436,467-475]. More interestingly, several studies found that SHP2 
exerts its functions via the activation of SRC [436,553-555]. Concomitantly, SRC has been 
shown to act downstream of several RTK such as MET, EGFR and PDGFR. On the other 
hand, SRC is also able to directly phosphorylate different RTKs leading to their activation 
[530,556]. Song and colleagues interestingly demonstrated the interdependency of MET, 
EGFR and IGFR signaling with SRC as central mediator in HCT116 and HT29 CRC cells 
[557]. SRC has also been shown to elicit a GAB1 signaling response dependent and 
independent of MET [558,559]. Moreover, a recent study revealed that SRC induced breast 
cancer in a PKA-dependent manner in vivo. Here, Beristain and colleagues further 
demonstrated that low PRKAR1A (leading to increased PKA activity)/high SRC expression 
characterizes basal-like and HER2 breast tumors with poor prognosis [560]. It is worth 
mentioning that some studies suggest an SRC-STAT5 axis promoting malignant phenotypes 
[561-563]. In our experimental setting however, we could not observe an elevated STAT5B 
activation at Y699 with MACC1 overexpression in response to HGF (results not shown), but 
this might present a mode of action in another cellular context depending on growth factor 
and entity.  
On this basis, we propose the novel MACC1/SHP2/SRC/ERK and MACC1/PKA/SRC/CREB 
axes conferring a malignant phenotype in response to different growth factor signals. So far, 
only very little is known about a link of RTKs to PKA signaling [564]. MACC1 might present a 
new connection of these pathways. In total, our data suggest that MACC1 is able to rewire 
the finely tuned pathway networks to promote specific routes of signaling, resulting in tumor 
enhancing and metastasis inducing functions. 
4.2.3 Intervention in MACC1 signaling reveals new possible treatment strategies 
Finally, to validate our signaling findings on the functional level and reveal potential drug 
intervention points in MACC1-dependent signaling, we preformed clonogenic assays in the 
presence of distinct inhibitors. We chose inhibitors of MET (Critzotinib, PHA-665752), SHP2 
(GS493), MEK (Cobimetinib) or SRC (Dasatinib, Bosutinib, PP2) to interfere with the newly 
discovered MACC1 pathways. Interestingly, all inhibitors restricted MACC1-induced colony 
formation to control cell level.  
More than half of the inhibitors used in this study have already been employed in clinical 
settings and, therefore, present ideal candidates for time and cost efficient drug repurposing 
in the context of MACC1 signaling [337]: Crizotinib is an ATP mimetic found to inhibit the 
RTKs MET, ALK and ROS-1. It has been employed in several clinical studies predominantly 
for the treatment of lung cancer and was firstly FDA approved in 2014 for the treatment of 
ALK positive advanced or metastatic non-small cell lung cancer. Further clinical 
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investigations including other entities are ongoing [565-570]. Crizotinib has also been 
reported to be effective in treatment of CRC in vitro and in vivo [571-573]. PHA-665752 
blocks the phosphorylation of MET at Y1234/1235 and with this its catalytic activity. While it 
has not been used in clinical trials, PHA-665752 showed cancer inhibiting effects in vitro and 
in vivo in different entities such as ovarian cancer, melanoma and CRC [574-578]. 
GS493 is a very recently emerged, competitive inhibitor of SHP2. The group of Birchmeier 
and colleagues developed it and demonstrated its efficacy in tumor inhibition for lung, breast 
and pancreatic cancer in vitro and in vivo [56,579,580]. Cobimetinib, a MEK1/2 inhibitor, has 
reported effects in the treatment of CRC and melanoma in different clinical trials usually in 
combination with other therapeutic agents [581-583]. It received its first FDA approval for the 
treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in 2015, but 
more clinical trials with different indications are in progress [584,585]. 
Dasatinib, an inhibitor of the kinases SRC and ABL, was approved by the FDA for the 
treatment of chronic myeloid leukemia in 2006. It has been shown to exert moderately 
positive effects in clinical trials for entities such as breast and prostate cancer whereas 
further trials are ongoing [586-588]. Clinical trials for CRC presented unsuccessful, but 
Dasatinib was effective in vitro and in vivo [589,590]. Another SRC/ABL inhibitor, Bosutinib, 
was also approved for CML treatment in 2013. Bosutinib further demonstrated positive 
therapeutic activity in patients with advanced breast cancer and moderate response in other 
solid tumors including CRC [591-593]. Further clinical trials are in progress [594]. Bosutinib 
has also been reported to reduce CRC growth in vitro and in vivo [595,596]. While PP2 has 
not been applied to clinical trials yet, Bertotti and colleagues showed that it inhibits 
anchorage-independent growth of breast cancer cells [436]. It has been further demonstrated 
to resensitize ovarian cancer cells to chemotherapeutic therapy and restrict tumor growth as 
well as metastasis formation in a mouse model for CRC metastasis [597,598]. 
Many clinical studies discussed above involve the combined treatment of different targeted or 
non-targeted inhibitors. Combinatorial drug treatment represents one of the currently 
predominant approaches to overcome drug resistance in cancer and achieve better therapy 
response [599]. In this regard, it is interesting to note that Song and colleagues combined 
PHA-665752 and Dasatinib to elicit a stronger apoptotic response in CRC cells [557]. Ruess 
et al. used GS493 in combination with the MEK inhibitors selumetinib or trametinib to 
overcome resistance against MEK inhibition in pancreatic and lung cancer in vitro and in vivo 
[56]. These findings demonstrate the potential of combinatorial treatment in MACC1 signaling 
and should be elucidated further. In this context, it would also be worth to test combinations 
of MACC1 signaling inhibitors with statins to potentially tackle MACC1 from two different 
sides.  
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Further investigations should also address the specificity of respective inhibitors: As 
described above, some inhibitors display inhibitory effects for several targets. For instance, 
the SRC inhibitors Dasatinib and Bosutinib also target ABL whereas PP2 has been shown to 
additionally act against ZAP-70, Janus kinase 2 (JAK2), stem cell factor receptor KIT, EGFR 
and PKA. Dasatinib demonstrated activity against PDGFR and EGFR as well [600]. Besides 
MET, Crizotinib also inhibits the RTKs Anaplastic Lymphoma Kinase (ALK) and ROS-1 [565]. 
The SHP2 inhibitor GS493 further presents off-target effects for PDGFR and SRC [601]. All 
of these off-target effects have to be taken into account for future research and 
considerations of therapeutic intervention in MACC1-induced signaling.  
Additionally, cell cycle and apoptosis assays could characterize the precise effect inhibitor 
intervention in MACC1 signaling exerts on the cellular phenotype. Naturally, more functional 
assays have to be employed to investigate the intervention potential on MACC1-dependent 
proliferation or migration. After this, drug application in vivo could validate our findings and 
possibly provide additional treatment options for the clinics.  
The finding that all tested inhibitors show approximately the same effect additionally suggest 
a high level of pathway crosstalk or a signaling cascade which is mainly mediated via the 
MACC1-induced MET overexpression as reported previously [215]. This is contradicted by 
our findings that MACC1 overexpression led to increased activation of most downstream 
targets including ERK, β-catenin, CREB and SRC already in unstimulated conditions (0 min). 
In contrast, MET overexpression has already been reported to activate downstream signaling 
independent of ligand binding [602]. We are currently working on a MET knock-out model 
with concomitant MACC1 overexpression which could shed more light on this issue. It would 
be further illuminating to employ these cells as well as MACC1 knock out cells or inhibitor 
treated cell to the DigiWest technology. This would reveal changes in pathway activation 
and, therefore, determine the specific signaling cascade order. 
Altogether, our data provide promising intervention points in the MACC1 signaling landscape. 
Still, some work must be done to entirely define the spatiotemporal regulation of cascades 
and specific therapy possibilities suitable for the clinical setting. 
 
The findings above are also particularly interesting for additional reasons: For instance, 
MACC1 protein levels appear to have a crucial influence on cellular signaling given the fact 
that signaling intervention reverts the overexpression effect on colony formation. This is in 
line with the original finding that patients with high MACC1 expression have a higher 
probability for metachronous metastasis and poorer survival prognosis than those with low 
MACC1 expression. MACC1 overexpression also determined cellular responses such as 
proliferation, migration and colony formation [100]. Several follow-up studies corroborated 
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our findings of the prognostic and phenotypical characteristics of MACC1 expression levels 
for metastasis and patient survival in more than 20 solid tumor entities [215]. This 
phenomenon has been reported for other proteins as well. For instance, the overexpression 
of SHP2, GRB2 or SRC have also been shown to influence cellular phenotype and cancer 
progression associated with poor prognosis [479,480,486,532,603-605]. On the other hand, 
physiological MACC1 also appears to be involved in exerting malignant functions: Otherwise, 
specific targeting of MACC1-dependent functions with statins would not have been 
successful in vitro and in vivo in this and the previous study [274]. Melvin et al. further 
showed that physiological MACC1 plays a role in embryonal development. MACC1 knock 
down led to severe craniofacial defects in the developing zebrafish [606]. In this study, we 
additionally demonstrated that MACC1 knock-out strongly reduced CRC cell proliferation. 
Some preliminary data suggest that this also remains true for colony formation ability. All 
results further emphasize the strong malignant influence MACC1 expression confers to cells. 
Still, some issues remain to be addressed. A valid opportunity should be the generation of 
certain mouse models to determine the role of physiological and overexpressed MACC1 in 
development and cancer in an in vivo situation. Our group currently works on the creation of 
conditional (inducible) and ubiquitous knock-in mice models via the Rosa26 locus to reflect 
physiological and/or varying MACC1 expression levels in several tissues as well as a 
MACC1 knock-out mouse model [607,608]. This could lead to even more crucial findings by 
reflecting an in vivo situation. 
 
4.3 Conclusion & Outlook 
With this study, we demonstrated that the statin family represents potent transcriptional 
inhibitors of MACC1 in different cancer entities. Their individual potency to reduce MACC1 
expression can be attributed to biophysical properties such as hydrophobicity and 
subsequent biochemical consequences. The additional ability to specifically restrict MACC1-
dependent functions in vitro as well as tumor progression and metastasis formation in vivo, 
shows the promising potential to repurpose them as therapeutic agents against cancer.  
While the transcriptional inhibition of MACC1 cannot account for the entire anticancer effect, 
the disturbance of the mevalonate pathway and subsequent molecular consequences 
represents a central process. However, there are different possible intersections or mergers 
of both functional interventions leading to a combined hinderance of cancer progression. 
Moreover, several studies, including ours (Gohlke & Zincke et al., submitted), document the 
chemopreventive character of statins with positive results in different, large patient 
populations.  
93 
 
Because of the usually long latency of a treatment effect and the predominant fatality of 
cancer diagnosis, the discovery and employment of biomarkers is inevitable for 
chemoprevention [399]. They help identifying the population at high risk for a certain disease 
course (prognostic biomarker) or can predict responsiveness to treatment (predictive 
biomarker) [425]. In view of the current literature and our present data, we recommend 
chemoprevention with statins in patients stratified for MACC1 expression. This is especially 
sensible because MACC1 serves as direct target of statins. For the evaluation of the 
predictive character of MACC1 upon statin treatment, more clinical research is warranted.  
Here, a combined approach with P53 status might be of interest as Moon and colleagues 
independently suggested P53 status as prognostic and predictive marker for statin therapy 
[366]. 
To eventually translate our findings to the clinics, known side effects of statins, such as 
muscular syndromes (e.g., myalgia, myositis or rhabdomyolysis), would have to be assessed 
on a case-by-case basis. The lack of validated diagnostic tools or clinical criteria besides 
creatinine levels may impede a precise evaluation of statin side effects [609]. Otherwise, side 
effects could be alleviated by using statins in combination with other drugs to achieve 
additive or synergistic effects with concomitant reduction in dose and side effects. Several 
studies already support this advantageous use of statins in combination therapy 
[341,610,611]. This is especially interesting because we revealed new inhibitors of MACC1-
dependent signaling which could be tested in combination with statins to potentially elicit a 
more comprehensive MACC1 inhibition. 
In this regard, we identified and confirmed pY-dependent interactions of MACC1 with crucial 
signaling proteins: SHP2, GRB2, SHC1, PLCG1 and STAT5B. Based on our current results, 
SHP2 and GRB2 bind to the phosphorylated Y379 peptide whereas SHC1 and STAT5B 
interacted with pY789 and pY365, respectively. PLCG1 binding was rather unspecific: It 
showed the strongest interaction with pY379 followed by pY789 and contradicting results for 
Y365. In consideration of the domain and binding motif architecture, the interaction between 
SH2 domain and the respective pY-site on MACC1 represents the most probable route of 
protein engagement but several other binding options could be assumed in the highly flexible 
and dynamic signaling process. Apparently, MACC1 recruits the interactors to govern a 
sophisticated signaling network in response to different RTKs, including MET and EGFR, 
exerting a malignant phenotype. SDM of Y379 and Y789 restricted MACC1-induced 
signaling as well as cellular functions such as proliferation and migration. Moreover, targeted 
intervention in the newly proposed MACC1/SHP2/SRC/ERK and MACC1/PKA/SRC/CREB 
axes with inhibitors of MET, MEK, SHP2 and SRC blocked MACC1-dependent colony 
formation. In total, our data suggest that MACC1 is able to rewire the finely tuned pathway 
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networks to promote specific routes of signaling, resulting in tumor enhancing and metastasis 
inducing functions. 
MACC1 obviously displays several similarities with the multi-adaptor and signaling mediator 
GAB1 (compare 4.2.1 and 4.2.2). Preliminary data on this matter suggest that MACC1 is 
able to uphold its signaling promoting functions also under GAB1 knock-down. We are 
currently working on a GAB1 knock-out cell model to elucidate this in more detail. The 
structural and possible functional similarities to SH3BP4 should also be researched in more 
detail. Especially, the recent findings of our group that MACC1 is also involved in 
endocytosis (Imbastari et al., submitted) indicate an additional role of MACC1 in endosomal 
signaling, which is known to regulate central cellular processes [612-614].  
As described above, all RTKs generally involve only a certain set of adaptors and mediators 
eliciting a variety of pathways with distinct functions. The signaling response differs 
depending on recruitment partners and patterns [48,449,466,535,543,552]. Considering this, 
it would be of utmost importance to uncover the spatiotemporal regulation of MACC1 
interactor recruitment and downstream signaling cascades. We are currently working on a 
MET -/- model to clarify the dependency of MACC1 signaling on receptor mediated activation 
and adaptor recruitment. Furthermore, we are trying to elucidate the spatiotemporal 
regulation of MACC1 signaling with size exclusion chromatography, 2D-Blue Native/SDS-
PAGE and total internal reflection fluorescence microscopy (TIRFM) [615-620]. These 
findings would significantly improve the knowledge about MACC1 signaling with concomitant 
increase in intervention precision and quality. 
In addition, the inhibitor studies should be extended to further cell models, cellular functions 
and inhibitor combinations. This includes the combination of different targeted inhibitors as 
well as the combination of targeted inhibitors with statins. It might be of additional interest to 
include inhibitors of GRB2 or PKA since they have been found effective in reducing tumor 
progression in vitro and in vivo [605,621-626]. Both apparently play a crucial role in MACC1 
signaling and GRB2 has additionally been demonstrated to control basal activity of FGFR 
and connected SHP2 activation [627-629]. An additionally promising strategy presents the 
development of an antibody blocking the MACC1 interaction sites (Y379 and Y789) similar to 
monoclonal antibody therapy already employed in cancer therapy [630]. 
Finally, another approach should be the generation of certain mouse models to determine 
the role of physiological and overexpressed MACC1 in development and cancer in an in vivo 
situation. Our group currently works on the creation of conditional (inducible) and ubiquitous 
knock-in mice models via the Rosa26 locus to reflect physiological and/or varying MACC1 
expression levels in several tissues as well as a MACC1 knock-out mouse model [607,608]. 
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Signaling of inhibitor treated vs untreated mice should be assessed via WB, DigiWest and/or 
MS to draw a highly precise picture of the MACC1 signaling network in vivo. 
The potential of MACC1 as multimodal biomarker and therapeutic target has not entirely 
been exploited yet. It could serve as crucial target in future cancer therapy and, particularly, 
the promising and advancing field of cancer prevention. 
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5. Abbreviations 
 
5-FU      5-fluoruracil 
18q     q-arm of chromosome 18 
ABL      Abelson murine leukemia viral oncogene homolog 1 
AC     adenylate cyclase 
AKT     protein kinase B 
ALK     Anaplastic Lymphoma Kinase 
ANOVA     analysis of variance 
AP-1     activator protein 1 
APC     adenomatous polyposis coli 
AREG      amphiregulin 
ATP     adenosine triphosphate 
ATPase    adenosinetriphosphatase 
AUC     area under the curve 
BAD     Bcl-2-associated death promoter (BAD) protein 
BAX     Bcl-2-associated X protein 
BCL2     B-cell lymphoma 2 
BRAF     v-Raf murine sarcoma viral oncogene homolog B 
BSA      bovine serum albumin 
C2     C2 domain 
cAMP     cyclic adenosine monophosphate 
CBL      casitas B-lineage lymphoma proto-oncogene 
CDC4     cell division control protein 4 
cDNA      complementary DNA 
CDK4/6    cyclin-dependent kinase 4/6 
CH1     CH1 domain 
CHK1/2    checkpoint kinase 1/2 
CIMP     CpG island methylator phenotype 
CK1α/δ     casein kinase 1 alpha/delta 
CKI     cyclin-dependent kinase inhibitor 
CMS      consensus molecular subtypes 
CMV     cytomegalovirus 
CpG islands    cytosine-guanosine dinucleotides 
CRC     colorectal cancer 
CREB     cAMP response element-binding protein 
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CSC     cancer stem cells 
CSF1R    colony stimulating factor 1 receptor 
CTC     circulating tumor cells 
CXCL12    C-X-C motif chemokine 12 
CYP     cytochrome P450 enzyme 
DAG      diacylglycerol 
DKFZ     German Cancer Research Center 
dMMR     MMR deficiency 
DMSO     dimethylsulfoxide 
Dox     doxycycline 
Dvl     dishevelled protein 
ECM     extracellular matrix 
EGFR     epidermal growth factor receptor 
EMAP-II     Endothelial-Monocyte-Activating Polypeptide–II 
EMBL     European Molecular Biology Laboratory 
EMT      epithelial-to-mesenchymal transition  
ER     estrogen receptor 
EREG      epiregulin 
ERK     extracellular signal–regulated kinase 
FAK     focal adhesion kinase 
FAP     familial adenomatous polyposis 
FASL      FAS ligand 
FDA     U. S. Food and Drug Administration 
FGFR     fibroblast growth factor receptor 
FLT-3     FMS-like tyrosine kinase 3 
FPP      farnesyl-diphosphate 
G6PD      glucose-6-phosphat-dehydrogenase 
GAB1     GRB2-associated binder 1 
GBM      glioblastoma multiforme 
GEF      guanine nucleotide exchange factor 
GFs     growth factors 
GGPP     geranyl-geranyl-diphosphate 
GLI     glioma-associated oncogene 
GPCR     G protein-coupled receptor 
GRB2     growth-factor-receptor-bound protein 2 
GSK3β     glycogen synthase kinase 3 beta 
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GTP     guanosine triphosphate 
HCC      hepatocellular carcinoma 
HDL      high-density lipoprotein 
HER2     human epidermal growth factor receptor 2 
HGFR      hepatocyte growth factor receptor 
HGF/SF    hepatocyte growth factor/scatter factor 
HIF1     hypoxia inducible factor 1 
HMGCR    3-hydroxy-3-methylglutaryl-CoA reductase  
HNPCC    hereditary nonpolyposis colorectal cancer 
HP1     heterochromatin protein-1 
HRP      horseradish peroxidase 
HR     hazard ratio 
HTS      high-throughput drug screening 
IGF2R     insulin-like growth factor 2 receptor 
IL6R     interleukin 6 receptor 
IP3     inositol(1,4,5)trisphosphate 
IRS     insulin receptor substrate 
ITGB8     integrin beta 8 
JAK2     Janus kinase 2 
KIT      stem cell factor receptor 
KRAS     Kirsten rat sarcoma viral oncogene homolog 
LDL      low-density lipoprotein 
lncRNA     long non-coding RNA 
LPA      Lysophosphatidic acid 
LRP     lipoprotein receptor-related protein 
MACC1    metastasis-associated in colon cancer 1 
MCL-1     induced myeloid leukemia cell differentiation protein 
MEK     MAPK/ERK kinases 
miRNA    microRNA 
MKP      MAPK phosphatases 
MLH1     MutL homolog 1  
MMP     matrix metalloprotease 
MMR     mismatch repair 
MOI      multiplicity of infection 
mRNA     messenger RNA 
MSH2     MutS protein homolog 2  
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MSI     microsatellite instability 
MS      mass spectrometry 
MSS      microsatellite stable 
mTORC1    mammalian target of rapamycin complex 1 
MYH      MutY homolog 
NANOG    homeobox protein NANOG 
NF-1     Neurofibromin 1 
NF-κB  nuclear factor kappa-light-chain-enhancer of activated 
B-cells 
OATP1B1    organic anion-transporting polypeptide 
OCT4     octamer-binding transcription factor 4 
OR     odds ratio 
p14ARF    ARF tumor suppressor 
PD1     programmed cell death protein 1 
PDGFR    platelet-derived growth factor receptor 
PDK1     3-phosphoinositide-dependent protein kinase-1 
PD-L1     programmed death-ligand 1 
PGF      placental growth factor 
PH     Pleckstrin homology domain 
PI3K     phosphatidylinositol 3-kinase 
PIP3     phosphatidylinositol (3,4,5)-trisphosphate 
PKA     protein kinase A 
PLCG      phospholipase C gamma 
PP2A      protein phosphatase 2 
PRD     proline rich domain 
PTEN      phosphatase and tensin homolog 
PTP     protein tyrosine phosphatase domain 
PTP-SL     receptor-type tyrosine-protein phosphatase R 
pY     phosphorylated tyrosine 
qRT-PCR     quantitative real-time polymerase chain reaction 
RAS:GTP    active/GTP-bound form of small GTPase RAS 
RAGE     receptor for advanced glycation endproducts 
Rb     retinoblastoma protein 
RET      rearranged during transfection receptor tyrosine kinase 
RNAi      RNA interference 
ROS      reactive oxygen species 
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RPL32     ribosomal protein L32 
RR     risk ratio 
RSK     90 kDa ribosomal S6 kinases 
RTK     receptor tyrosine kinase 
RWE      real-world evidence 
S100A4    S100 calcium-binding protein A4 
SDM      site-directed mutagenesis 
SDS-PAGE   sodium dodecyl sulphate - polyacrylamide gel 
electrophoresis 
SH2/3     Src homology 2/3 
SH3BP4    SH3 domain-binding protein 4 
SHC1     SH2 domain containing transforming protein 
SHP2     SH2 domain-containing protein tyrosine phosphatase 2 
shRNA     small hairpin RNA 
SIC1     cyclin-dependent protein kinase-1 
siRNA      small interfering RNA 
SLUG      zinc finger protein SNAI2 
SMAD4    SMA & MAD homolog 4 
SNAIL     zinc finger protein SNAI1 
SOS      son of sevenless 
SP1     specificity protein 1 
SPON2    spondin 2 
SRC     non-receptor tyrosine kinase SRC  
STAT     signal transducer and activator of transcription 
TCF4     Transcription factor 4 
TCF/LEF     T-cell factor/lymphoid enhancer-binding factor 
TGFBR2    transforming growth factor beta receptor 2 
TNFR     tumor necrosis factor receptor 
TP53     tumor suppressor P53 
TRAIL      tumor necrosis factor related apoptosis inducing ligand 
TSC1/2    tuberous sclerosis 1/2 
TSS      transcription start site 
TUM     Technical University Munich 
TWIST1    twist basic helix-loop-helix transcription factor 1 
UVB      ultraviolet B 
VASP     vasodilator-stimulated phosphoprotein 
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VEGFR    vascular endothelial growth factor receptor 
VHL     von Hippel–Lindau tumor suppressor 
WB     Western blot 
Wnt     wingless/integrated 
ZAP-70    ζ-chain (T-cell receptor)-associated protein kinase  
70 kDa 
ZEB      zinc finger E-box binding homeobox 1 
ZFP36     zinc finger protein 36 homolog 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
102 
 
6. Statement of Contribution 
 
Ich versichere hiermit, dass die von mir vorgelegte Dissertation eigenständig und ohne 
Benutzung anderer als der angegebenen Hilfsmittel angefertigt wurde. Ich versichere, dass 
alle aus anderen Quellen übernommenen Daten und Konzepte, sowie Ergebnisse aus 
Kooperationsprojekten unter Angabe der Referenz gekennzeichnet sind.  
 
Außerdem versichere ich, dass mir die aktuelle Promotionsordnung bekannt ist und ich mich 
nicht anderwärts um einen Doktorgrad bewerbe, bzw. noch keinen entsprechenden 
Doktorgrad besitze. Diese Arbeit wurde in gleicher oder ähnlicher Form nicht einer anderen 
Prüfungsbehörde vorgelegt. 
 
 
Berlin, den 06.01.2020   _________________________ 
        Fabian Zincke 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
7. References 
 
1 Hanahan D & Weinberg RA (2000). The Hallmarks of Cancer. Cell 100(1): 57-70. doi or PMID: 
10.1016/S0092-8674(00)81683-9 
2 Hanahan D & Weinberg RA (2011). Hallmarks of Cancer: The Next Generation. Cell 144(5): 
646-674. doi or PMID: 10.1016/j.cell.2011.02.013 
3 Vogelstein B, Papadopoulos N, Velculescu VE et al. (2013). Cancer genome landscapes. 
Science 339(6127): 1546-1558. doi or PMID: 10.1126/science.1235122 
4 Fearon ER & Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell 61(5): 
759-767. doi or PMID: 10.1016/0092-8674(90)90186-i 
5 Pino MS & Chung DC (2010). The chromosomal instability pathway in colon cancer. 
Gastroenterology 138(6): 2059-2072. doi or PMID: 10.1053/j.gastro.2009.12.065 
6 Markowitz SD & Bertagnolli MM (2009). Molecular origins of cancer: Molecular basis of 
colorectal cancer. N Engl J Med 361(25): 2449-2460. doi or PMID: 10.1056/NEJMra0804588 
7 Boland CR & Goel A (2010). Microsatellite instability in colorectal cancer. Gastroenterology 
138(6): 2073-2087.e2073. doi or PMID: 10.1053/j.gastro.2009.12.064 
8 Issa JP, Baylin SB & Belinsky SA (1996). Methylation of the estrogen receptor CpG island in 
lung tumors is related to the specific type of carcinogen exposure. Cancer Res 56(16): 3655-
3658. doi or PMID: 8706002 
9 Issa JP, Ahuja N, Toyota M et al. (2001). Accelerated age-related CpG island methylation in 
ulcerative colitis. Cancer Res 61(9): 3573-3577. doi or PMID: 11325821 
10 Burt RW (2000). Colon cancer screening. Gastroenterology 119(3): 837-853. doi or PMID: 
10982778 
11 DeMarini DM (2004). Genotoxicity of tobacco smoke and tobacco smoke condensate: a 
review. Mutat Res 567(2): 447-474. doi or PMID: 10.1016/j.mrrev.2004.02.001 
12 Waris G & Ahsan H (2006). Reactive oxygen species: role in the development of cancer and 
various chronic conditions. J Carcinog 5: 14-14. doi or PMID: 10.1186/1477-3163-5-14 
13 Ikehata H & Ono T (2011). The mechanisms of UV mutagenesis. J Radiat Res 52(2): 115-125. 
doi or PMID: 21436607 
14 Tomasetti C, Marchionni L, Nowak MA et al. (2015). Only three driver gene mutations are 
required for the development of lung and colorectal cancers. Proc Natl Acad Sci U S A 112(1): 
118-123. doi or PMID: 10.1073/pnas.1421839112 
15 Bozic I, Antal T, Ohtsuki H et al. (2010). Accumulation of driver and passenger mutations 
during tumor progression. Proc Natl Acad Sci U S A 107(43): 18545. doi or PMID: 
10.1073/pnas.1010978107 
16 Cancer Genome Atlas Network (2012). Comprehensive molecular characterization of human 
colon and rectal cancer. Nature 487, 330-337. doi or PMID: 10.1038/nature11252 
17 Walther A, Johnstone E, Swanton C et al. (2009). Genetic prognostic and predictive markers 
in colorectal cancer. Nat Rev Cancer 9(7): 489-499. doi or PMID: 10.1038/nrc2645 
18 Chung DC (2000). The genetic basis of colorectal cancer: Insights into critical pathways of 
tumorigenesis. Gastroenterology 119(3): 854-865. doi or PMID: 10.1053/gast.2000.16507 
19 IJspeert JE, Vermeulen L, Meijer GA et al. (2015). Serrated neoplasia-role in colorectal 
carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol 12(7): 401-409. doi or 
PMID: 10.1038/nrgastro.2015.73 
20 Luo C & Zhang H (2017). The Role of Proinflammatory Pathways in the Pathogenesis of 
Colitis-Associated Colorectal Cancer. Mediators Inflamm 2017: 5126048. doi or PMID: 
10.1155/2017/5126048 
21 Leedham SJ, Graham TA, Oukrif D et al. (2009). Clonality, Founder Mutations, and Field 
Cancerization in Human Ulcerative Colitis–Associated Neoplasia. Gastroenterology 136(2): 
542-550.e546. doi or PMID: 10.1053/j.gastro.2008.10.086 
104 
 
22 Grivennikov SI (2013). Inflammation and colorectal cancer: colitis-associated neoplasia. 
Semin Immunopathol 35(2): 229-244. doi or PMID: 10.1007/s00281-012-0352-6 
23 Sever R & Brugge JS (2015). Signal transduction in cancer. Cold Spring Harb Perspect Med 
5(4): a006098. doi or PMID: 10.1101/cshperspect.a006098 
24 Miklos GL & Maleszka R (2004). Microarray reality checks in the context of a complex 
disease. Nat Biotechnol 22(5): 615-621. doi or PMID: 10.1038/nbt965 
25 Schafer R, Schramme A, Tchernitsa OI et al. (2007). Oncogenic signaling pathways and 
deregulated target genes. Recent Results Cancer Res 176: 7-24. doi or PMID: 17607912 
26 Vogelstein B & Kinzler KW (2004). Cancer genes and the pathways they control. Nature 
Medicine 10: 789. doi or PMID: 10.1038/nm1087 
27 Lemmon MA & Schlessinger J (2010). Cell Signaling by Receptor Tyrosine Kinases. Cell 141(7): 
1117-1134. doi or PMID: 10.1016/j.cell.2010.06.011 
28 Park M, Dean M, Cooper CS et al. (1986). Mechanism of met oncogene activation. Cell 45(6): 
895-904. doi or PMID: 2423252 
29 Bottaro DP, Rubin JS, Faletto DL et al. (1991). Identification of the hepatocyte growth factor 
receptor as the c-met proto-oncogene product. Science 251(4995): 802-804. doi or PMID: 
1846706 
30 Stoker M, Gherardi E, Perryman M et al. (1987). Scatter factor is a fibroblast-derived 
modulator of epithelial cell mobility. Nature 327(6119): 239-242. doi or PMID: 
10.1038/327239a0 
31 Nakamura T, Nishizawa T, Hagiya M et al. (1989). Molecular cloning and expression of human 
hepatocyte growth factor. Nature 342(6248): 440-443. doi or PMID: 10.1038/342440a0 
32 Miyazawa K, Tsubouchi H, Naka D et al. (1989). Molecular cloning and sequence analysis of 
cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun 163(2): 967-973. 
doi or PMID: 2528952 
33 Zarnegar R & Michalopoulos G (1989). Purification and biological characterization of human 
hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res 49(12): 3314-3320. 
doi or PMID: 2524251 
34 Montesano R, Matsumoto K, Nakamura T et al. (1991). Identification of a fibroblast-derived 
epithelial morphogen as hepatocyte growth factor. Cell 67(5): 901-908. doi or PMID: 1835669 
35 Schmidt C, Bladt F, Goedecke S et al. (1995). Scatter factor/hepatocyte growth factor is 
essential for liver development. Nature 373(6516): 699-702. doi or PMID: 10.1038/373699a0 
36 Uehara Y, Minowa O, Mori C et al. (1995). Placental defect and embryonic lethality in mice 
lacking hepatocyte growth factor/scatter factor. Nature 373: 702. doi or PMID: 
10.1038/373702a0 
37 Bladt F, Riethmacher D, Isenmann S et al. (1995). Essential role for the c-met receptor in the 
migration of myogenic precursor cells into the limb bud. Nature 376(6543): 768-771. doi or 
PMID: 10.1038/376768a0 
38 Schmidt L, Duh FM, Chen F et al. (1997). Germline and somatic mutations in the tyrosine 
kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16(1): 
68-73. doi or PMID: 10.1038/ng0597-68 
39 Boccaccio C & Comoglio PM (2014). MET, a driver of invasive growth and cancer clonal 
evolution under therapeutic pressure. Curr Opin Cell Biol 31: 98-105. doi or PMID: 
10.1016/j.ceb.2014.09.008 
40 Gherardi E, Birchmeier W, Birchmeier C et al. (2012). Targeting MET in cancer: rationale and 
progress. Nat Rev Cancer 12(2): 89-103. doi or PMID: 10.1038/nrc3205 
41 Comoglio PM, Giordano S & Trusolino L (2008). Drug development of MET inhibitors: 
targeting oncogene addiction and expedience. Nat Rev Drug Discov 7(6): 504-516. doi or 
PMID: 10.1038/nrd2530 
42 Boccaccio C & Comoglio PM (2006). Invasive growth: a MET-driven genetic programme for 
cancer and stem cells. Nat Rev Cancer 6: 637. doi or PMID: 10.1038/nrc1912 
105 
 
43 Gherardi E, Youles ME, Miguel RN et al. (2003). Functional map and domain structure of 
MET, the product of the c-met protooncogene and receptor for hepatocyte growth 
factor/scatter factor. Proc Natl Acad Sci U S A 100(21): 12039-12044. doi or PMID: 
10.1073/pnas.2034936100 
44 Ponzetto C, Bardelli A, Zhen Z et al. (1994). A multifunctional docking site mediates signaling 
and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 
77(2): 261-271. doi or PMID: 10.1016/0092-8674(94)90318-2 
45 Weidner KM, Di Cesare S, Sachs M et al. (1996). Interaction between Gab1 and the c-Met 
receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384(6605): 173-
176. doi or PMID: 10.1038/384173a0 
46 Sachs M, Brohmann H, Zechner D et al. (2000). Essential role of Gab1 for signaling by the c-
Met receptor in vivo. J Cell Biol 150(6): 1375-1384. doi or PMID: 10995442 
47 Lock LS, Royal I, Naujokas MA et al. (2000). Identification of an atypical Grb2 carboxyl-
terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -
independent recruitment of Gab1 to receptor tyrosine kinases. J Biol Chem 275(40): 31536-
31545. doi or PMID: 10.1074/jbc.M003597200 
48 Gu H & Neel BG (2003). The "Gab" in signal transduction. Trends Cell Biol 13(3): 122-130. doi 
or PMID: 12628344 
49 Rosario M & Birchmeier W (2003). How to make tubes: signaling by the Met receptor 
tyrosine kinase. Trends Cell Biol 13(6): 328-335. doi or PMID: 12791299 
50 Raabe T, Riesgo–Escovar J, Liu X et al. (1996). DOS, a Novel Pleckstrin Homology Domain–
Containing Protein Required for Signal Transduction between Sevenless and Ras1 in 
Drosophila. Cell 85(6): 911-920. doi or PMID: 10.1016/s0092-8674(00)81274-x 
51 Schutzman JL, Borland CZ, Newman JC et al. (2001). The Caenorhabditis elegans EGL-15 
signaling pathway implicates a DOS-like multisubstrate adaptor protein in fibroblast growth 
factor signal transduction. Mol Cell Biol 21(23): 8104-8116. doi or PMID: 
10.1128/mcb.21.23.8104-8116.2001 
52 Schaeper U, Gehring NH, Fuchs KP et al. (2000). Coupling of Gab1 to c-Met, Grb2, and Shp2 
mediates biological responses. J Cell Biol 149(7): 1419-1432. doi or PMID: 10871282 
53 Cunnick JM, Meng S, Ren Y et al. (2002). Regulation of the mitogen-activated protein kinase 
signaling pathway by SHP2. J Biol Chem 277(11): 9498-9504. doi or PMID: 
10.1074/jbc.M110547200 
54 Bunda S, Burrell K, Heir P et al. (2015). Inhibition of SHP2-mediated dephosphorylation of Ras 
suppresses oncogenesis. Nat Commun 6: 8859. doi or PMID: 10.1038/ncomms9859 
55 Boccaccio C, Ando M, Tamagnone L et al. (1998). Induction of epithelial tubules by growth 
factor HGF depends on the STAT pathway. Nature 391(6664): 285-288. doi or PMID: 
10.1038/34657 
56 Ruess DA, Heynen GJ, Ciecielski KJ et al. (2018). Mutant KRAS-driven cancers depend on 
PTPN11/SHP2 phosphatase. Nat Med 24(7): 954-960. doi or PMID: 10.1038/s41591-018-
0024-8 
57 Pierre S, Bats AS & Coumoul X (2011). Understanding SOS (Son of Sevenless). Biochem 
Pharmacol 82(9): 1049-1056. doi or PMID: 10.1016/j.bcp.2011.07.072 
58 Shaul YD & Seger R (2007). The MEK/ERK cascade: From signaling specificity to diverse 
functions. Biochim Biophys Acta 1773(8): 1213-1226. doi or PMID: 
10.1016/j.bbamcr.2006.10.005 
59 Vivanco I & Sawyers CL (2002). The phosphatidylinositol 3-Kinase AKT pathway in human 
cancer. Nat Rev Cancer 2(7): 489-501. doi or PMID: 10.1038/nrc839 
60 Jimenez C, Hernandez C, Pimentel B et al. (2002). The p85 regulatory subunit controls 
sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J Biol Chem 
277(44): 41556-41562. doi or PMID: 10.1074/jbc.M205893200 
106 
 
61 Hurley JH & Misra S (2000). Signaling and subcellular targeting by membrane-binding 
domains. Annu Rev Biophys Biomol Struct 29: 49-79. doi or PMID: 
10.1146/annurev.biophys.29.1.49 
62 Mora A, Komander D, van Aalten DM et al. (2004). PDK1, the master regulator of AGC kinase 
signal transduction. Semin Cell Dev Biol 15(2): 161-170. doi or PMID: 15209375 
63 White MF (1998). The IRS-signalling system: a network of docking proteins that mediate 
insulin action. Mol Cell Biochem 182(1-2): 3-11. doi or PMID: 9609109 
64 Kiyatkin A, Aksamitiene E, Markevich NI et al. (2006). Scaffolding protein Grb2-associated 
binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by 
multiple positive feedback loops. J Biol Chem 281(29): 19925-19938. doi or PMID: 
10.1074/jbc.M600482200 
65 Rodrigues GA, Falasca M, Zhang Z et al. (2000). A novel positive feedback loop mediated by 
the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor 
receptor signaling. Mol Cell Biol 20(4): 1448-1459. doi or PMID: 10648629 
66 Roymans D & Slegers H (2001). Phosphatidylinositol 3-kinases in tumor progression. Eur J 
Biochem 268(3): 487-498. doi or PMID: 11168386 
67 Franke TF, Hornik CP, Segev L et al. (2003). PI3K/Akt and apoptosis: size matters. Oncogene 
22(56): 8983-8998. doi or PMID: 10.1038/sj.onc.1207115 
68 Sarbassov DD, Guertin DA, Ali SM et al. (2005). Phosphorylation and regulation of Akt/PKB by 
the rictor-mTOR complex. Science 307(5712): 1098-1101. doi or PMID: 
10.1126/science.1106148 
69 Manning BD & Cantley LC (2007). AKT/PKB signaling: navigating downstream. Cell 129(7): 
1261-1274. doi or PMID: 10.1016/j.cell.2007.06.009 
70 Aksamitiene E, Kiyatkin A & Kholodenko BN (2012). Cross-talk between mitogenic Ras/MAPK 
and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 40(1): 139-146. doi or 
PMID: 10.1042/bst20110609 
71 Ding Q, Xia W, Liu JC et al. (2005). Erk associates with and primes GSK-3beta for its 
inactivation resulting in upregulation of beta-catenin. Mol Cell 19(2): 159-170. doi or PMID: 
10.1016/j.molcel.2005.06.009 
72 Tashiro E, Henmi S, Odake H et al. (2016). Involvement of the MEK/ERK pathway in EGF-
induced E-cadherin down-regulation. Biochem Biophys Res Commun 477(4): 801-806. doi or 
PMID: 10.1016/j.bbrc.2016.06.138 
73 Lu Z, Ghosh S, Wang Z et al. (2003). Downregulation of caveolin-1 function by EGF leads to 
the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor 
cell invasion. Cancer Cell 4(6): 499-515. doi or PMID: 14706341 
74 Engelman JA, Zhang XL, Razani B et al. (1999). p42/44 MAP kinase-dependent and -
independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP 
kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 
promoter activity. J Biol Chem 274(45): 32333-32341. doi or PMID: 10542274 
75 Fang D, Hawke D, Zheng Y et al. (2007). Phosphorylation of beta-catenin by AKT promotes 
beta-catenin transcriptional activity. J Biol Chem 282(15): 11221-11229. doi or PMID: 
10.1074/jbc.M611871200 
76 Korkaya H, Paulson A, Charafe-Jauffret E et al. (2009). Regulation of Mammary 
Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling. PLoS Biol 7(6): e1000121. doi or 
PMID: 10.1371/journal.pbio.1000121 
77 Sharma M, Chuang WW & Sun Z (2002). Phosphatidylinositol 3-kinase/Akt stimulates 
androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J 
Biol Chem 277(34): 30935-30941. doi or PMID: 10.1074/jbc.M201919200 
78 Vlad A, Rohrs S, Klein-Hitpass L et al. (2008). The first five years of the Wnt targetome. Cell 
Signal 20(5): 795-802. doi or PMID: 10.1016/j.cellsig.2007.10.031 
107 
 
79 Logan CY & Nusse R (2004). The Wnt signaling pathway in development and disease. Annu 
Rev Cell Dev Biol 20: 781-810. doi or PMID: 10.1146/annurev.cellbio.20.010403.113126 
80 Aberle H, Bauer A, Stappert J et al. (1997). beta-catenin is a target for the ubiquitin-
proteasome pathway. Embo j 16(13): 3797-3804. doi or PMID: 10.1093/emboj/16.13.3797 
81 Li VS, Ng SS, Boersema PJ et al. (2012). Wnt signaling through inhibition of beta-catenin 
degradation in an intact Axin1 complex. Cell 149(6): 1245-1256. doi or PMID: 
10.1016/j.cell.2012.05.002 
82 Behrens J, von Kries JP, Kuhl M et al. (1996). Functional interaction of beta-catenin with the 
transcription factor LEF-1. Nature 382(6592): 638-642. doi or PMID: 10.1038/382638a0 
83 Molenaar M, van de Wetering M, Oosterwegel M et al. (1996). XTcf-3 transcription factor 
mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 86(3): 391-399. doi 
or PMID: 8756721 
84 Kimelman D & Xu W (2006). beta-catenin destruction complex: insights and questions from a 
structural perspective. Oncogene 25(57): 7482-7491. doi or PMID: 10.1038/sj.onc.1210055 
85 Pantel K & Brakenhoff RH (2004). Dissecting the metastatic cascade. Nat Rev Cancer 4(6): 
448-456. doi or PMID: 10.1038/nrc1370 
86 Lambert AW, Pattabiraman DR & Weinberg RA (2017). Emerging Biological Principles of 
Metastasis. Cell 168(4): 670-691. doi or PMID: 10.1016/j.cell.2016.11.037 
87 Fidler IJ (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis 
revisited. Nat Rev Cancer 3(6): 453-458. doi or PMID: 10.1038/nrc1098 
88 Gupta GP & Massague J (2006). Cancer metastasis: building a framework. Cell 127(4): 679-
695. doi or PMID: 10.1016/j.cell.2006.11.001 
89 Talmadge JE & Fidler IJ (2010). AACR centennial series: the biology of cancer metastasis: 
historical perspective. Cancer Res 70(14): 5649-5669. doi or PMID: 10.1158/0008-5472.can-
10-1040 
90 Weidle UH, Birzele F & Kruger A (2015). Molecular targets and pathways involved in liver 
metastasis of colorectal cancer. Clin Exp Metastasis 32(6): 623-635. doi or PMID: 
10.1007/s10585-015-9732-3 
91 Sceneay J, Smyth MJ & Moller A (2013). The pre-metastatic niche: finding common ground. 
Cancer Metastasis Rev 32(3-4): 449-464. doi or PMID: 10.1007/s10555-013-9420-1 
92 Wan L, Pantel K & Kang Y (2013). Tumor metastasis: moving new biological insights into the 
clinic. Nat Med 19(11): 1450-1464. doi or PMID: 10.1038/nm.3391 
93 Klaver YLB, Lemmens VEPP, Nienhuijs SW et al. (2012). Peritoneal carcinomatosis of 
colorectal origin: Incidence, prognosis and treatment options. World J Gastroenterol 18(39): 
5489-5494. doi or PMID: 10.3748/wjg.v18.i39.5489 
94 Segelman J, Granath F, Holm T et al. (2012). Incidence, prevalence and risk factors for 
peritoneal carcinomatosis from colorectal cancer. Br J Surg 99(5): 699-705. doi or PMID: 
10.1002/bjs.8679 
95 Gómez-Cuadrado L, Tracey N, Ma R et al. (2017). Mouse models of metastasis: progress and 
prospects. Dis Model Mech 10(9): 1061-1074. doi or PMID: 10.1242/dmm.030403 
96 Lamouille S, Xu J & Derynck R (2014). Molecular mechanisms of epithelial–mesenchymal 
transition. Nat Rev Mol Cell Biol 15(3): 178-196. doi or PMID: 10.1038/nrm3758 
97 Gialeli C, Theocharis AD & Karamanos NK (2010). Roles of matrix metalloproteinases in 
cancer progression and their pharmacological targeting. The FEBS Journal 278(1): 16-27. doi 
or PMID: 10.1111/j.1742-4658.2010.07919.x 
98 Luraghi P, Schelter F, Krüger A et al. (2012). The MET Oncogene as a Therapeutical Target in 
Cancer Invasive Growth. Front Pharmacol 3: 164-164. doi or PMID: 
10.3389/fphar.2012.00164 
99 Birchmeier C, Birchmeier W, Gherardi E et al. (2003). Met, metastasis, motility and more. Nat 
Rev Mol Cell Biol 4(12): 915-925. doi or PMID: 10.1038/nrm1261 
108 
 
100 Stein U, Walther W, Arlt F et al. (2009). MACC1, a newly identified key regulator of HGF-MET 
signaling, predicts colon cancer metastasis. Nat Med 15(1): 59-67. doi or PMID: 
10.1038/nm.1889 
101 Stein U, Arlt F, Walther W et al. (2006). The metastasis-associated gene S100A4 is a novel 
target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 131(5): 1486-
1500. doi or PMID: 10.1053/j.gastro.2006.08.041 
102 Dahlmann M, Sack U, Herrmann P et al. (2012). Systemic shRNA mediated knock down of 
S100A4 in colorectal cancer xenografted mice reduces metastasis formation. Oncotarget 
3(8): 783-797. doi or PMID: 10.18632/oncotarget.572 
103 Seubert B, Grunwald B, Kobuch J et al. (2015). Tissue inhibitor of metalloproteinases (TIMP)-1 
creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil 
recruitment in mice. Hepatology 61(1): 238-248. doi or PMID: 10.1002/hep.27378 
104 Stein U & Schlag PM (2007). Clinical, biological, and molecular aspects of metastasis in 
colorectal cancer. Recent Results Cancer Res 176: 61-80. doi or PMID: 17607917 
105 Christofori G (2006). New signals from the invasive front. Nature 441(7092): 444-450. doi or 
PMID: 10.1038/nature04872 
106 Chaffer CL & Weinberg RA (2011). A perspective on cancer cell metastasis. Science 
331(6024): 1559-1564. doi or PMID: 10.1126/science.1203543 
107 Steeg PS (2006). Tumor metastasis: mechanistic insights and clinical challenges. Nature 
Medicine 12: 895. doi or PMID: 10.1038/nm1469 
108 Sun Y & Ma L (2015). The emerging molecular machinery and therapeutic targets of 
metastasis. Trends Pharmacol Sci 36(6): 349-359. doi or PMID: 10.1016/j.tips.2015.04.001 
109 Compton CC & Greene FL (2009). The Staging of Colorectal Cancer: 2004 and Beyond. CA 
Cancer J Clin 54(6): 295-308. doi or PMID: 10.3322/canjclin.54.6.295 
110 Etzioni R, Urban N, Ramsey S et al. (2003). The case for early detection. Nat Rev Cancer 3(4): 
243-252. doi or PMID: 10.1038/nrc1041 
111 Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, 
Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2017). SEER Cancer Statistics Review. 
https://seer.cancer.gov/csr/1975_2014/  
112 Stein U (2013). MACC1 - a novel target for solid cancers. Expert Opin Ther Targets 17(9): 
1039-1052. doi or PMID: 10.1517/14728222.2013.815727 
113 Amado NG, Predes D, Moreno MM et al. (2014). Flavonoids and Wnt/β-catenin signaling: 
potential role in colorectal cancer therapies. Int J Mol Sci 15(7): 12094-12106. doi or PMID: 
10.3390/ijms150712094 
114 Van Cutsem E & Oliveira J (2009). Advanced colorectal cancer: ESMO Clinical 
Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(suppl_4): 61-63. doi 
or PMID: 10.1093/annonc/mdp130 
115 Schmoll HJ, Van Cutsem E, Stein A et al. (2012). ESMO Consensus Guidelines for management 
of patients with colon and rectal cancer. A personalized approach to clinical decision making. 
Ann Oncol 23(10): 2479-2516. doi or PMID: 10.1093/annonc/mds236 
116 Andre T, de Gramont A, Vernerey D et al. (2015). Adjuvant Fluorouracil, Leucovorin, and 
Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According 
to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol 33(35): 
4176-4187. doi or PMID: 10.1200/jco.2015.63.4238 
117 Babcock BD, Aljehani MA, Jabo B et al. (2018). High-Risk Stage II Colon Cancer: Not All Risks 
Are Created Equal. Ann Surg Oncol 25(7): 1980-1985. doi or PMID: 10.1245/s10434-018-
6484-8 
118 de Gramont A, Figer A, Seymour M et al. (2000). Leucovorin and fluorouracil with or without 
oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16): 2938-
2947. doi or PMID: 10.1200/jco.2000.18.16.2938 
109 
 
119 Hurwitz H, Fehrenbacher L, Novotny W et al. (2004). Bevacizumab plus Irinotecan, 
Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 350(23): 2335-
2342. doi or PMID: 10.1056/NEJMoa032691 
120 Saltz LB, Clarke S, Diaz-Rubio E et al. (2008). Bevacizumab in combination with oxaliplatin-
based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized 
phase III study. J Clin Oncol 26(12): 2013-2019. doi or PMID: 10.1200/jco.2007.14.9930 
121 Van Cutsem E, Kohne CH, Hitre E et al. (2009). Cetuximab and chemotherapy as initial 
treatment for metastatic colorectal cancer. N Engl J Med 360(14): 1408-1417. doi or PMID: 
10.1056/NEJMoa0805019 
122 Douillard JY, Siena S, Cassidy J et al. (2010). Randomized, phase III trial of panitumumab with 
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-
line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME 
study. J Clin Oncol 28(31): 4697-4705. doi or PMID: 10.1200/jco.2009.27.4860 
123 Peeters M, Price TJ, Cervantes A et al. (2010). Randomized phase III study of panitumumab 
with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as 
second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28(31): 
4706-4713. doi or PMID: 10.1200/jco.2009.27.6055 
124 van Gijn W, Marijnen CA, Nagtegaal ID et al. (2011). Preoperative radiotherapy combined 
with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the 
multicentre, randomised controlled TME trial. Lancet Oncol 12(6): 575-582. doi or PMID: 
10.1016/s1470-2045(11)70097-3 
125 Bosset JF, Collette L, Calais G et al. (2006). Chemotherapy with preoperative radiotherapy in 
rectal cancer. N Engl J Med 355(11): 1114-1123. doi or PMID: 10.1056/NEJMoa060829 
126 Wood LD, Parsons DW, Jones S et al. (2007). The genomic landscapes of human breast and 
colorectal cancers. Science 318(5853): 1108-1113. doi or PMID: 10.1126/science.1145720 
127 Yachida S, Jones S, Bozic I et al. (2010). Distant metastasis occurs late during the genetic 
evolution of pancreatic cancer. Nature 467(7319): 1114-1117. doi or PMID: 
10.1038/nature09515 
128 Sottoriva A, Spiteri I, Shibata D et al. (2013). Single-molecule genomic data delineate patient-
specific tumor profiles and cancer stem cell organization. Cancer Res 73(1): 41-49. doi or 
PMID: 10.1158/0008-5472.can-12-2273 
129 Navin N, Kendall J, Troge J et al. (2011). Tumour evolution inferred by single-cell sequencing. 
Nature 472(7341): 90-94. doi or PMID: 10.1038/nature09807 
130 Gerlinger M, Rowan AJ, Horswell S et al. (2012). Intratumor heterogeneity and branched 
evolution revealed by multiregion sequencing. N Engl J Med 366(10): 883-892. doi or PMID: 
10.1056/NEJMoa1113205 
131 De Sousa EMF, Vermeulen L, Fessler E et al. (2013). Cancer heterogeneity--a multifaceted 
view. EMBO Rep 14(8): 686-695. doi or PMID: 10.1038/embor.2013.92 
132 Vermeulen L, de Sousa e Melo F, Richel DJ et al. (2012). The developing cancer stem-cell 
model: clinical challenges and opportunities. Lancet Oncol 13(2): e83-89. doi or PMID: 
10.1016/s1470-2045(11)70257-1 
133 Fan CW, Chen T, Shang YN et al. (2013). Cancer-initiating cells derived from human rectal 
adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies. Cell Death 
Dis 4(10): e828-e828. doi or PMID: 10.1038/cddis.2013.337 
134 Zeuner A, Todaro M, Stassi G et al. (2014). Colorectal cancer stem cells: from the crypt to the 
clinic. Cell Stem Cell 15(6): 692-705. doi or PMID: 10.1016/j.stem.2014.11.012 
135 Todaro M, Alea MP, Di Stefano AB et al. (2007). Colon cancer stem cells dictate tumor growth 
and resist cell death by production of interleukin-4. Cell Stem Cell 1(4): 389-402. doi or PMID: 
10.1016/j.stem.2007.08.001 
110 
 
136 Colak S, Zimberlin CD, Fessler E et al. (2014). Decreased mitochondrial priming determines 
chemoresistance of colon cancer stem cells. Cell Death Differ 21(7): 1170-1177. doi or PMID: 
10.1038/cdd.2014.37 
137 Nunes T, Hamdan D, Leboeuf C et al. (2018). Targeting Cancer Stem Cells to Overcome 
Chemoresistance. Int J Mol Sci 19(12) doi or PMID: 10.3390/ijms19124036 
138 Zhao J (2016). Cancer stem cells and chemoresistance: The smartest survives the raid. 
Pharmacol Ther 160: 145-158. doi or PMID: 10.1016/j.pharmthera.2016.02.008 
139 Kreso A, O'Brien CA, van Galen P et al. (2013). Variable clonal repopulation dynamics 
influence chemotherapy response in colorectal cancer. Science 339(6119): 543-548. doi or 
PMID: 10.1126/science.1227670 
140 Sharma SV, Lee DY, Li B et al. (2010). A chromatin-mediated reversible drug-tolerant state in 
cancer cell subpopulations. Cell 141(1): 69-80. doi or PMID: 10.1016/j.cell.2010.02.027 
141 Schweizer L & Zhang L (2013). Enhancing Cancer Drug Discovery through Novel Cell Signaling 
Pathway Panel Strategy. Cancer Growth Metastasis 6: 53-59. doi or PMID: 
10.4137/CGM.S11134 
142 Hunter T (2000). Signaling—2000 and Beyond. Cell 100(1): 113-127. doi or PMID: 
10.1016/s0092-8674(00)81688-8 
143 Ke X & Shen L (2017). Molecular targeted therapy of cancer: The progress and future 
prospect. Front Lab Med 1(2): 69-75. doi or PMID: 10.1016/j.flm.2017.06.001 
144 Geng F, Wang Z, Yin H et al. (2017). Molecular Targeted Drugs and Treatment of Colorectal 
Cancer: Recent Progress and Future Perspectives. Cancer Biother Radiopharm 32(5): 149-160. 
doi or PMID: 10.1089/cbr.2017.2210 
145 Mocellin S, Lise M & Nitti D (2005). Targeted therapy for colorectal cancer: mapping the way. 
Trends Mol Med 11(7): 327-335. doi or PMID: 10.1016/j.molmed.2005.05.002 
146 Loupakis F, Cremolini C, Masi G et al. (2014). Initial therapy with FOLFOXIRI and bevacizumab 
for metastatic colorectal cancer. N Engl J Med 371(17): 1609-1618. doi or PMID: 
10.1056/NEJMoa1403108 
147 Kabbinavar FF, Schulz J, McCleod M et al. (2005). Addition of bevacizumab to bolus 
fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized 
phase II trial. J Clin Oncol 23(16): 3697-3705. doi or PMID: 10.1200/jco.2005.05.112 
148 Amado RG, Wolf M, Peeters M et al. (2008). Wild-type KRAS is required for panitumumab 
efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10): 1626-1634. doi or 
PMID: 10.1200/jco.2007.14.7116 
149 Karapetis CS, Khambata-Ford S, Jonker DJ et al. (2008). K-ras mutations and benefit from 
cetuximab in advanced colorectal cancer. N Engl J Med 359(17): 1757-1765. doi or PMID: 
10.1056/NEJMoa0804385 
150 Van Cutsem E, Tabernero J, Lakomy R et al. (2012). Addition of aflibercept to fluorouracil, 
leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with 
metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin 
Oncol 30(28): 3499-3506. doi or PMID: 10.1200/jco.2012.42.8201 
151 Tabernero J, Yoshino T, Cohn AL et al. (2015). Ramucirumab versus placebo in combination 
with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed 
during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine 
(RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5): 499-
508. doi or PMID: 10.1016/s1470-2045(15)70127-0 
152 Grothey A, Van Cutsem E, Sobrero A et al. (2013). Regorafenib monotherapy for previously 
treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, 
placebo-controlled, phase 3 trial. Lancet 381(9863): 303-312. doi or PMID: 10.1016/s0140-
6736(12)61900-x 
111 
 
153 Corcoran RB, Atreya CE, Falchook GS et al. (2015). Combined BRAF and MEK Inhibition With 
Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol 33(34): 
4023-4031. doi or PMID: 10.1200/jco.2015.63.2471 
154 Atreya CE, Van Cutsem E, Bendell JC et al. (2015). Updated efficacy of the MEK inhibitor 
trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in 
patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin 
Oncol 33(15_suppl): 103-103. doi or PMID: 10.1200/jco.2015.33.15_suppl.103 
155 Prahallad A, Sun C, Huang S et al. (2012). Unresponsiveness of colon cancer to BRAF(V600E) 
inhibition through feedback activation of EGFR. Nature 483(7387): 100-103. doi or PMID: 
10.1038/nature10868 
156 Sartore-Bianchi A, Trusolino L, Martino C et al. (2016). Dual-targeted therapy with 
trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-
positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-
label, phase 2 trial. Lancet Oncol 17(6): 738-746. doi or PMID: 10.1016/s1470-
2045(16)00150-9 
157 Le DT, Uram JN, Wang H et al. (2015). PD-1 Blockade in Tumors with Mismatch-Repair 
Deficiency. N Engl J Med 372(26): 2509-2520. doi or PMID: 10.1056/NEJMoa1500596 
158 Van Cutsem E, Yoshino T, Lenz HJ et al. (2018). Nintedanib for the treatment of patients with 
refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, 
randomized, placebo-controlled study. Ann Oncol 29(9): 1955-1963. doi or PMID: 
10.1093/annonc/mdy241 
159 Xu RH, Shen L, Wang KM et al. (2017). Famitinib versus placebo in the treatment of 
refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-
controlled, phase II clinical trial. Chin J Cancer 36(1): 97. doi or PMID: 10.1186/s40880-017-
0263-y 
160 Pietrantonio F, Perrone F, de Braud F et al. (2014). Activity of temozolomide in patients with 
advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol 
25(2): 404-408. doi or PMID: 10.1093/annonc/mdt547 
161 Hickish T, Andre T, Wyrwicz L et al. (2017). MABp1 as a novel antibody treatment for 
advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. 
Lancet Oncol 18(2): 192-201. doi or PMID: 10.1016/s1470-2045(17)30006-2 
162 Punt CJA, Koopman M & Vermeulen L (2016). From tumour heterogeneity to advances in 
precision treatment of colorectal cancer. Nat Rev Clin Oncol 14: 235. doi or PMID: 
10.1038/nrclinonc.2016.171 
163 Lito P, Rosen N & Solit DB (2013). Tumor adaptation and resistance to RAF inhibitors. Nat 
Med 19(11): 1401-1409. doi or PMID: 10.1038/nm.3392 
164 Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC et al. (2011). mTOR kinase inhibition 
causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1(3): 248-
259. doi or PMID: 10.1158/2159-8290.cd-11-0085 
165 Pratilas CA & Solit DB (2010). Targeting the mitogen-activated protein kinase pathway: 
physiological feedback and drug response. Clin Cancer Res 16(13): 3329-3334. doi or PMID: 
10.1158/1078-0432.ccr-09-3064 
166 Castells M, Thibault B, Delord J-P et al. (2012). Implication of tumor microenvironment in 
chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J 
Mol Sci 13(8): 9545-9571. doi or PMID: 10.3390/ijms13089545 
167 Holohan C, Van Schaeybroeck S, Longley DB et al. (2013). Cancer drug resistance: an evolving 
paradigm. Nat Rev Cancer 13(10): 714-726. doi or PMID: 10.1038/nrc3599 
168 Holzel M, Bovier A & Tuting T (2013). Plasticity of tumour and immune cells: a source of 
heterogeneity and a cause for therapy resistance? Nat Rev Cancer 13(5): 365-376. doi or 
PMID: 10.1038/nrc3498 
112 
 
169 Bray F, Ferlay J, Soerjomataram I et al. (2018). Global cancer statistics 2018: GLOBOCAN 
estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J 
Clin 68(6): 394-424. doi or PMID: 10.3322/caac.21492 
170 Hölzel D, Schubert-Fritschle G, Schmidt M et al. (2016). Klinisch-epidemiologische 
Krebsregistrierung in Deutschland. Der Pathologe 37(4): 371-387. doi or PMID: 
10.1007/s00292-016-0188-2 
171 Popat S, Hubner R & Houlston RS (2005). Systematic Review of Microsatellite Instability and 
Colorectal Cancer Prognosis. J Clin Oncol 23(3): 609-618. doi or PMID: 
10.1200/JCO.2005.01.086 
172 Jo WS & Carethers JM (2006). Chemotherapeutic implications in microsatellite unstable 
colorectal cancer. Cancer Biomark 2(1-2): 51-60. doi or PMID: 17192059 
173 Cunningham D, Humblet Y, Siena S et al. (2004). Cetuximab Monotherapy and Cetuximab 
plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N Engl J Med 351(4): 
337-345. doi or PMID: 10.1056/NEJMoa033025 
174 De Roock W, Claes B, Bernasconi D et al. (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA 
mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory 
metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11(8): 753-
762. doi or PMID: 10.1016/s1470-2045(10)70130-3 
175 Tol J, Koopman M, Cats A et al. (2009). Chemotherapy, Bevacizumab, and Cetuximab in 
Metastatic Colorectal Cancer. N Engl J Med 360(6): 563-572. doi or PMID: 
10.1056/NEJMoa0808268 
176 Sargent DJ, Marsoni S, Monges G et al. (2010). Defective mismatch repair as a predictive 
marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 
28(20): 3219-3226. doi or PMID: 10.1200/JCO.2009.27.1825 
177 Ribic CM, Sargent DJ, Moore MJ et al. (2003). Tumor Microsatellite-Instability Status as a 
Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. N 
Engl J Med 349(3): 247-257. doi or PMID: 10.1056/NEJMoa022289 
178 Siena S, Sartore-Bianchi A, Lonardi S et al. (2015). Trastuzumab and lapatinib in HER2-
amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol 
33(15_suppl): 3508-3508. doi or PMID: 10.1200/jco.2015.33.15_suppl.3508 
179 Stahler A, Heinemann V, Giessen-Jung C et al. (2016). Influence of mRNA expression of 
epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer 
treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment 
(FIRE 1-trial). Int J Cancer 138(3): 739-746. doi or PMID: 10.1002/ijc.29807 
180 Jing C, Jin YH, You Z et al. (2016). Prognostic value of amphiregulin and epiregulin mRNA 
expression in metastatic colorectal cancer patients. Oncotarget 7(34): 55890-55899. doi or 
PMID: 10.18632/oncotarget.10151 
181 Ma Y, Zhang P, Wang F et al. (2012). miR-150 as a potential biomarker associated with 
prognosis and therapeutic outcome in colorectal cancer. Gut 61(10): 1447-1453. doi or PMID: 
10.1136/gutjnl-2011-301122 
182 Liu H, Du L, Wen Z et al. (2013). Up-regulation of miR-182 expression in colorectal cancer 
tissues and its prognostic value. Int J Colorectal Dis 28(5): 697-703. doi or PMID: 
10.1007/s00384-013-1674-0 
183 Guinney J, Dienstmann R, Wang X et al. (2015). The consensus molecular subtypes of 
colorectal cancer. Nat Med 21(11): 1350-1356. doi or PMID: 10.1038/nm.3967 
184 Shirahata A, Sakata M, Kitamura Y et al. (2010). MACC 1 as a marker for peritoneal-
disseminated gastric carcinoma. Anticancer Res 30(9): 3441-3444. doi or PMID: 20944120 
185 Lang AH, Geller-Rhomberg S, Winder T et al. (2012). A common variant of the MACC1 gene is 
significantly associated with overall survival in colorectal cancer patients. BMC Cancer 12: 20. 
doi or PMID: 10.1186/1471-2407-12-20 
113 
 
186 Isella C, Mellano A, Galimi F et al. (2013). MACC1 mRNA levels predict cancer recurrence 
after resection of colorectal cancer liver metastases. Ann Surg 257(6): 1089-1095. doi or 
PMID: 10.1097/SLA.0b013e31828f96bc 
187 Shirahata A, Shinmura K, Kitamura Y et al. (2010). MACC1 as a marker for advanced 
colorectal carcinoma. Anticancer Res 30(7): 2689-2692. doi or PMID:  
188 Wisniewski JR, Ostasiewicz P & Mann M (2011). High recovery FASP applied to the proteomic 
analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known 
colon cancer markers. J Proteome Res 10(7): 3040-3049. doi or PMID: 10.1021/pr200019m 
189 Harpaz N, Taboada S, Ko HM et al. (2014). Expression of MACC1 and MET in inflammatory 
bowel disease-associated colonic neoplasia. Inflamm Bowel Dis 20(4): 703-711. doi or PMID: 
10.1097/01.mib.0000442679.39804.48 
190 Galimi F, Torti D, Sassi F et al. (2011). Genetic and expression analysis of MET, MACC1, and 
HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and 
pathologic correlations. Clin Cancer Res 17(10): 3146-3156. doi or PMID:  
191 Stein U, Dahlmann M & Walther W (2010). MACC1 - more than metastasis? Facts and 
predictions about a novel gene. J Mol Med 88(1): 11-18. doi or PMID: 10.1007/s00109-009-
0537-1 
192 Zlobec I (2013). Novel biomarkers for the prediction of metastasis in colorectal cancer. Expert 
Opin Med Diagn 7(2): 137-146. doi or PMID: 10.1517/17530059.2013.753054 
193 Kopczyńska EK (2016). The potential therapeutic applications and prognostic significance of 
metastasis-associated in colon cancer-1 (MACC1) in cancers. Contemp Oncol (Pozn) 20(4): 
273-280. doi or PMID: 10.5114/wo.2016.61846 
194 Wu Z-Z, Chen L-S, Zhou R et al. (2016). Metastasis-associated in colon cancer-1 in gastric 
cancer: Beyond metastasis. World J Gastroenterol 22(29): 6629-6637. doi or PMID: 
10.3748/wjg.v22.i29.6629 
195 Mudduluru G, Ilm K, Dahlmann M et al. in Mechanisms of Molecular Carcinogenesis; MACC1, 
a Novel Player in Solid Cancer Carcinogenesis. Vol. 1, 11-38 (Springer International 
Publishing, 2017). 
196 Wang G, Fu Z & Li D (2015). MACC1 overexpression and survival in solid tumors: a meta-
analysis. Tumour Biol 36(2): 1055-1065. doi or PMID: 10.1007/s13277-014-2736-9 
197 Wu Z, Zhou R, Su Y et al. (2015). Prognostic Value of MACC1 in Digestive System Neoplasms: 
A Systematic Review and Meta-Analysis. Biomed Res Int 2015: 252043. doi or PMID: 
10.1155/2015/252043 
198 Sun DW, Zhang YY, Qi Y et al. (2015). Prognostic and clinicopathological significance of 
MACC1 expression in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med 
8(4): 4769-4777. doi or PMID: 26131051 
199 Zhao Y, Dai C, Wang M et al. (2016). Clinicopathological and prognostic significance of 
metastasis-associated in colon cancer-1 (MACC1) overexpression in colorectal cancer: a 
meta-analysis. Oncotarget 7(39): 62966-62975. doi or PMID: 10.18632/oncotarget.11287 
200 Huang Y, Zhang H, Cai J et al. (2013). Overexpression of MACC1 and Its significance in human 
Breast Cancer Progression. Cell Biosci 3(1): 16. doi or PMID: 10.1186/2045-3701-3-16 
201 Chundong G, Uramoto H, Onitsuka T et al. (2011). Molecular diagnosis of MACC1 status in 
lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 31(4): 1141-1145. 
doi or PMID: 21508357 
202 Qiu J, Huang P, Liu Q et al. (2011). Identification of MACC1 as a novel prognostic marker in 
hepatocellular carcinoma. J Transl Med 9: 166. doi or PMID: 10.1186/1479-5876-9-166 
203 Hagemann C, Fuchs S, Monoranu CM et al. (2013). Impact of MACC1 on human malignant 
glioma progression and patients' unfavorable prognosis. Neuro Oncol 15(12): 1696-1709. doi 
or PMID: 10.1093/neuonc/not136 
114 
 
204 Wang Y, Hong Q, Wang J et al. (2014). Downregulated expression of metastasis associated in 
colon cancer 1 (MACC1) reduces gallbladder cancer cell proliferation and invasion. Tumour 
Biol 35(4): 3771-3778. doi or PMID: 10.1007/s13277-013-1499-z 
205 Zhu M, Xu Y, Mao X et al. (2013). Overexpression of metastasis-associated in colon cancer-1 
associated with poor prognosis in patients with esophageal cancer. Pathol Oncol Res 19(4): 
749-753. doi or PMID: 10.1007/s12253-013-9638-9 
206 Jin Y, Zhou K, Zhao W et al. (2019). Clinicopathological and prognostic significance of 
metastasis-associated in colon cancer-1 in gastric cancer: A meta-analysis. Int J Biol Markers 
34(1): 27-32. doi or PMID: 10.1177/1724600818813634 
207 Stein U, Burock S, Herrmann P et al. (2012). Circulating MACC1 transcripts in colorectal 
cancer patient plasma predict metastasis and prognosis. PLoS One 7(11): e49249. doi or 
PMID: 10.1371/journal.pone.0049249 
208 Wang G, Kang MX, Lu WJ et al. (2012). MACC1: A potential molecule associated with 
pancreatic cancer metastasis and chemoresistance. Oncol Lett 4(4): 783-791. doi or PMID: 
10.3892/ol.2012.784 
209 Burock S, Herrmann P, Wendler I et al. (2015). Circulating Metastasis Associated in Colon 
Cancer 1 transcripts in gastric cancer patient plasma as diagnostic and prognostic biomarker. 
World J Gastroenterol 21(1): 333-341. doi or PMID: 10.3748/wjg.v21.i1.333 
210 Wang Z, Cai M, Weng Y et al. (2015). Circulating MACC1 as a novel diagnostic and prognostic 
biomarker for nonsmall cell lung cancer. J Cancer Res Clin Oncol 141(8): 1353-1361. doi or 
PMID: 10.1007/s00432-014-1903-0 
211 Tan W, Xie X, Li L et al. (2016). Diagnostic and prognostic value of serum MACC1 in breast 
cancer patients. Oncotarget 7(51): 84408-84415. doi or PMID: 10.18632/oncotarget.12910 
212 Ashktorab H, Hermann P, Nouraie M et al. (2016). Increased MACC1 levels in tissues and 
blood identify colon adenoma patients at high risk. J Transl Med 14(1): 215. doi or PMID: 
10.1186/s12967-016-0971-0 
213 Shimokawa H, Uramoto H, Onitsuka T et al. (2011). Overexpression of MACC1 mRNA in lung 
adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg 
141(4): 895-898. doi or PMID: 10.1016/j.jtcvs.2010.09.044 
214 Gao S, Lin B-Y, Yang Z et al. (2014). Role of overexpression of MACC1 and/or FAK in predicting 
prognosis of hepatocellular carcinoma after liver transplantation. Int J Med Sci 11(3): 268-
275. doi or PMID: 10.7150/ijms.7769 
215 Radhakrishnan H, Walther W, Zincke F et al. (2018). MACC1-the first decade of a key 
metastasis molecule from gene discovery to clinical translation. Cancer Metastasis Rev 37(4): 
805-820. doi or PMID: 10.1007/s10555-018-9771-8 
216 Li HF, Liu YQ, Shen ZJ et al. (2015). Downregulation of MACC1 inhibits invasion, migration and 
proliferation, attenuates cisplatin resistance and induces apoptosis in tongue squamous cell 
carcinoma. Oncol Rep 33(2): 651-660. doi or PMID: 10.3892/or.2014.3612 
217 Shang C, Hong Y, Guo Y et al. (2015). Influence of the MACC1 Gene on Sensitivity to 
Chemotherapy in Human U251 Glioblastoma Cells. Asian Pac J Cancer Prev 16(1): 195-199. 
doi or PMID: 10.7314/APJCP.2015.16.1.195 
218 Chen ZM, Shi HR, Li X et al. (2015). Downregulation of MACC1 expression enhances cisplatin 
sensitivity in SKOV-3/DDP cells. Genet Mol Res 14(4): 17134-17144. doi or PMID: 
10.4238/2015.December.16.13 
219 Zhang R, Shi H, Ren F et al. (2016). Knockdown of MACC1 expression increases cisplatin 
sensitivity in cisplatin-resistant epithelial ovarian cancer cells. Oncol Rep 35(4): 2466-2472. 
doi or PMID: 10.3892/or.2016.4585 
220 Wang C, Wen Z, Xie J et al. (2017). MACC1 mediates chemotherapy sensitivity of 5-FU and 
cisplatin via regulating MCT1 expression in gastric cancer. Biochem Biophys Res Commun 
485(3): 665-671. doi or PMID: 10.1016/j.bbrc.2017.02.096 
115 
 
221 Zhang Q, Zhang B, Sun L et al. (2018). Cisplatin resistance in lung cancer is mediated by 
MACC1 expression through PI3K/AKT signaling pathway activation. Acta Biochim Biophys Sin 
(Shanghai) 50(8): 748-756. doi or PMID: 10.1093/abbs/gmy074 
222 Duan J, Chen L, Zhou M et al. (2017). MACC1 decreases the chemosensitivity of gastric cancer 
cells to oxaliplatin by regulating FASN expression. Oncol Rep 37(5): 2583-2592. doi or PMID: 
10.3892/or.2017.5519 
223 Wang J, Wang W, Cai H et al. (2017). MACC1 facilitates chemoresistance and cancer stem 
cell-like properties of colon cancer cells through the PI3K/AKT signaling pathway. Mol Med 
Rep 16(6): 8747-8754. doi or PMID: 10.3892/mmr.2017.7721 
224 Rohr UP, Herrmann P, Ilm K et al. (2017). Prognostic value of MACC1 and proficient mismatch 
repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID 
studies. Annals of Oncology 28(8): 1869-1875. doi or PMID: 10.1093/annonc/mdx207 
225 Zhou W, Liu L, Xue Y et al. (2017). Combination of Endothelial-Monocyte-Activating 
Polypeptide-II with Temozolomide Suppress Malignant Biological Behaviors of Human 
Glioblastoma Stem Cells via miR-590-3p/MACC1 Inhibiting PI3K/AKT/mTOR Signal Pathway. 
Front Mol Neurosci 10: 68. doi or PMID: 10.3389/fnmol.2017.00068 
226 Kawamura M, Saigusa S, Toiyama Y et al. (2012). Correlation of MACC1 and MET expression 
in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res 32(4): 1527-1531. doi 
or PMID: 22493396 
227 Yang Y-P, Qu J-H, Chang X-J et al. (2013). High intratumoral metastasis-associated in colon 
cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced 
hepatocellular carcinoma. J Transl Med 11(1): 41. doi or PMID: 10.1186/1479-5876-11-41 
228 Zhou X, Xu CJ, Wang JX et al. (2015). Metastasis-Associated in Colon Cancer-1 Associates 
With Poor Prognosis and Promotes Cell Invasion and Angiogenesis in Human Cervical Cancer. 
Int J Gynecol Cancer 25(8): 1353-1363. doi or PMID: 10.1097/igc.0000000000000524 
229 Yang T, Kong B, Kuang YQ et al. (2014). Overexpression of MACC1 protein and its clinical 
implications in patients with glioma. Tumour Biol 35(1): 815-819. doi or PMID: 
10.1007/s13277-013-1112-5 
230 Koelzer VH, Herrmann P, Zlobec I et al. (2015). Heterogeneity analysis of Metastasis 
Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a 
retrospective cohort study. BMC Cancer 15: 160. doi or PMID: 10.1186/s12885-015-1150-z 
231 Barbazan J, Dunkel Y, Li H et al. (2016). Prognostic Impact of Modulators of G proteins in 
Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer. Sci Rep 6: 22112. doi 
or PMID: 10.1038/srep22112 
232 Ren B, Zakharov V, Yang Q et al. (2013). MACC1 is related to colorectal cancer initiation and 
early-stage invasive growth. Am J Clin Pathol 140(5): 701-707. doi or PMID: 
10.1309/ajcprh1h5rwwsxrb 
233 Zhang R, Shi H, Chen Z et al. (2011). Effects of metastasis-associated in colon cancer 1 
inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. J Exp Clin Cancer Res 30: 
83. doi or PMID: 10.1186/1756-9966-30-83 
234 Zhang Y, Wang Z, Chen M et al. (2012). MicroRNA-143 targets MACC1 to inhibit cell invasion 
and migration in colorectal cancer. Mol Cancer 11: 23. doi or PMID: 10.1186/1476-4598-11-
23 
235 Gao J, Ding F, Liu Q et al. (2013). Knockdown of MACC1 expression suppressed hepatocellular 
carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol 
Cell Biochem 376(1-2): 21-32. doi or PMID: 10.1007/s11010-012-1545-y 
236 Wang L, Wu Y, Lin L et al. (2013). Metastasis-associated in colon cancer-1 upregulation 
predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and 
invasion. Int J Cancer 133(6): 1419-1430. doi or PMID: 10.1002/ijc.28140 
116 
 
237 Meng F, Li H, Shi H et al. (2013). MACC1 down-regulation inhibits proliferation and 
tumourigenicity of nasopharyngeal carcinoma cells through Akt/beta-catenin signaling 
pathway. PLoS One 8(4): 3. doi or PMID: 10.1371/journal.pone.0060821 
238 Juneja M, Ilm K, Schlag PM et al. (2013). Promoter identification and transcriptional 
regulation of the metastasis gene MACC1 in colorectal cancer. Mol Oncol 7(5): 929-943. doi 
or PMID: 10.1016/j.molonc.2013.05.003 
239 Lemos C, Hardt MS, Juneja M et al. (2016). MACC1 Induces Tumor Progression in Transgenic 
Mice and Colorectal Cancer Patients via Increased Pluripotency Markers Nanog and Oct4. Clin 
Cancer Res 22(11): 2812-2824. doi or PMID: 10.1158/1078-0432.ccr-15-1425 
240 Pichorner A, Sack U, Kobelt D et al. (2012). In vivo imaging of colorectal cancer growth and 
metastasis by targeting MACC1 with shRNA in xenografted mice. Clin Exp Metastasis 29(6): 
573-583. doi or PMID: 10.1007/s10585-012-9472-6 
241 Yao Y, Dou C, Lu Z et al. (2015). MACC1 suppresses cell apoptosis in hepatocellular carcinoma 
by targeting the HGF/c-MET/AKT pathway. Cell Physiol Biochem 35(3): 983-996. doi or PMID: 
10.1159/000369754 
242 Liu J, Pan C, Guo L et al. (2016). A new mechanism of trastuzumab resistance in gastric 
cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling 
pathway. J Hematol Oncol 9(1): 76. doi or PMID: 10.1186/s13045-016-0302-1 
243 Stein U, Smith J, Walther W et al. (2009). MACC1 controls Met: what a difference an Sp1 site 
makes. Cell Cycle 8(15): 2467-2469. doi or PMID: 10.4161/cc.8.15.9018 
244 Arlt F & Stein U (2009). Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. 
Int J Biochem Cell Biol 41(12): 2356-2359. doi or PMID: 10.1016/j.biocel.2009.08.001 
245 Sun L, Duan J, Jiang Y et al. (2015). Metastasis-associated in colon cancer-1 upregulates 
vascular endothelial growth factor-C/D to promote lymphangiogenesis in human gastric 
cancer. Cancer Lett 357(1): 242-253. doi or PMID: 10.1016/j.canlet.2014.11.035 
246 Xia J, Wang H, Huang H et al. (2016). Elevated Orai1 and STIM1 expressions upregulate 
MACC1 expression to promote tumor cell proliferation, metabolism, migration, and invasion 
in human gastric cancer. Cancer Lett 381(1): 31-40. doi or PMID: 
10.1016/j.canlet.2016.07.014 
247 Wang L, Lin L, Chen X et al. (2015). Metastasis-associated in colon cancer-1 promotes 
vasculogenic mimicry in gastric cancer by upregulating TWIST1/2. Oncotarget 6(13): 11492-
11506. doi or PMID: 10.18632/oncotarget.3416 
248 Wang L, Zhou R, Zhao Y et al. (2016). MACC-1 Promotes Endothelium-Dependent 
Angiogenesis in Gastric Cancer by Activating TWIST1/VEGF-A Signal Pathway. PLoS One 11(6): 
e0157137. doi or PMID: 10.1371/journal.pone.0157137 
249 Huang N, Wu Z, Lin L et al. (2015). MiR-338-3p inhibits epithelial-mesenchymal transition in 
gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. Oncotarget 6(17): 
15222-15234. doi or PMID: 10.18632/oncotarget.3835 
250 Zhen T, Dai S, Li H et al. (2014). MACC1 promotes carcinogenesis of colorectal cancer via 
beta-catenin signaling pathway. Oncotarget 5(11): 3756-3769. doi or PMID: 
10.18632/oncotarget.1993 
251 Chen S, Zong Z-H, Wu D-d et al. (2016). The role of metastasis-associated in colon cancer 1 
(MACC1) in endometrial carcinoma tumorigenesis and progression. Molecular Carcinogenesis 
56(4): 1361-1371. doi or PMID: 10.1002/mc.22599 
252 Ding Y, Li X, Hong D et al. (2016). Silence of MACC1 decreases cell migration and invasion in 
human malignant melanoma through inhibiting the EMT. Biosci Trends 10(4): 258-264. doi or 
PMID: 10.5582/bst.2016.01091 
253 Montorsi L, Guizzetti F, Alecci C et al. (2016). Loss of ZFP36 expression in colorectal cancer 
correlates to wnt/ ss-catenin activity and enhances epithelial-to-mesenchymal transition 
through upregulation of ZEB1, SOX9 and MACC1. Oncotarget 7(37): 59144-59157. doi or 
PMID: 10.18632/oncotarget.10828 
117 
 
254 Zhou L, Yu L, Zhu B et al. (2016). Metastasis-associated in colon cancer-1 and aldehyde 
dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer. 
BMC Cancer 16(1): 876. doi or PMID: 10.1186/s12885-016-2903-z 
255 Evran E, Sahin H, Akbas K et al. (2016). Investigation of MACC1 Gene Expression in Head and 
Neck Cancer and Cancer Stem Cells. Clin Invest Med 39(6): 27506. doi or PMID: 27917797 
256 Yu L, Zhu B, Wu S et al. (2017). Evaluation of the correlation of vasculogenic mimicry, ALDH1, 
KiSS-1, and MACC1 in the prediction of metastasis and prognosis in ovarian carcinoma. Diagn 
Pathol 12(1): 23. doi or PMID: 10.1186/s13000-017-0612-9 
257 Nair RM, Balla MM, Khan I et al. (2017). In vitro characterization of CD133(lo) cancer stem 
cells in Retinoblastoma Y79 cell line. BMC Cancer 17(1): 779. doi or PMID: 10.1186/s12885-
017-3750-2 
258 Lin L, Huang H, Liao W et al. (2014). MACC1 supports human gastric cancer growth under 
metabolic stress by enhancing the Warburg effect. Oncogene 21(10): 204. doi or PMID: 
10.1038/onc.2014.204 
259 Zhao Y, Liu Y, Lin L et al. (2018). The lncRNA MACC1-AS1 promotes gastric cancer cell 
metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1. Molecular Cancer 
17(1): 69. doi or PMID: 10.1186/s12943-018-0820-2 
260 Ji D, Lu ZT, Li YQ et al. (2014). MACC1 expression correlates with PFKFB2 and survival in 
hepatocellular carcinoma. Asian Pac J Cancer Prev 15(2): 999-1003. doi or PMID: 24568531 
261 Li Y, Lu Z, Liang Z et al. (2015). Metastasis-associated in colon cancer-1 is associated with 
poor prognosis in hepatocellular carcinoma, partly by promoting proliferation through 
enhanced glucose metabolism. Mol Med Rep 12(1): 426-434. doi or PMID: 
10.3892/mmr.2015.3416 
262 Zhang T, Liu W, Zeng XC et al. (2016). Down-regulation of microRNA-338-3p promoted 
angiogenesis in hepatocellular carcinoma. Biomed Pharmacother 84: 583-591. doi or PMID: 
10.1016/j.biopha.2016.09.056 
263 Elding H, Lau W, Swallow DM et al. (2013). Refinement in localization and identification of 
gene regions associated with Crohn disease. Am J Hum Genet 92(1): 107-113. doi or PMID: 
10.1016/j.ajhg.2012.11.004 
264 Dulai PS, Sandborn WJ & Gupta S (2016). Colorectal Cancer and Dysplasia in Inflammatory 
Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. 
Cancer Prev Res (Phila). 9(12): 887-894. doi or PMID: 10.1158/1940-6207.CAPR-16-0124 
265 Erreni M, Mantovani A & Allavena P (2011). Tumor-associated Macrophages (TAM) and 
Inflammation in Colorectal Cancer. Cancer Microenviron 4(2): 141-154. doi or PMID: 
10.1007/s12307-010-0052-5 
266 Low-Marchelli JM, Ardi VC, Vizcarra EA et al. (2013). Twist1 induces CCL2 and recruits 
macrophages to promote angiogenesis. Cancer Res 73(2): 662-671. doi or PMID: 
10.1158/0008-5472.can-12-0653 
267 Sun L, Li G, Dai B et al. (2015). Silence of MACC1 expression by RNA interference inhibits 
proliferation, invasion and metastasis, and promotes apoptosis in U251 human malignant 
glioma cells. Mol Med Report 12(3): 3423-3431. doi or PMID: 10.3892/mmr.2015.3886 
268 Radhakrishnan H, Ilm K, Walther W et al. (2017). MACC1 regulates Fas mediated apoptosis 
through STAT1/3 - Mcl-1 signaling in solid cancers. Cancer Lett 403: 231-245. doi or PMID: 
10.1016/j.canlet.2017.06.020 
269 Chen XP, Ren XP, Lan JY et al. (2014). Analysis of HGF, MACC1, C-met and apoptosis-related 
genes in cervical carcinoma mice. Mol Biol Rep 41(3): 1247-1256. doi or PMID: 
10.1007/s11033-013-2969-5 
270 Zhang X, Zhang L, Jia C et al. (2017). MACC1 overexpression induces cisplatin resistance in 
lung adenocarcinoma A549 cells by activating c-Met/Akt pathway. Int J Clin Exp Med 10(8): 
11778-11786. doi or PMID: 1940-5901/IJCEM0052397 
118 
 
271 Zhang K, Tian F, Zhang Y et al. (2014). MACC1 is involved in the regulation of proliferation, 
colony formation, invasion ability, cell cycle distribution, apoptosis and tumorigenicity by 
altering Akt signaling pathway in human osteosarcoma. Tumour Biol 35(3): 2537-2548. doi or 
PMID: 10.1007/s13277-013-1335-5 
272 Schmid F, Wang Q, Huska MR et al. (2016). SPON2, a newly identified target gene of MACC1, 
drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient 
survival. Oncogene 35(46): 5942-5952. doi or PMID: 10.1038/onc.2015.451 
273 Qian LQ, Li XQ, Ye PH et al. (2017). Downregulation of MACC1 inhibits the viability, invasion 
and migration and induces apoptosis in esophageal carcinoma cells through the phosphatase 
and tensin homolog/phosphoinositide 3-kinase/protein kinase B signaling pathway. Oncol 
Lett 14(4): 4897-4905. doi or PMID: 10.3892/ol.2017.6790 
274 Juneja M, Kobelt D, Walther W et al. (2017). Statin and rottlerin small-molecule inhibitors 
restrict colon cancer progression and metastasis via MACC1. PLoS Biol 15(6): e2000784. doi 
or PMID: 10.1371/journal.pbio.2000784 
275 Guo T, Zhao S, Wang P et al. (2017). YB-1 regulates tumor growth by promoting MACC1/c-
Met pathway in human lung adenocarcinoma. Oncotarget 8(29): 48110-48125. doi or PMID: 
10.18632/oncotarget.18262 
276 Li S, Zhu J, Li J et al. (2018). MicroRNA-141 inhibits proliferation of gastric cardia 
adenocarcinoma by targeting MACC1. Arch Med Sci 14(3): 588-596. doi or PMID: 
10.5114/aoms.2017.68757 
277 Tokarz P & Blasiak J (2012). The role of microRNA in metastatic colorectal cancer and its 
significance in cancer prognosis and treatment. Acta Biochim Pol 59(4): 467-474. doi or 
PMID: 23173124 
278 Wang G, Gu J & Gao Y (2016). MicroRNA target for MACC1 and CYR61 to inhibit tumor 
growth in mice with colorectal cancer. Tumour Biol 37(10): 13983-13993. doi or PMID: 
10.1007/s13277-016-5252-2 
279 Feng J, Wang J, Chen M et al. (2015). miR-200a suppresses cell growth and migration by 
targeting MACC1 and predicts prognosis in hepatocellular carcinoma. Oncol Rep 33(2): 713-
720. doi or PMID: 10.3892/or.2014.3642 
280 Ilm K, Fuchs S, Mudduluru G et al. (2016). MACC1 is post-transcriptionally regulated by miR-
218 in colorectal cancer. Oncotarget 7(33): 53443-53458. doi or PMID: 
10.18632/oncotarget.10803 
281 Shang C, Hong Y, Guo Y et al. (2016). Mir-338-3p Inhibits Malignant Biological Behaviors of 
Glioma Cells by Targeting MACC1 Gene. Med Sci Monit 22: 710-716. doi or PMID: 26936749 
282 Hua FF, Liu SS, Zhu LH et al. (2017). MiRNA-338-3p regulates cervical cancer cells 
proliferation by targeting MACC1 through MAPK signaling pathway. Eur Rev Med Pharmacol 
Sci 21(23): 5342-5352. doi or PMID: 10.26355/eurrev_201712_13919 
283 Li J, Mao X, Wang X et al. (2017). miR-433 reduces cell viability and promotes cell apoptosis 
by regulating MACC1 in colorectal cancer. Oncol Lett 13(1): 81-88. doi or PMID: 
10.3892/ol.2016.5445 
284 Wang S, Zhang Y, Yuan S et al. (2018). MicroRNA485 targets MACC1 and inhibits cervical 
cancer cell proliferation and invasion. Mol Med Rep 18(2): 2407-2416. doi or PMID: 
10.3892/mmr.2018.9186 
285 Ma L, Zhou Y, Luo X et al. (2017). Long non-coding RNA XIST promotes cell growth and 
invasion through regulating miR-497/MACC1 axis in gastric cancer. Oncotarget 8(3): 4125-
4135. doi or PMID: 10.18632/oncotarget.13670 
286 Cui Z, Tang J, Chen J et al. (2014). Hsa-miR-574-5p negatively regulates MACC-1 expression to 
suppress colorectal cancer liver metastasis. Cancer Cell Int 14: 47-47. doi or PMID: 
10.1186/1475-2867-14-47 
119 
 
287 Wang N, Zhang Y & Liang H (2018). MicroRNA-598 Inhibits Cell Proliferation and Invasion of 
Glioblastoma by Directly Targeting Metastasis Associated in Colon Cancer-1 (MACC1). Oncol 
Res 26(8): 1275-1283. doi or PMID: 10.3727/096504018x15185735627746 
288 Pan T, Chen W, Yuan X et al. (2017). miR-944 inhibits metastasis of gastric cancer by 
preventing the epithelial-mesenchymal transition via MACC1/Met/AKT signaling. FEBS Open 
Bio 7(7): 905-914. doi or PMID: 10.1002/2211-5463.12215 
289 Wen L, Li Y, Jiang Z et al. (2017). miR-944 inhibits cell migration and invasion by targeting 
MACC1 in colorectal cancer. Oncol Rep 37(6): 3415-3422. doi or PMID: 10.3892/or.2017.5611 
290 Zerbino DR, Achuthan P, Akanni W et al. (2018). Ensembl 2018. Nucleic Acids Res 46(D1): 
D754-d761. doi or PMID: 10.1093/nar/gkx1098 
291 Thierry-Mieg D & Thierry-Mieg J (2006). AceView: a comprehensive cDNA-supported gene 
and transcripts annotation. Genome Biol 7(1): S12. doi or PMID: 10.1186/gb-2006-7-s1-s12 
292 Kurochkina N & Guha U (2012). SH3 domains: modules of protein-protein interactions. 
Biophys Rev 5(1): 29-39. doi or PMID: 10.1007/s12551-012-0081-z 
293 Yasunaga M, Ipsaro JJ & Mondragon A (2012). Structurally similar but functionally diverse 
ZU5 domains in human erythrocyte ankyrin. J Mol Biol 417(4): 336-350. doi or PMID: 
10.1016/j.jmb.2012.01.041 
294 Wang C, Yu C, Ye F et al. (2012). Structure of the ZU5-ZU5-UPA-DD tandem of ankyrin-B 
reveals interaction surfaces necessary for ankyrin function. Proc Natl Acad Sci U S A 109(13): 
4822-4827. doi or PMID: 10.1073/pnas.1200613109 
295 Park HH, Lo YC, Lin SC et al. (2007). The death domain superfamily in intracellular signaling of 
apoptosis and inflammation. Annu Rev Immunol 25: 561-586. doi or PMID: 
10.1146/annurev.immunol.25.022106.141656 
296 Felder S, Zhou M, Hu P et al. (1993). SH2 domains exhibit high-affinity binding to tyrosine-
phosphorylated peptides yet also exhibit rapid dissociation and exchange. Mol Cell Biol 13 
doi or PMID: 10.1128/mcb.13.3.1449 
297 Filippakopoulos P, Müller S & Knapp S (2009). SH2 domains: modulators of nonreceptor 
tyrosine kinase activity. Current Opinion in Structural Biology 19(6): 643-649. doi or PMID: 
10.1016/j.sbi.2009.10.001 
298 Cohen P (2002). The origins of protein phosphorylation. Nat Cell Biol 4: E127. doi or PMID: 
10.1038/ncb0502-e127 
299 Manning G, Whyte DB, Martinez R et al. (2002). The protein kinase complement of the 
human genome. Science 298(5600): 1912-1934. doi or PMID: 10.1126/science.1075762 
300 Kobelt D, Perez-Hernandez D, Fleuter C et al. (2019). Clinically applicable MEK1 inhibitors 
restrict metastasis driven by the novel MEK1 substrate MACC1. submitted doi or PMID:  
301 Sack U, Walther W, Scudiero D et al. (2011). Novel effect of antihelminthic Niclosamide on 
S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst 103(13): 1018-
1036. doi or PMID: 10.1093/jnci/djr190 
302 Ran FA, Hsu PD, Wright J et al. (2013). Genome engineering using the CRISPR-Cas9 system. 
Nat Protoc 8: 2281. doi or PMID: 10.1038/nprot.2013.143 
303 abcam (2019). Stripping for reprobing. 
https://www.abcam.com/ps/pdf/protocols/stripping%20for%20reprobing.pdf  
304 Treindl F, Ruprecht B, Beiter Y et al. (2016). A bead-based western for high-throughput 
cellular signal transduction analyses. Nat Commun 7: 12852. doi or PMID: 
10.1038/ncomms12852 
305 Puck TT & Marcus PI (1956). Action of x-rays on mammalian cells. J Exp Med 103(5): 653-666. 
doi or PMID: 13319584 
306 Franken NAP, Rodermond HM, Stap J et al. (2006). Clonogenic assay of cells in vitro. Nat 
Protoc 1: 2315. doi or PMID: 10.1038/nprot.2006.339 
307 Rafehi H, Orlowski C, Georgiadis GT et al. (2011). Clonogenic assay: adherent cells. J Vis 
Exp(49): 2573. doi or PMID: 10.3791/2573 
120 
 
308 Rajadurai CV, Havrylov S, Zaoui K et al. (2012). Met receptor tyrosine kinase signals through a 
cortactin-Gab1 scaffold complex, to mediate invadopodia. J Cell Sci 125(Pt 12): 2940-2953. 
doi or PMID: 10.1242/jcs.100834 
309 PamGene International B.V. (2019). PamChip Content, Tyrosine Kinase Arrays. 
https://www.pamgene.com/upload/image/Files/PTK%20PamChip%2086312.pdf 
310 PamGene International B.V. (2019). PamChip Content, Serine/Threonine Kinase Arrays. 
https://www.pamgene.com/upload/image/Files/STK%20PamChip%2087102.pdf 
311 PamGene International B.V. (2019). Tyrosine Kinase PamChip assay principle. 
https://www.pamgene.com/en/Tyrosine-PamChip.htm 
312 PamGene International B.V. (2019). Ser/Thr Kinase (STK) PamChip assay principle. 
https://www.pamgene.com/en/SerThr-PamChip.htm 
313 Medard G, Pachl F, Ruprecht B et al. (2015). Optimized chemical proteomics assay for kinase 
inhibitor profiling. J Proteome Res 14(3): 1574-1586. doi or PMID: 10.1021/pr5012608 
314 Cox J & Mann M (2008). MaxQuant enables high peptide identification rates, individualized 
p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26: 
1367. doi or PMID: 10.1038/nbt.1511 
315 Cox J, Neuhauser N, Michalski A et al. (2011). Andromeda: A Peptide Search Engine 
Integrated into the MaxQuant Environment. J Proteome Res 10(4): 1794-1805. doi or PMID: 
10.1021/pr101065j 
316 Nair AB & Jacob S (2016). A simple practice guide for dose conversion between animals and 
human. J Basic Clin Pharm 7(2): 27-31. doi or PMID: 10.4103/0976-0105.177703 
317 Stone NJ, Robinson JG, Lichtenstein AH et al. (2014). 2013 ACC/AHA Guideline on the 
Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A 
Report of the American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines. J Am Coll Cardiol 63(25, Part B): 2889-2934. doi or PMID: 
10.1016/j.jacc.2013.11.002 
318 Ray MA, Johnston NA, Verhulst S et al. (2010). Identification of markers for imminent death 
in mice used in longevity and aging research. J Am Assoc Lab Anim Sci 49(3): 282-288. doi or 
PMID: 20587157 
319 Wu M, Zhang R, Zou Q et al. (2018). Comparison of the Biological Characteristics of 
Mesenchymal Stem Cells Derived from the Human Placenta and Umbilical Cord. Scientific 
Reports 8(1): 5014. doi or PMID: 10.1038/s41598-018-23396-1 
320 Uhlén M, Fagerberg L, Hallström BM et al. (2015). Tissue-based map of the human proteome. 
Science 347(6220): 1260419. doi or PMID: 10.1126/science.1260419 
321 The Human Protein Atlas (2019). The placenta-specific proteome. 
https://www.proteinatlas.org/humanproteome/tissue/placenta 
322 Lin JS & Lai EM (2017). Protein-Protein Interactions: Co-Immunoprecipitation. Methods Mol 
Biol 1615: 211-219. doi or PMID: 10.1007/978-1-4939-7033-9_17 
323 Scaltriti M & Baselga J (2006). The Epidermal Growth Factor Receptor Pathway: A Model for 
Targeted Therapy. Clin Cancer Res 12(18): 5268. doi or PMID: 10.1158/1078-0432.CCR-05-
1554 
324 Sampaio C, Dance M, Montagner A et al. (2008). Signal strength dictates phosphoinositide 3-
kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via 
differential Gab1/Shp2 recruitment: consequences for resistance to epidermal growth factor 
receptor inhibition. Mol Cell Biol 28(2): 587-600. doi or PMID: 10.1128/mcb.01318-07 
325 Wee P & Wang Z (2017). Epidermal Growth Factor Receptor Cell Proliferation Signaling 
Pathways. Cancers 9(5) doi or PMID: 10.3390/cancers9050052 
326 Bhullar KS, Lagarón NO, McGowan EM et al. (2018). Kinase-targeted cancer therapies: 
progress, challenges and future directions. Mol Cancer 17(1): 48-48. doi or PMID: 
10.1186/s12943-018-0804-2 
121 
 
327 Bajorath J (2002). Integration of virtual and high-throughput screening. Nat Rev Drug Discov 
1(11): 882-894. doi or PMID: 10.1038/nrd941 
328 Broach JR & Thorner J (1996). High-throughput screening for drug discovery. Nature 
384(6604 Suppl): 14-16. doi or PMID: 10.1038/384014a0 
329 van de Klundert MAA, Zaaijer HL & Kootstra NA (2016). Identification of FDA-approved drugs 
that target hepatitis B virus transcription. J Viral Hepat 23(3): 191-201. doi or PMID: 
10.1111/jvh.12479 
330 Kolosenko I, Yu Y, Busker S et al. (2017). Identification of novel small molecules that inhibit 
STAT3-dependent transcription and function. PLOS ONE 12(6): e0178844. doi or PMID: 
10.1371/journal.pone.0178844 
331 Muller PY & Milton MN (2012). The determination and interpretation of the therapeutic 
index in drug development. Nat Rev Drug Discov 11: 751. doi or PMID: 10.1038/nrd3801 
332 Adams SP, Sekhon SS, Tsang M et al. (2018). Fluvastatin for lowering lipids. Cochrane 
Database Syst Rev 3(3): CD012282-CD012282. doi or PMID: 
10.1002/14651858.CD012282.pub2 
333 Abbas R & Hsyu P-H (2016). Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib. 
Clin Pharmacokinet 55(10): 1191-1204. doi or PMID: 10.1007/s40262-016-0391-6 
334 Dorsey JF, Cunnick JM, Lanehart R et al. (2002). Interleukin-3 protects Bcr-Abl-transformed 
hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. 
Leukemia 16(9): 1589-1595. doi or PMID: 10.1038/sj.leu.2402678 
335 Tamm C, Galitó SP & Annerén C (2012). Differential effects on cell motility, embryonic stem 
cell self-renewal and senescence by diverse Src kinase family inhibitors. Exp Cell Res 318(4): 
336-349. doi or PMID: 10.1016/j.yexcr.2011.12.008 
336 Lo AK-F, Dawson CW, Young LS et al. (2015). Activation of the FGFR1 signalling pathway by 
the Epstein–Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of 
human nasopharyngeal epithelial cells. J Pathol 237(2): 238-248. doi or PMID: 
10.1002/path.4575 
337 Pushpakom S, Iorio F, Eyers PA et al. (2018). Drug repurposing: progress, challenges and 
recommendations. Nat Rev Drug Discov 18: 41. doi or PMID: 10.1038/nrd.2018.168 
338 Ramkumar S, Raghunath A & Raghunath S (2016). Statin Therapy: Review of Safety and 
Potential Side Effects. Acta Cardiol Sin 32(6): 631-639. doi or PMID: 10.6515/ACS20160611A 
339 Pirillo A & Catapano A (2015). Statin Intolerance: Diagnosis and Remedies. Curr Cardiol Rep 
17(5): 27. doi or PMID: 10.1007/s11886-015-0582-z 
340 Oesterle A, Laufs U & Liao JK (2017). Pleiotropic Effects of Statins on the Cardiovascular 
System. Circ Res 120(1): 229-243. doi or PMID: 10.1161/circresaha.116.308537 
341 Matusewicz L, Meissner J, Toporkiewicz M et al. (2015). The effect of statins on cancer cells--
review. Tumour Biol 36(7): 4889-4904. doi or PMID: 10.1007/s13277-015-3551-7 
342 Hu M & Tomlinson B (2014). Evaluation of the pharmacokinetics and drug interactions of the 
two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab 
Toxicol 10(1): 51-65. doi or PMID: 10.1517/17425255.2014.851667 
343 Schachter M (2005). Chemical, pharmacokinetic and pharmacodynamic properties of statins: 
an update. Fundam Clin Pharmacol 19(1): 117-125. doi or PMID: 10.1111/j.1472-
8206.2004.00299.x 
344 Hagenbuch B & Meier PJ (2004). Organic anion transporting polypeptides of the OATP/ SLC21 
family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and 
molecular/functional properties. Pflugers Arch 447(5): 653-665. doi or PMID: 
10.1007/s00424-003-1168-y 
345 Menter DG, Ramsauer VP, Harirforoosh S et al. (2011). Differential Effects of Pravastatin and 
Simvastatin on the Growth of Tumor Cells from Different Organ Sites. PloS One 6(12): 
e28813. doi or PMID: 10.1371/journal.pone.0028813 
122 
 
346 Hirano M, Maeda K, Shitara Y et al. (2006). Drug-drug interaction between pitavastatin and 
various drugs via OATP1B1. Drug Metab Dispos 34(7): 1229-1236. doi or PMID: 
10.1124/dmd.106.009290 
347 Brown MS, Faust JR, Goldstein JL et al. (1978). Induction of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a 
competitive inhibitor of the reductase. J Biol Chem 253(4): 1121-1128. doi or PMID: 624722 
348 Davies JT, Delfino SF, Feinberg CE et al. (2016). Current and Emerging Uses of Statins in 
Clinical Therapeutics: A Review. Lipid insights 9: 13-29. doi or PMID: 10.4137/LPI.S37450 
349 Willumsen BM, Papageorge AG, Hubbert N et al. (1985). Transforming p21 ras protein: 
flexibility in the major variable region linking the catalytic and membrane-anchoring 
domains. EMBO J 4(11): 2893-2896. doi or PMID: 2998761 
350 Hart KC & Donoghue DJ (1997). Derivatives of activated H-ras lacking C-terminal lipid 
modifications retain transforming ability if targeted to the correct subcellular location. 
Oncogene 14(8): 945-953. doi or PMID: 10.1038/sj.onc.1200908 
351 Clarke S, Vogel JP, Deschenes RJ et al. (1988). Posttranslational modification of the Ha-ras 
oncogene protein: evidence for a third class of protein carboxyl methyltransferases. Proc 
Natl Acad Sci U S A 85(13): 4643-4647. doi or PMID: 10.1073/pnas.85.13.4643 
352 Moores SL, Schaber MD, Mosser SD et al. (1991). Sequence dependence of protein 
isoprenylation. J Biol Chem 266(22): 14603-14610. doi or PMID: 1860864 
353 Mohamed A, Smith K & Posse de Chaves E. in Alzheimer's Disease - Challenges for the Future; 
The Mevalonate Pathway in Alzheimer’s Disease - Cholesterol and Non-Sterol Isoprenoids.  
(IntechOpen, 2015). 
354 Endo A (2010). A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys 
Biol Sci 86(5): 484-493. doi or PMID: 20467214 
355 Hobbs FDR (2004). Cardiovascular disease: different strategies for primary and secondary 
prevention? Heart 90(10): 1217. doi or PMID: 10.1136/hrt.2003.027680 
356 Liao JK & Laufs U (2005). Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-
118. doi or PMID: 10.1146/annurev.pharmtox.45.120403.095748 
357 Kavalipati N, Shah J, Ramakrishan A et al. (2015). Pleiotropic effects of statins. Indian J 
Endocrinol Metab 19(5): 554-562. doi or PMID: 10.4103/2230-8210.163106 
358 Wang ST, Ho HJ, Lin JT et al. (2017). Simvastatin-induced cell cycle arrest through inhibition 
of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in 
hepatocellular carcinoma cells. Cell Death Dis 8(2): e2626. doi or PMID: 
10.1038/cddis.2016.472 
359 Crescencio ME, Rodríguez E, Páez A et al. (2009). Statins Inhibit the Proliferation and Induce 
Cell Death of Human Papilloma Virus Positive and Negative Cervical Cancer Cells. Int J Biomed 
Sci 5(4): 411-420. doi or PMID: 23675166 
360 Wang G, Cao R, Wang Y et al. (2016). Simvastatin induces cell cycle arrest and inhibits 
proliferation of bladder cancer cells via PPARγ signalling pathway. Sci Rep 6: 35783. doi or 
PMID: 10.1038/srep35783 
361 Clendening JW, Pandyra A, Li Z et al. (2010). Exploiting the mevalonate pathway to 
distinguish statin-sensitive multiple myeloma. Blood 115(23): 4787-4797. doi or PMID: 
10.1182/blood-2009-07-230508 
362 Goard CA, Chan-Seng-Yue M, Mullen PJ et al. (2014). Identifying molecular features that 
distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Res Treat 143(2): 301-312. 
doi or PMID: 10.1007/s10549-013-2800-y 
363 Keyomarsi K, Sandoval L, Band V et al. (1991). Synchronization of tumor and normal cells 
from G1 to multiple cell cycles by lovastatin. Cancer Res 51(13): 3602-3609. doi or PMID: 
1711413 
123 
 
364 Dimitroulakos J, Nohynek D, Backway KL et al. (1999). Increased Sensitivity of Acute Myeloid 
Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach. Blood 93(4): 
1308-1318. doi or PMID: 9949174 
365 Dimitroulakos J, Marhin WH, Tokunaga J et al. (2002). Microarray and biochemical analysis of 
lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 4(4): 337-346. doi or 
PMID: 10.1038/sj.neo.7900247 
366 Moon S-H, Huang C-H, Houlihan SL et al. (2019). p53 Represses the Mevalonate Pathway to 
Mediate Tumor Suppression. Cell 176(3): 564-580.e519. doi or PMID: 
10.1016/j.cell.2018.11.011 
367 Horiguchi A, Sumitomo M, Asakuma J et al. (2004). 3-Hydroxy-3-Methylglutaryl-Coenzyme A 
Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis. 
Clin Cancer Res 10(24): 8648-8655. doi or PMID: 10.1158/1078-0432.ccr-04-1568 
368 Paragh G, Kertai P, Kovacs P et al. (2003). HMG CoA reductase inhibitor fluvastatin arrests the 
development of implanted hepatocarcinoma in rats. Anticancer Res 23(5a): 3949-3954. doi or 
PMID: 14666702 
369 Jiang S-Y, Li H, Tang J-J et al. (2018). Discovery of a potent HMG-CoA reductase degrader that 
eliminates statin-induced reductase accumulation and lowers cholesterol. Nat Commun 9(1): 
5138. doi or PMID: 10.1038/s41467-018-07590-3 
370 Liu Y & Bodmer WF (2006). Analysis of P53 mutations and their expression in 56 colorectal 
cancer cell lines. Proc Natl Acad Sci U S A 103(4): 976-981. doi or PMID: 
10.1073/pnas.0510146103 
371 Kosakowska-Cholody T, Cholody W, Hariprakasha H et al. (2007). Gene expression profiles in 
HCT116 and HT29 cells exposed to RTA 502 lead to insights into the mechanism of action. 
Cancer Res 67(9 Supplement): 4895-4895. doi or PMID:  
372 Lamy V, Bousserouel S, Gossé F et al. (2010). p53 Activates Either Survival or Apoptotic 
Signaling Responses in Lupulone-Treated Human Colon Adenocarcinoma Cells and Derived 
Metastatic Cells. Transl Oncol 3(5): 286-292. doi or PMID: 10.1593/tlo.10124 
373 Deng Y-Z, Cai Z, Shi S et al. (2017). Cilia loss sensitizes cells to transformation by activating 
the mevalonate pathway. J Exp Med doi or PMID: 10.1084/jem.20170399 
374 Clarke S (1992). Protein Isoprenylation and Methylation at Carboxyl-terminal Cysteine 
Residues. Annu Rev Biochem 61(1): 355-386. doi or PMID: 
10.1146/annurev.bi.61.070192.002035 
375 Glomset JA & Farnsworth CC (1994). Role of Protein Modification Reactions in Programming 
Interactions Between Ras-Related GTPases and Cell Membranes. Annu Rev Cell Biol 10(1): 
181-205. doi or PMID: 10.1146/annurev.cb.10.110194.001145 
376 Haga RB & Ridley AJ (2016). Rho GTPases: Regulation and roles in cancer cell biology. Small 
GTPases 7(4): 207-221. doi or PMID: 10.1080/21541248.2016.1232583 
377 Sebti SM & Hamilton AD (1997). Inhibition of Ras prenylation: a novel approach to cancer 
chemotherapy. Pharmacol Ther 74(1): 103-114. doi or PMID: 9336018 
378 Berndt N, Hamilton AD & Sebti SM (2011). Targeting protein prenylation for cancer therapy. 
Nat Rev Cancer 11(11): 775-791. doi or PMID: 10.1038/nrc3151 
379 Kang S, Kim ES & Moon A (2009). Simvastatin and lovastatin inhibit breast cell invasion 
induced by H-Ras. Oncol Rep 21(5): 1317-1322. doi or PMID: 10.3892/or_00000357 
380 Wong WW, Clendening JW, Martirosyan A et al. (2007). Determinants of sensitivity to 
lovastatin-induced apoptosis in multiple myeloma. Mol Cancer Ther 6(6): 1886-1897. doi or 
PMID: 10.1158/1535-7163.mct-06-0745 
381 Agarwal B, Halmos B, Feoktistov AS et al. (2002). Mechanism of lovastatin-induced apoptosis 
in intestinal epithelial cells. Carcinogenesis 23(3): 521-528. doi or PMID: 
10.1093/carcin/23.3.521 
124 
 
382 Jiang Z, Zheng X, Lytle RA et al. (2004). Lovastatin-induced up-regulation of the BH3-only 
protein, Bim, and cell death in glioblastoma cells. J Neurochem 89(1): 168-178. doi or PMID: 
10.1111/j.1471-4159.2004.02319.x 
383 Shellman YG, Ribble D, Miller L et al. (2005). Lovastatin-induced apoptosis in human 
melanoma cell lines. Melanoma Res 15(2): 83-89. doi or PMID: 15846140 
384 Xia Z, Tan MM, Wong WW et al. (2001). Blocking protein geranylgeranylation is essential for 
lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15(9): 1398-
1407. doi or PMID: 11516100 
385 Gbelcová H, Rimpelová S, Knejzlík Z et al. (2017). Isoprenoids responsible for protein 
prenylation modulate the biological effects of statins on pancreatic cancer cells. Lipids Health 
Dis 16(1): 250-250. doi or PMID: 10.1186/s12944-017-0641-0 
386 Denoyelle C, Vasse M, Körner M et al. (2001). Cerivastatin, an inhibitor of HMG-CoA 
reductase, inhibits the signaling pathways involved in the invasiveness and metastatic 
properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22(8): 
1139-1148. doi or PMID: 10.1093/carcin/22.8.1139 
387 Kusama T, Mukai M, Iwasaki T et al. (2001). Inhibition of Epidermal Growth Factor-induced 
RhoA Translocation and Invasion of Human Pancreatic Cancer Cells by 3-Hydroxy-3-
methylglutaryl-coenzyme A Reductase Inhibitors. Cancer Res 61(12): 4885-4891. doi or PMID: 
11406567 
388 Kusama T, Mukai M, Iwasaki T et al. (2002). 3-hydroxy-3-methylglutaryl-coenzyme a 
reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. 
Gastroenterology 122(2): 308-317. doi or PMID: 11832446 
389 Kusama T, Mukai M, Ayaki M et al. (2003). Inhibition of lysophosphatidic acid-induced RhoA 
activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
inhibitors. Int J Oncol 23(4): 1173-1178. doi or PMID: 12964001 
390 Lawson CD & Ridley AJ (2018). Rho GTPase signaling complexes in cell migration and 
invasion. J Cell Biol 217(2): 447-457. doi or PMID: 10.1083/jcb.201612069 
391 De Wever O, Pauwels P, De Craene B et al. (2008). Molecular and pathological signatures of 
epithelial–mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 130(3): 
481. doi or PMID: 10.1007/s00418-008-0464-1 
392 Sivaprasad U, Abbas T & Dutta A (2006). Differential efficacy of 3-hydroxy-3-methylglutaryl 
CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 5(9): 
2310-2316. doi or PMID: 10.1158/1535-7163.mct-06-0175 
393 Rao S, Porter DC, Chen X et al. (1999). Lovastatin-mediated G1 arrest is through inhibition of 
the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U 
S A 96(14): 7797-7802. doi or PMID: 10.1073/pnas.96.14.7797 
394 Tu YS, Kang XL, Zhou JG et al. (2011). Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in 
simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur J 
Pharmacol 670(2-3): 356-364. doi or PMID: 10.1016/j.ejphar.2011.09.031 
395 Yu X, Luo Y, Zhou Y et al. (2008). BRCA1 overexpression sensitizes cancer cells to lovastatin 
via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell 
line and tumoral xenograft model. Int J Oncol 33(3): 555-563. doi or PMID: 18695886 
396 Feldt M, Bjarnadottir O, Kimbung S et al. (2015). Statin-induced anti-proliferative effects via 
cyclin D1 and p27 in a window-of-opportunity breast cancer trial. J Transl Med 13: 133-133. 
doi or PMID: 10.1186/s12967-015-0486-0 
397 Gniadecki R (2004). Depletion of membrane cholesterol causes ligand-independent 
activation of Fas and apoptosis. Biochem Biophys Res Commun 320(1): 165-169. doi or PMID: 
10.1016/j.bbrc.2004.05.145 
398 Beckwitt CH, Shiraha K & Wells A (2018). Lipophilic statins limit cancer cell growth and 
survival, via involvement of Akt signaling. PloS One 13(5): e0197422. doi or PMID: 
10.1371/journal.pone.0197422 
125 
 
399 Steward WP & Brown K (2013). Cancer chemoprevention: a rapidly evolving field. Br J Cancer 
109(1): 1-7. doi or PMID: 10.1038/bjc.2013.280 
400 Sporn MB, Dunlop NM, Newton DL et al. (1976). Prevention of chemical carcinogenesis by 
vitamin A and its synthetic analogs (retinoids). Fed Proc 35(6): 1332-1338. doi or PMID: 
770206 
401 Benetou V, Lagiou A & Lagiou P (2015). Chemoprevention of cancer: current evidence and 
future prospects. F1000Res. 4(F1000 Faculty Rev): 916-916. doi or PMID: 
10.12688/f1000research.6684.1 
402 Lytras T, Nikolopoulos G & Bonovas S (2014). Statins and the risk of colorectal cancer: an 
updated systematic review and meta-analysis of 40 studies. World J Gastroenterol 20(7): 
1858-1870. doi or PMID: 10.3748/wjg.v20.i7.1858 
403 Undela K, Shah CS & Mothe RK (2017). Statin use and risk of cancer: An overview of meta-
analyses. World J Meta-Anal 5(2): 41-53. doi or PMID: 10.13105/wjma.v5.i2.41 
404 Bansal D, Undela K, D'Cruz S et al. (2012). Statin use and risk of prostate cancer: a meta-
analysis of observational studies. PLoS One 7(10): e46691. doi or PMID: 
10.1371/journal.pone.0046691 
405 Jeong GH, Lee KH, Kim JY et al. (2019). Effect of Statin on Cancer Incidence: An Umbrella 
Systematic Review and Meta-Analysis. J Clin Med 8(6) doi or PMID: 10.3390/jcm8060819 
406 Dale KM, Coleman CI, Henyan NN et al. (2006). Statins and cancer risk: a meta-analysis. JAMA 
295(1): 74-80. doi or PMID: 10.1001/jama.295.1.74 
407 Undela K, Srikanth V & Bansal D (2012). Statin use and risk of breast cancer: a meta-analysis 
of observational studies. Breast Cancer Res Treat 135(1): 261-269. doi or PMID: 
10.1007/s10549-012-2154-x 
408 Wang J, Li C, Tao H et al. (2013). Statin Use and Risk of Lung Cancer: a Meta-Analysis of 
Observational Studies and Randomized Controlled Trials. PLoS One 8(10): e77950. doi or 
PMID: 10.1371/journal.pone.0077950 
409 Yang J, Zhu Q, Liu Q et al. (2017). Statin use and endometrial cancer risk: a meta-analysis. 
Oncotarget 8(37): 62425-62434. doi or PMID: 10.18632/oncotarget.18658 
410 Poynter JN, Gruber SB, Higgins PD et al. (2005). Statins and the risk of colorectal cancer. N 
Engl J Med 352(21): 2184-2192. doi or PMID: 10.1056/NEJMoa043792 
411 Voorneveld PW, Reimers MS, Bastiaannet E et al. (2017). Statin Use After Diagnosis of Colon 
Cancer and Patient Survival. Gastroenterology 153(2): 470-479.e474. doi or PMID: 
10.1053/j.gastro.2017.05.011 
412 Cardwell CR, Hicks BM, Hughes C et al. (2014). Statin use after colorectal cancer diagnosis 
and survival: a population-based cohort study. J Clin Oncol 32(28): 3177-3183. doi or PMID: 
10.1200/jco.2013.54.4569 
413 Gray RT, Coleman HG, Hughes C et al. (2016). Statin use and survival in colorectal cancer: 
Results from a population-based cohort study and an updated systematic review and meta-
analysis. Cancer Epidemiol 45: 71-81. doi or PMID: 10.1016/j.canep.2016.10.004 
414 Archibugi L, Piciucchi M, Stigliano S et al. (2017). Exclusive and Combined Use of Statins and 
Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Sci Rep 7(1): 13024. doi or 
PMID: 10.1038/s41598-017-13430-z 
415 Walker EJ, Ko AH, Holly EA et al. (2014). Statin use and risk of pancreatic cancer: Results from 
a large clinic-based case-control study. J Clin Oncol 32(15_suppl): 4117-4117. doi or PMID: 
10.1200/jco.2014.32.15_suppl.4117 
416 Bradley MC, Hughes CM, Cantwell MM et al. (2010). Statins and pancreatic cancer risk: a 
nested case–control study. Cancer Causes Control 21(12): 2093-2100. doi or PMID: 
10.1007/s10552-010-9628-0 
417 Ma Z, Wang W, Jin G et al. (2014). Effect of statins on gastric cancer incidence: a meta-
analysis of case control studies. J Cancer Res Ther 10(4): 859-865. doi or PMID: 
10.4103/0973-1482.138218 
126 
 
418 Spence AD, Busby J, Hughes CM et al. (2019). Statin use and survival in patients with gastric 
cancer in two independent population-based cohorts. Pharmacoepidemiol Drug Saf 28(4): 
460-470. doi or PMID: 10.1002/pds.4688 
419 Shimoyama S (2011). Statins and gastric cancer risk. Hepatogastroenterology 58(107-108): 
1057-1061. doi or PMID: 21830442 
420 King GT, Yun JH, Chae YK et al. (2012). Statin use and the development of bone metastasis in 
breast cancer patients. J Clin Oncol 30(27_suppl): 40-40. doi or PMID: 
10.1200/jco.2012.30.27_suppl.40 
421 Abdel-Rahman O (2019). Statin treatment and outcomes of metastatic pancreatic cancer: a 
pooled analysis of two phase III studies. Clin Transl Oncol 21(6): 810-816. doi or PMID: 
10.1007/s12094-018-1992-3 
422 Jones CW & Platts-Mills TF (2012). Understanding commonly encountered limitations in 
clinical research: an emergency medicine resident's perspective. Ann Emerg Med 59(5): 425-
431.e411. doi or PMID: 10.1016/j.annemergmed.2011.05.024 
423 Corrigan-Curay J, Sacks L & Woodcock J (2018). Real-World Evidence and Real-World Data for 
Evaluating Drug Safety and Effectiveness. JAMA 320(9): 867-868. doi or PMID: 
10.1001/jama.2018.10136 
424 Sherman RE, Anderson SA, Dal Pan GJ et al. (2016). Real-World Evidence — What Is It and 
What Can It Tell Us? N Engl J Med 375(23): 2293-2297. doi or PMID: 
10.1056/NEJMsb1609216 
425 Pritzker KPH (2015). Predictive and prognostic cancer biomarkers revisited. Expert Rev Mol 
Diagn 15(8): 971-974. doi or PMID: 10.1586/14737159.2015.1063421 
426 Bantscheff M, Eberhard D, Abraham Y et al. (2007). Quantitative chemical proteomics reveals 
mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035. doi or PMID: 
10.1038/nbt1328 
427 Lemeer S, Zörgiebel C, Ruprecht B et al. (2013). Comparing Immobilized Kinase Inhibitors and 
Covalent ATP Probes for Proteomic Profiling of Kinase Expression and Drug Selectivity. J 
Proteome Res 12(4): 1723-1731. doi or PMID: 10.1021/pr301073j 
428 Cunnick JM, Mei L, Doupnik CA et al. (2001). Phosphotyrosines 627 and 659 of Gab1 
constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and 
activation of SHP2. J Biol Chem 276(26): 24380-24387. doi or PMID: 
10.1074/jbc.M010275200 
429 Cunnick JM, Dorsey JF, Munoz-Antonia T et al. (2000). Requirement of SHP2 binding to Grb2-
associated binder-1 for mitogen-activated protein kinase activation in response to 
lysophosphatidic acid and epidermal growth factor. J Biol Chem 275(18): 13842-13848. doi or 
PMID: 10788507 
430 Laramee M, Chabot C, Cloutier M et al. (2007). The scaffolding adapter Gab1 mediates 
vascular endothelial growth factor signaling and is required for endothelial cell migration and 
capillary formation. J Biol Chem 282(11): 7758-7769. doi or PMID: 10.1074/jbc.M611327200 
431 Maroun CR, Naujokas MA, Holgado-Madruga M et al. (2000). The tyrosine phosphatase SHP-
2 is required for sustained activation of extracellular signal-regulated kinase and epithelial 
morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 20(22): 
8513-8525. doi or PMID: 10.1128/mcb.20.22.8513-8525.2000 
432 Kallin A, Demoulin JB, Nishida K et al. (2004). Gab1 contributes to cytoskeletal reorganization 
and chemotaxis in response to platelet-derived growth factor. J Biol Chem 279(17): 17897-
17904. doi or PMID: 10.1074/jbc.M312996200 
433 Schaeper U, Vogel R, Chmielowiec J et al. (2007). Distinct requirements for Gab1 in Met and 
EGF receptor signaling in vivo. Proc Natl Acad Sci U S A 104(39): 15376-15381. doi or PMID: 
10.1073/pnas.0702555104 
127 
 
434 Meng S, Chen Z, Munoz-Antonia T et al. (2005). Participation of both Gab1 and Gab2 in the 
activation of the ERK/MAPK pathway by epidermal growth factor. Biochem J 391(Pt 1): 143-
151. doi or PMID: 10.1042/BJ20050229 
435 Eulenfeld R & Schaper F (2009). A new mechanism for the regulation of Gab1 recruitment to 
the plasma membrane. J Cell Sci 122(Pt 1): 55-64. doi or PMID: 10.1242/jcs.037226 
436 Bertotti A, Comoglio PM & Trusolino L (2006). Beta4 integrin activates a Shp2-Src signaling 
pathway that sustains HGF-induced anchorage-independent growth. J Cell Biol 175(6): 993-
1003. doi or PMID: 10.1083/jcb.200605114 
437 Pawson T & Nash P (2000). Protein-protein interactions define specificity in signal 
transduction. Genes Dev 14(9): 1027-1047. doi or PMID: 10809663 
438 Songyang Z, Shoelson SE, Chaudhuri M et al. (1993). SH2 domains recognize specific 
phosphopeptide sequences. Cell 72(5): 767-778. doi or PMID: 10.1016/0092-8674(93)90404-
e 
439 Ravichandran KS (2001). Signaling via Shc family adapter proteins. Oncogene 20(44): 6322-
6330. doi or PMID: 10.1038/sj.onc.1204776 
440 Songyang Z, Shoelson SE, McGlade J et al. (1994). Specific motifs recognized by the SH2 
domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol 14(4): 2777-2785. 
doi or PMID: 10.1128/mcb.14.4.2777 
441 Salcini AE, McGlade J, Pelicci G et al. (1994). Formation of Shc-Grb2 complexes is necessary 
to induce neoplastic transformation by overexpression of Shc proteins. Oncogene 9(10): 
2827-2836. doi or PMID: 8084588 
442 May P, Gerhartz C, Heesel B et al. (1996). Comparative study on the phosphotyrosine motifs 
of different cytokine receptors involved in STAT5 activation. FEBS Lett 394(2): 221-226. doi or 
PMID: 10.1016/0014-5793(96)00955-6 
443 Ravetch JV & Lanier LL (2000). Immune Inhibitory Receptors. Science 290(5489): 84-89. doi or 
PMID: 10.1126/science.290.5489.84 
444 Imhof D, Wavreille AS, May A et al. (2006). Sequence specificity of SHP-1 and SHP-2 Src 
homology 2 domains. Critical roles of residues beyond the pY+3 position. J Biol Chem 
281(29): 20271-20282. doi or PMID: 10.1074/jbc.M601047200 
445 Higashi H, Tsutsumi R, Fujita A et al. (2002). Biological activity of the Helicobacter pylori 
virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc 
Natl Acad Sci U S A 99(22): 14428. doi or PMID: 10.1073/pnas.222375399 
446 Ji QS, Chattopadhyay A, Vecchi M et al. (1999). Physiological requirement for both SH2 
domains for phospholipase C-gamma1 function and interaction with platelet-derived growth 
factor receptors. Mol Cell Biol 19(7): 4961-4970. doi or PMID: 10.1128/mcb.19.7.4961 
447 Rameh LE, Rhee SG, Spokes K et al. (1998). Phosphoinositide 3-kinase regulates 
phospholipase Cgamma-mediated calcium signaling. J Biol Chem 273(37): 23750-23757. doi 
or PMID: 10.1074/jbc.273.37.23750 
448 Park MJ, Sheng R, Silkov A et al. (2016). SH2 Domains Serve as Lipid-Binding Modules for 
pTyr-Signaling Proteins. Mol Cell 62(1): 7-20. doi or PMID: 10.1016/j.molcel.2016.01.027 
449 Pawson T & Nash P (2003). Assembly of cell regulatory systems through protein interaction 
domains. Science 300(5618): 445-452. doi or PMID: 10.1126/science.1083653 
450 Trub T, Choi WE, Wolf G et al. (1995). Specificity of the PTB domain of Shc for beta turn-
forming pentapeptide motifs amino-terminal to phosphotyrosine. J Biol Chem 270(31): 
18205-18208. doi or PMID: 10.1074/jbc.270.31.18205 
451 van der Geer P, Wiley S, Lai VK et al. (1995). A conserved amino-terminal Shc domain binds to 
phosphotyrosine motifs in activated receptors and phosphopeptides. Curr Biol 5(4): 404-412. 
doi or PMID: 7542991 
452 Wolf G, Trub T, Ottinger E et al. (1995). PTB domains of IRS-1 and Shc have distinct but 
overlapping binding specificities. J Biol Chem 270(46): 27407-27410. doi or PMID: 
10.1074/jbc.270.46.27407 
128 
 
453 Park JB, Lee CS, Jang JH et al. (2012). Phospholipase signalling networks in cancer. Nat Rev 
Cancer 12(11): 782-792. doi or PMID: 10.1038/nrc3379 
454 Lowenstein EJ, Daly RJ, Batzer AG et al. (1992). The SH2 and SH3 domain-containing protein 
GRB2 links receptor tyrosine kinases to ras signaling. Cell 70 doi or PMID: 10.1016/0092-
8674(92)90167-b 
455 Ren L, Chen X, Luechapanichkul R et al. (2011). Substrate Specificity of Protein Tyrosine 
Phosphatases 1B, RPTPα, SHP-1, and SHP-2. Biochemistry 50(12): 2339-2356. doi or PMID: 
10.1021/bi1014453 
456 Neel BG, Gu H & Pao L (2003). The ‘Shp'ing news: SH2 domain-containing tyrosine 
phosphatases in cell signaling. Trends Biochem Sci 28(6): 284-293. doi or PMID: 
10.1016/S0968-0004(03)00091-4 
457 Hof P, Pluskey S, Dhe-Paganon S et al. (1998). Crystal structure of the tyrosine phosphatase 
SHP-2. Cell 92(4): 441-450. doi or PMID: 10.1016/s0092-8674(00)80938-1 
458 Barford D & Neel BG (1998). Revealing mechanisms for SH2 domain mediated regulation of 
the protein tyrosine phosphatase SHP-2. Structure 6(3): 249-254. doi or PMID: 
10.1016/S0969-2126(98)00027-6 
459 Chan G, Kalaitzidis D & Neel BG (2008). The tyrosine phosphatase Shp2 (PTPN11) in cancer. 
Cancer Metastasis Rev 27(2): 179-192. doi or PMID: 10.1007/s10555-008-9126-y 
460 Fischle W, Tseng BS, Dormann HL et al. (2005). Regulation of HP1-chromatin binding by 
histone H3 methylation and phosphorylation. Nature 438(7071): 1116-1122. doi or PMID: 
10.1038/nature04219 
461 Hirota T, Lipp JJ, Toh BH et al. (2005). Histone H3 serine 10 phosphorylation by Aurora B 
causes HP1 dissociation from heterochromatin. Nature 438(7071): 1176-1180. doi or PMID: 
10.1038/nature04254 
462 Hatada MH, Lu X, Laird ER et al. (1995). Molecular basis for interaction of the protein tyrosine 
kinase ZAP-70 with the T-cell receptor. Nature 377(6544): 32-38. doi or PMID: 
10.1038/377032a0 
463 Nash P, Tang X, Orlicky S et al. (2001). Multisite phosphorylation of a CDK inhibitor sets a 
threshold for the onset of DNA replication. Nature 414(6863): 514-521. doi or PMID: 
10.1038/35107009 
464 Orlicky S, Tang X, Willems A et al. (2003). Structural basis for phosphodependent substrate 
selection and orientation by the SCFCdc4 ubiquitin ligase. Cell 112(2): 243-256. doi or PMID: 
10.1016/s0092-8674(03)00034-5 
465 Haglund K & Dikic I (2005). Ubiquitylation and cell signaling. EMBO J 24(19): 3353-3359. doi 
or PMID: 10.1038/sj.emboj.7600808 
466 Wohrle FU, Daly RJ & Brummer T (2009). Function, regulation and pathological roles of the 
Gab/DOS docking proteins. Cell Commun Signal 7: 22. doi or PMID: 10.1186/1478-811x-7-22 
467 Tartaglia M, Niemeyer CM, Fragale A et al. (2003). Somatic mutations in PTPN11 in juvenile 
myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat 
Genet 34: 148. doi or PMID: 10.1038/ng1156 
468 Loh ML, Vattikuti S, Schubbert S et al. (2004). Mutations in PTPN11 implicate the SHP-2 
phosphatase in leukemogenesis. Blood 103(6): 2325. doi or PMID: 10.1182/blood-2003-09-
3287 
469 Tartaglia M, Martinelli S, Iavarone I et al. (2005). Somatic PTPN11 mutations in childhood 
acute myeloid leukaemia. Br J Haematol 129(3): 333-339. doi or PMID: 10.1111/j.1365-
2141.2005.05457.x 
470 Bentires-Alj M, Paez JG, David FS et al. (2004). Activating mutations of the noonan syndrome-
associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous 
leukemia. Cancer Res 64(24): 8816-8820. doi or PMID: 10.1158/0008-5472.CAN-04-1923 
129 
 
471 Loh ML, Reynolds MG, Vattikuti S et al. (2004). PTPN11 mutations in pediatric patients with 
acute myeloid leukemia: results from the Children´s Cancer Group. Leukemia 18: 1831. doi or 
PMID: 10.1038/sj.leu.2403492 
472 Tartaglia M, Martinelli S, Cazzaniga G et al. (2004). Genetic evidence for lineage-related and 
differentiation stage–related contribution of somatic PTPN11 mutations to leukemogenesis 
in childhood acute leukemia. Blood 104(2): 307-313. doi or PMID: 10.1182/blood-2003-11-
3876 
473 Yamamoto T, Isomura M, Xu Y et al. (2006). PTPN11, RAS and FLT3 mutations in childhood 
acute lymphoblastic leukemia. Leuk Res 30(9): 1085-1089. doi or PMID: 
10.1016/j.leukres.2006.02.004 
474 Schneeberger VE, Luetteke N, Ren Y et al. (2014). SHP2E76K mutant promotes lung 
tumorigenesis in transgenic mice. Carcinogenesis 35(8): 1717-1725. doi or PMID: 
10.1093/carcin/bgu025 
475 Schneeberger VE, Ren Y, Luetteke N et al. (2015). Inhibition of Shp2 suppresses mutant EGFR-
induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget 6(8): 
6191-6202. doi or PMID: 10.18632/oncotarget.3356 
476 Gale NW, Kaplan S, Lowenstein EJ et al. (1993). Grb2 mediates the EGF-dependent activation 
of guanine nucleotide exchange on Ras. Nature 363(6424): 88-92. doi or PMID: 
10.1038/363088a0 
477 Li N, Batzer A, Daly R et al. (1993). Guanine-nucleotide-releasing factor hSos1 binds to Grb2 
and links receptor tyrosine kinases to Ras signalling. Nature 363(6424): 85-88. doi or PMID: 
10.1038/363085a0 
478 Chardin P, Camonis JH, Gale NW et al. (1993). Human Sos1: a guanine nucleotide exchange 
factor for Ras that binds to GRB2. Science 260 doi or PMID: 10.1126/science.8493579 
479 Daly RJ, Binder MD & Sutherland RL (1994). Overexpression of the Grb2 gene in human 
breast cancer cell lines. Oncogene 9(9): 2723-2727. doi or PMID: 8058337 
480 Verbeek BS, Adriaansen-Slot SS, Rijksen G et al. (1997). Grb2 overexpression in nuclei and 
cytoplasm of human breast cells: a histochemical and biochemical study of normal and 
neoplastic mammary tissue specimens. J Pathol 183(2): 195-203. doi or PMID: 
10.1002/(sici)1096-9896(199710)183:2<195::aid-path901>3.0.co;2-y 
481 Zang XP, Siwak DR, Nguyen TX et al. (2004). KGF-induced motility of breast cancer cells is 
dependent on Grb2 and Erk1,2. Clin Exp Metastasis 21(5): 437-443. doi or PMID: 15672868 
482 Xu Y, Zhang H, Lit LC et al. (2014). The kinase LMTK3 promotes invasion in breast cancer 
through GRB2-mediated induction of integrin beta(1). Sci Signal 7(330): ra58. doi or PMID: 
10.1126/scisignal.2005170 
483 Dankort D, Maslikowski B, Warner N et al. (2001). Grb2 and Shc adapter proteins play distinct 
roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast 
cancer. Mol Cell Biol 21(5): 1540-1551. doi or PMID: 10.1128/mcb.21.5.1540-1551.2001 
484 Watanabe T, Shinohara N, Moriya K et al. (2000). Significance of the Grb2 and son of 
sevenless (Sos) proteins in human bladder cancer cell lines. IUBMB Life 49(4): 317-320. doi or 
PMID: 10.1080/15216540050033195 
485 Pomerleau V, Landry M, Bernier J et al. (2014). Met receptor-induced Grb2 or Shc signals 
both promote transformation of intestinal epithelial cells, albeit they are required for distinct 
oncogenic functions. BMC Cancer 14: 240. doi or PMID: 10.1186/1471-2407-14-240 
486 Chang W, Gao X, Han Y et al. (2014). Gene expression profiling-derived 
immunohistochemistry signature with high prognostic value in colorectal carcinoma. Gut 
63(9): 1457-1467. doi or PMID: 10.1136/gutjnl-2013-305475 
487 Yu GZ, Chen Y, Long YQ et al. (2008). New insight into the key proteins and pathways 
involved in the metastasis of colorectal carcinoma. Oncol Rep 19(5): 1191-1204. doi or PMID: 
18425376 
130 
 
488 Rozakis-Adcock M, McGlade J, Mbamalu G et al. (1992). Association of the Shc and 
Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by 
tyrosine kinases. Nature 360(6405): 689-692. doi or PMID: 10.1038/360689a0 
489 Pelicci G, Lanfrancone L, Grignani F et al. (1992). A novel transforming protein (SHC) with an 
SH2 domain is implicated in mitogenic signal transduction. Cell 70(1): 93-104. doi or PMID: 
10.1016/0092-8674(92)90536-l 
490 Jackson JG, Yoneda T, Clark GM et al. (2000). Elevated levels of p66 Shc are found in breast 
cancer cell lines and primary tumors with high metastatic potential. Clin Cancer Res 6(3): 
1135-1139. doi or PMID: 10741744 
491 Fixman ED, Fournier TM, Kamikura DM et al. (1996). Pathways downstream of Shc and Grb2 
are required for cell transformation by the tpr-Met oncoprotein. J Biol Chem 271(22): 13116-
13122. doi or PMID: 10.1074/jbc.271.22.13116 
492 Saucier C, Papavasiliou V, Palazzo A et al. (2002). Use of signal specific receptor tyrosine 
kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for 
cell transformation and metastasis. Oncogene 21(12): 1800-1811. doi or PMID: 
10.1038/sj.onc.1205261 
493 Ursini-Siegel J, Hardy WR, Zuo D et al. (2008). ShcA signalling is essential for tumour 
progression in mouse models of human breast cancer. EMBO J 27(6): 910-920. doi or PMID: 
10.1038/emboj.2008.22 
494 Gresset A, Sondek J & Harden TK (2012). The phospholipase C isozymes and their regulation. 
Subcell Biochem 58: 61-94. doi or PMID: 10.1007/978-94-007-3012-0_3 
495 Gual P, Giordano S, Williams TA et al. (2000). Sustained recruitment of phospholipase C-γ to 
Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 19: 1509. doi or PMID: 
10.1038/sj.onc.1203514 
496 Paliouras GN, Naujokas MA & Park M (2009). Pak4, a novel Gab1 binding partner, modulates 
cell migration and invasion by the Met receptor. Mol Cell Biol 29(11): 3018-3032. doi or 
PMID: 10.1128/mcb.01286-08 
497 Jones NP & Katan M (2007). Role of phospholipase Cgamma1 in cell spreading requires 
association with a beta-Pix/GIT1-containing complex, leading to activation of Cdc42 and 
Rac1. Mol Cell Biol 27(16): 5790-5805. doi or PMID: 10.1128/MCB.00778-07 
498 Jones NP, Peak J, Brader S et al. (2005). PLCgamma1 is essential for early events in integrin 
signalling required for cell motility. J Cell Sci 118(Pt 12): 2695-2706. doi or PMID: 
10.1242/jcs.02374 
499 Huang PS, Davis L, Huber H et al. (1995). An SH3 domain is required for the mitogenic activity 
of microinjected phospholipase C-gamma 1. FEBS Lett 358(3): 287-292. doi or PMID: 
10.1016/0014-5793(94)01453-8 
500 Smith MR, Liu YL, Matthews NT et al. (1994). Phospholipase C-gamma 1 can induce DNA 
synthesis by a mechanism independent of its lipase activity. Proc Natl Acad Sci U S A 91(14): 
6554-6558. doi or PMID: 10.1073/pnas.91.14.6554 
501 Kim MJ, Chang JS, Park SK et al. (2000). Direct interaction of SOS1 Ras exchange protein with 
the SH3 domain of phospholipase C-gamma1. Biochemistry 39(29): 8674-8682. doi or PMID: 
10.1021/bi992558t 
502 Choi JH, Yang YR, Lee SK et al. (2007). Phospholipase C-gamma1 potentiates integrin-
dependent cell spreading and migration through Pyk2/paxillin activation. Cell Signal 19(8): 
1784-1796. doi or PMID: 10.1016/j.cellsig.2007.04.002 
503 Tvorogov D, Wang XJ, Zent R et al. (2005). Integrin-dependent PLC-gamma1 phosphorylation 
mediates fibronectin-dependent adhesion. J Cell Sci 118(Pt 3): 601-610. doi or PMID: 
10.1242/jcs.01643 
504 Mouneimne G, Soon L, DesMarais V et al. (2004). Phospholipase C and cofilin are required for 
carcinoma cell directionality in response to EGF stimulation. J Cell Biol 166(5): 697-708. doi or 
PMID: 10.1083/jcb.200405156 
131 
 
505 Sala G, Dituri F, Raimondi C et al. (2008). Phospholipase Cgamma1 is required for metastasis 
development and progression. Cancer Res 68(24): 10187-10196. doi or PMID: 10.1158/0008-
5472.can-08-1181 
506 Thomas SM, Coppelli FM, Wells A et al. (2003). Epidermal growth factor receptor-stimulated 
activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell 
carcinoma. Cancer Res 63(17): 5629-5635. doi or PMID: 14500405 
507 Shepard CR, Kassis J, Whaley DL et al. (2006). PLCγ contributes to metastasis of in situ-
occurring mammary and prostate tumors. Oncogene 26: 3020. doi or PMID: 
10.1038/sj.onc.1210115 
508 Peak JC, Jones NP, Hobbs S et al. (2008). Phospholipase C gamma 1 regulates the Rap GEF1-
Rap1 signalling axis in the control of human prostate carcinoma cell adhesion. Oncogene 
27(20): 2823-2832. doi or PMID: 10.1038/sj.onc.1210954 
509 Rani A & Murphy JJ (2016). STAT5 in Cancer and Immunity. J Interferon Cytokine Res 36(4): 
226-237. doi or PMID: 10.1089/jir.2015.0054 
510 Yu CL, Jin YJ & Burakoff SJ (2000). Cytosolic tyrosine dephosphorylation of STAT5. Potential 
role of SHP-2 in STAT5 regulation. J Biol Chem 275(1): 599-604. doi or PMID: 
10.1074/jbc.275.1.599 
511 Chen Y, Wen R, Yang S et al. (2003). Identification of Shp-2 as a Stat5A phosphatase. J Biol 
Chem 278(19): 16520-16527. doi or PMID: 10.1074/jbc.M210572200 
512 Wingelhofer B, Neubauer HA, Valent P et al. (2018). Implications of STAT3 and STAT5 
signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia 
32(8): 1713-1726. doi or PMID: 10.1038/s41375-018-0117-x 
513 Gu L, Vogiatzi P, Puhr M et al. (2010). Stat5 promotes metastatic behavior of human prostate 
cancer cells in vitro and in vivo. Endocr Relat Cancer 17(2): 481-493. doi or PMID: 
10.1677/erc-09-0328 
514 Xi S, Zhang Q, Gooding WE et al. (2003). Constitutive activation of Stat5b contributes to 
carcinogenesis in vivo. Cancer Res 63(20): 6763-6771. doi or PMID: 14583472 
515 Kloth MT, Laughlin KK, Biscardi JS et al. (2003). STAT5b, a Mediator of Synergism between c-
Src and the Epidermal Growth Factor Receptor. J Biol Chem 278(3): 1671-1679. doi or PMID: 
10.1074/jbc.M207289200 
516 Zhou X, Wang H, Burg MB et al. (2013). Inhibitory phosphorylation of GSK-3β by AKT, PKA, 
and PI3K contributes to high NaCl-induced activation of the transcription factor NFAT5 
(TonEBP/OREBP). Am J Physiol Renal Physiol 304(7): F908-F917. doi or PMID: 
10.1152/ajprenal.00591.2012 
517 Kaidanovich-Beilin O & Woodgett JR (2011). GSK-3: Functional Insights from Cell Biology and 
Animal Models. Front Mol Neurosci 4: 40. doi or PMID: 10.3389/fnmol.2011.00040 
518 Fang X, Yu SX, Lu Y et al. (2000). Phosphorylation and inactivation of glycogen synthase 
kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97(22): 11960-11965. doi or PMID: 
10.1073/pnas.220413597 
519 Cross DA, Alessi DR, Cohen P et al. (1995). Inhibition of glycogen synthase kinase-3 by insulin 
mediated by protein kinase B. Nature 378(6559): 785-789. doi or PMID: 10.1038/378785a0 
520 He XC, Yin T, Grindley JC et al. (2007). PTEN-deficient intestinal stem cells initiate intestinal 
polyposis. Nat Genet 39(2): 189-198. doi or PMID: 10.1038/ng1928 
521 Taurin S, Sandbo N, Qin Y et al. (2006). Phosphorylation of beta-catenin by cyclic AMP-
dependent protein kinase. J Biol Chem 281(15): 9971-9976. doi or PMID: 
10.1074/jbc.M508778200 
522 Isensee J, Diskar M, Waldherr S et al. (2014). Pain modulators regulate the dynamics of PKA-
RII phosphorylation in subgroups of sensory neurons. J Cell Sci 127(1): 216-229. doi or PMID: 
10.1242/jcs.136580 
132 
 
523 Isensee J, Kaufholz M, Knape MJ et al. (2018). PKA-RII subunit phosphorylation precedes 
activation by cAMP and regulates activity termination. J Cell Biol 217(6): 2167-2184. doi or 
PMID: 10.1083/jcb.201708053 
524 Manni S, Mauban JH, Ward CW et al. (2008). Phosphorylation of the cAMP-dependent 
protein kinase (PKA) regulatory subunit modulates PKA-AKAP interaction, substrate 
phosphorylation, and calcium signaling in cardiac cells. J Biol Chem 283(35): 24145-24154. 
doi or PMID: 10.1074/jbc.M802278200 
525 Everett LJ, Le Lay J, Lukovac S et al. (2013). Integrative genomic analysis of CREB defines a 
critical role for transcription factor networks in mediating the fed/fasted switch in liver. BMC 
genomics 14: 337-337. doi or PMID: 10.1186/1471-2164-14-337 
526 Döppler H & Storz P (2013). Regulation of VASP by phosphorylation: consequences for cell 
migration. Cell Adh Migr 7(6): 482-486. doi or PMID: 10.4161/cam.27351 
527 Anton KA, Sinclair J, Ohoka A et al. (2014). PKA-regulated VASP phosphorylation promotes 
extrusion of transformed cells from the epithelium. J Cell Sci 127(Pt 16): 3425-3433. doi or 
PMID: 10.1242/jcs.149674 
528 Steven A & Seliger B (2016). Control of CREB expression in tumors: from molecular 
mechanisms and signal transduction pathways to therapeutic target. Oncotarget 7(23): 
35454-35465. doi or PMID: 10.18632/oncotarget.7721 
529 Yu W, Li L, Zheng F et al. (2017). beta-Catenin Cooperates with CREB Binding Protein to 
Promote the Growth of Tumor Cells. Cell Physiol Biochem 44(2): 467-478. doi or PMID: 
10.1159/000485013 
530 Sulzmaier FJ, Jean C & Schlaepfer DD (2014). FAK in cancer: mechanistic findings and clinical 
applications. Nat Rev Cancer 14: 598. doi or PMID: 10.1038/nrc3792 
531 Mitra SK & Schlaepfer DD (2006). Integrin-regulated FAK-Src signaling in normal and cancer 
cells. Curr Opin Cell Biol 18(5): 516-523. doi or PMID: 10.1016/j.ceb.2006.08.011 
532 Irby RB & Yeatman TJ (2000). Role of Src expression and activation in human cancer. 
Oncogene 19: 5636. doi or PMID: 10.1038/sj.onc.1203912 
533 Wheeler DL, Iida M & Dunn EF (2009). The role of Src in solid tumors. Oncologist 14(7): 667-
678. doi or PMID: 10.1634/theoncologist.2009-0009 
534 Brandman O & Meyer T (2008). Feedback loops shape cellular signals in space and time. 
Science 322(5900): 390-395. doi or PMID: 10.1126/science.1160617 
535 Kolch W, Halasz M, Granovskaya M et al. (2015). The dynamic control of signal transduction 
networks in cancer cells. Nat Rev Cancer 15(9): 515-527. doi or PMID: 10.1038/nrc3983 
536 Corbalan-Garcia S, Yang SS, Degenhardt KR et al. (1996). Identification of the mitogen-
activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with 
Grb2. Mol Cell Biol 16(10): 5674-5682. doi or PMID: 10.1128/mcb.16.10.5674 
537 Dougherty MK, Muller J, Ritt DA et al. (2005). Regulation of Raf-1 by direct feedback 
phosphorylation. Mol Cell 17(2): 215-224. doi or PMID: 10.1016/j.molcel.2004.11.055 
538 Rushworth LK, Hindley AD, O'Neill E et al. (2006). Regulation and role of Raf-1/B-Raf 
heterodimerization. Mol Cell Biol 26(6): 2262-2272. doi or PMID: 10.1128/mcb.26.6.2262-
2272.2006 
539 Eblen ST, Slack-Davis JK, Tarcsafalvi A et al. (2004). Mitogen-activated protein kinase 
feedback phosphorylation regulates MEK1 complex formation and activation during cellular 
adhesion. Mol Cell Biol 24(6): 2308-2317. doi or PMID: 10.1128/mcb.24.6.2308-2317.2004 
540 Murphy LO, Smith S, Chen R-H et al. (2002). Molecular interpretation of ERK signal duration 
by immediate early gene products. Nat Cell Biol 4: 556. doi or PMID: 10.1038/ncb822 
541 Uhlitz F, Sieber A, Wyler E et al. (2017). An immediate–late gene expression module decodes 
ERK signal duration. Mol Syst Biol 13(5): 928. doi or PMID: 10.15252/msb.20177554 
542 Sarkisian CJ, Keister BA, Stairs DB et al. (2007). Dose-dependent oncogene-induced 
senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9: 493. doi 
or PMID: 10.1038/ncb1567 
133 
 
543 Dengjel J, Akimov V, Olsen JV et al. (2007). Quantitative proteomic assessment of very early 
cellular signaling events. Nat Biotechnol 25: 566. doi or PMID: 10.1038/nbt1301 
544 Reddy RJ, Gajadhar AS, Swenson EJ et al. (2016). Early signaling dynamics of the epidermal 
growth factor receptor. Proc Natl Acad Sci U S A 113(11): 3114-3119. doi or PMID: 
10.1073/pnas.1521288113 
545 Catalanotti F, Reyes G, Jesenberger V et al. (2009). A Mek1–Mek2 heterodimer determines 
the strength and duration of the Erk signal. Nat Struct Mol Biol 16: 294. doi or PMID: 
10.1038/nsmb.1564 
546 Schade AE & Levine AD (2004). Cutting Edge: Extracellular Signal-Regulated Kinases 1/2 
Function as Integrators of TCR Signal Strength. J Immunol 172(10): 5828-5832. doi or PMID: 
10.4049/jimmunol.172.10.5828 
547 Cai T, Nishida K, Hirano T et al. (2002). Gab1 and SHP-2 promote Ras/MAPK regulation of 
epidermal growth and differentiation. J Cell Biol 159(1): 103-112. doi or PMID: 
10.1083/jcb.200205017 
548 Francavilla C, Rigbolt KT, Emdal KB et al. (2013). Functional proteomics defines the molecular 
switch underlying FGF receptor trafficking and cellular outputs. Mol Cell 51(6): 707-722. doi 
or PMID: 10.1016/j.molcel.2013.08.002 
549 Borisov N, Aksamitiene E, Kiyatkin A et al. (2009). Systems-level interactions between insulin-
EGF networks amplify mitogenic signaling. Mol Syst Biol 5: 256-256. doi or PMID: 
10.1038/msb.2009.19 
550 Wolf A, Eulenfeld R, Bongartz H et al. (2015). MAPK-induced Gab1 translocation to the 
plasma membrane depends on a regulated intramolecular switch. Cell Signal 27(2): 340-352. 
doi or PMID: 10.1016/j.cellsig.2014.11.017 
551 Aasrum M, Odegard J, Thoresen GH et al. (2015). Gab1 amplifies signaling in response to low-
intensity stimulation by HGF. Cell Biol Int 39(10): 1177-1184. doi or PMID: 
10.1002/cbin.10511 
552 Volinsky N & Kholodenko BN (2013). Complexity of receptor tyrosine kinase signal 
processing. Cold Spring Harb Perspect Biol 5(8): a009043. doi or PMID: 
10.1101/cshperspect.a009043 
553 Ren Y, Meng S, Mei L et al. (2004). Roles of Gab1 and SHP2 in paxillin tyrosine 
dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem 
279(9): 8497-8505. doi or PMID: 10.1074/jbc.M312575200 
554 Yu DH, Qu CK, Henegariu O et al. (1998). Protein-tyrosine phosphatase Shp-2 regulates cell 
spreading, migration, and focal adhesion. J Biol Chem 273(33): 21125-21131. doi or PMID: 
10.1074/jbc.273.33.21125 
555 Zhang SQ, Yang W, Kontaridis MI et al. (2004). Shp2 regulates SRC family kinase activity and 
Ras/Erk activation by controlling Csk recruitment. Mol Cell 13(3): 341-355. doi or PMID: 
14967142 
556 Bromann PA, Korkaya H & Courtneidge SA (2004). The interplay between Src family kinases 
and receptor tyrosine kinases. Oncogene 23(48): 7957-7968. doi or PMID: 
10.1038/sj.onc.1208079 
557 Song N, Qu X, Liu S et al. (2017). Dual inhibition of MET and SRC kinase activity as a combined 
targeting strategy for colon cancer. Exp Ther Med 14(2): 1357-1366. doi or PMID: 
10.3892/etm.2017.4692 
558 Chan PC, Chen YL, Cheng CH et al. (2003). Src phosphorylates Grb2-associated binder 1 upon 
hepatocyte growth factor stimulation. J Biol Chem 278(45): 44075-44082. doi or PMID: 
10.1074/jbc.M305745200 
559 Chan PC, Sudhakar JN, Lai CC et al. (2010). Differential phosphorylation of the docking 
protein Gab1 by c-Src and the hepatocyte growth factor receptor regulates different aspects 
of cell functions. Oncogene 29(5): 698-710. doi or PMID: 10.1038/onc.2009.363 
134 
 
560 Beristain AG, Molyneux SD, Joshi PA et al. (2014). PKA signaling drives mammary 
tumorigenesis through Src. Oncogene 34: 1160. doi or PMID: 10.1038/onc.2014.41 
561 Hayakawa F & Naoe T (2006). SFK–STAT Pathway: An Alternative and Important Way to 
Malignancies. Ann N Y Acad Sc 1086(1): 213-222. doi or PMID: 10.1196/annals.1377.002 
562 Kazansky AV, Kabotyanski EB, Wyszomierski SL et al. (1999). Differential effects of prolactin 
and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem 274(32): 
22484-22492. doi or PMID: 10.1074/jbc.274.32.22484 
563 Sato K, Nagao T, Kakumoto M et al. (2002). Adaptor protein Shc is an isoform-specific direct 
activator of the tyrosine kinase c-Src. J Biol Chem 277(33): 29568-29576. doi or PMID: 
10.1074/jbc.M203179200 
564 Caldwell GB, Howe AK, Nickl CK et al. (2012). Direct modulation of the protein kinase A 
catalytic subunit alpha by growth factor receptor tyrosine kinases. J Cell Biochem 113(1): 39-
48. doi or PMID: 10.1002/jcb.23325 
565 Puig de la Bellacasa R, Karachaliou N, Estrada-Tejedor R et al. (2013). ALK and ROS1 as a joint 
target for the treatment of lung cancer: a review. Transl Lung Cancer Res 2(2): 72-86. doi or 
PMID: 10.3978/j.issn.2218-6751.2013.03.1 
566 Shaw AT, Riely GJ, Bang Y-J et al. (2019). Crizotinib in ROS1-rearranged advanced non-small-
cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann 
Oncol 30(7): 1121-1126. doi or PMID: 10.1093/annonc/mdz131 
567 Shaw AT, Kim D-W, Nakagawa K et al. (2013). Crizotinib versus Chemotherapy in Advanced 
ALK-Positive Lung Cancer. N Engl J Med 368(25): 2385-2394. doi or PMID: 
10.1056/NEJMoa1214886 
568 Camidge DR, Otterson GA, Clark JW et al. (2018). Crizotinib in patients (pts) with MET-
amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a 
phase 1 trial. J Clin Oncol 36(15_suppl): 9062-9062. doi or PMID: 
10.1200/JCO.2018.36.15_suppl.9062 
569 Malik SM, Maher VE, Bijwaard KE et al. (2014). U.S. Food and Drug Administration approval: 
crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is 
anaplastic lymphoma kinase positive. Clin Cancer Res 20(8): 2029-2034. doi or PMID: 
10.1158/1078-0432.ccr-13-3077 
570 National Cancer Institute (2019). Clinical Trials Using Crizotinib. 
https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/crizotinib 
571 Zheng X, He K, Zhang L et al. (2013). Crizotinib induces PUMA-dependent apoptosis in colon 
cancer cells. Mol Cancer Ther 12(5): 777-786. doi or PMID: 10.1158/1535-7163.MCT-12-1146 
572 van der Waals LM, Laoukili J, Jongen JMJ et al. (2019). Differential anti-tumour effects of 
MTH1 inhibitors in patient-derived 3D colorectal cancer cultures. Sci Rep 9(1): 819. doi or 
PMID: 10.1038/s41598-018-37316-w 
573 Lev A, Deihimi S, Shagisultanova E et al. (2017). Preclinical rationale for combination of 
crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biol Ther 
18(9): 694-704. doi or PMID: 10.1080/15384047.2017.1364323 
574 Hassan W, Chitcholtan K, Sykes P et al. (2016). A Combination of Two Receptor Tyrosine 
Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D 
Cell Models. Oncol Ther 4(2): 257-274. doi or PMID: 10.1007/s40487-016-0031-1 
575 Demkova L & Kucerova L (2018). Role of the HGF/c-MET tyrosine kinase inhibitors in 
metastasic melanoma. Mol Cancer 17(1): 26-26. doi or PMID: 10.1186/s12943-018-0795-z 
576 Zhi J, Li Z, Lv J et al. (2018). Effects of PHA-665752 and vemurafenib combination treatment 
on in vitro and murine xenograft growth of human colorectal cancer cells with BRAF(V600E) 
mutations. Oncol Lett 15(3): 3904-3910. doi or PMID: 10.3892/ol.2018.7770 
577 Jia Y, Dai G, Wang J et al. (2016). c-MET inhibition enhances the response of the colorectal 
cancer cells to irradiation in vitro and in vivo. Oncol Lett 11(4): 2879-2885. doi or PMID: 
10.3892/ol.2016.4303 
135 
 
578 Jia YT, Yang DH, Zhao Z et al. (2018). Effects of PHA-665752 and Cetuximab Combination 
Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with 
KRAS or BRAF Mutations. Curr Cancer Drug Targets 18(3): 278-286. doi or PMID: 
10.2174/1568009617666170330112841 
579 Grosskopf S, Eckert C, Arkona C et al. (2015). Selective inhibitors of the protein tyrosine 
phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. 
ChemMedChem 10(5): 815-826. doi or PMID: 10.1002/cmdc.201500015 
580 Lan L, Holland JD, Qi J et al. (2015). Shp2 signaling suppresses senescence in PyMT-induced 
mammary gland cancer in mice. EMBO J 34(11): 1493-1508. doi or PMID: 
10.15252/embj.201489004 
581 Bendell JC, Kim TW, Goh BC et al. (2016). Clinical activity and safety of cobimetinib (cobi) and 
atezolizumab in colorectal cancer (CRC). J Clin Oncol 34(15_suppl): 3502-3502. doi or PMID: 
10.1200/JCO.2016.34.15_suppl.3502 
582 Bendell JC, Bang Y-J, Chee CE et al. (2018). A phase Ib study of safety and clinical activity of 
atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer 
(mCRC). J Clin Oncol 36(4_suppl): 560-560. doi or PMID: 10.1200/JCO.2018.36.4_suppl.560 
583 Larkin J, Ascierto PA, Dréno B et al. (2014). Combined Vemurafenib and Cobimetinib in BRAF-
Mutated Melanoma. N Engl J Med 371(20): 1867-1876. doi or PMID: 
10.1056/NEJMoa1408868 
584 Garnock-Jones KP (2015). Cobimetinib: First Global Approval. Drugs 75(15): 1823-1830. doi or 
PMID: 10.1007/s40265-015-0477-8 
585 National Cancer Institute (2019). Clinical Trials Using Cobimetinib. 
https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/cobimetinib 
586 Conchon M, Freitas CM, Rego MA et al. (2011). Dasatinib - clinical trials and management of 
adverse events in imatinib resistant/intolerant chronic myeloid leukemia. Rev Bras Hematol 
Hemoter 33(2): 131-139. doi or PMID: 10.5581/1516-8484.20110034 
587 Mitri Z, Nanda R, Blackwell K et al. (2016). TBCRC-010: Phase I/II Study of Dasatinib in 
Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clin 
Cancer Res 22(23): 5706-5712. doi or PMID: 10.1158/1078-0432.ccr-15-2845 
588 National Cancer Institute (2019). Clinical Trials Using Dasatinib. 
https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/dasatinib 
589 Sharma MR, Wroblewski K, Polite BN et al. (2012). Dasatinib in previously treated metastatic 
colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New 
Drugs 30(3): 1211-1215. doi or PMID: 10.1007/s10637-011-9681-x 
590 Scott AJ, Song EK, Bagby S et al. (2017). Evaluation of the efficacy of dasatinib, a Src/Abl 
inhibitor, in colorectal cancer cell lines and explant mouse model. PLoS One 12(11): 
e0187173. doi or PMID: 10.1371/journal.pone.0187173 
591 Rusconi F, Piazza R, Vagge E et al. (2014). Bosutinib : a review of preclinical and clinical 
studies in chronic myelogenous leukemia. Expert Opin Pharmacother 15(5): 701-710. doi or 
PMID: 10.1517/14656566.2014.882898 
592 Campone M, Bondarenko I, Brincat S et al. (2011). Phase II study of single-agent bosutinib, a 
Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast 
cancer pretreated with chemotherapy. Ann Oncol 23(3): 610-617. doi or PMID: 
10.1093/annonc/mdr261 
593 Isakoff SJ, Wang D, Campone M et al. (2014). Bosutinib plus capecitabine for selected 
advanced solid tumours: results of a phase 1 dose-escalation study. Br J Cancer 111(11): 
2058-2066. doi or PMID: 10.1038/bjc.2014.508 
594 National Cancer Institute (2019). Clinical Trials Using Bosutinib. 
https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/bosutinib 
136 
 
595 Golas JM, Lucas J, Etienne C et al. (2005). SKI-606, a Src/Abl inhibitor with in vivo activity in 
colon tumor xenograft models. Cancer Res 65(12): 5358-5364. doi or PMID: 10.1158/0008-
5472.can-04-2484 
596 Mologni L, Cleris L, Magistroni V et al. (2009). Valproic acid enhances bosutinib cytotoxicity in 
colon cancer cells. Int J Cancer 124(8): 1990-1996. doi or PMID: 10.1002/ijc.24158 
597 Pengetnze Y, Steed M, Roby KF et al. (2003). Src tyrosine kinase promotes survival and 
resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res 
Commun 309(2): 377-383. doi or PMID: 10.1016/j.bbrc.2003.08.012 
598 Nam J-S, Ino Y, Sakamoto M et al. (2002). Src Family Kinase Inhibitor PP2 Restores the E-
Cadherin/Catenin Cell Adhesion System in Human Cancer Cells and Reduces Cancer 
Metastasis. Clin Cancer Res 8(7): 2430-2436. doi or PMID: 12114449 
599 Housman G, Byler S, Heerboth S et al. (2014). Drug resistance in cancer: an overview. Cancers 
6(3): 1769-1792. doi or PMID: 10.3390/cancers6031769 
600 El-Rashedy AA & Magd El-Din AA (2018). Drug design of Src Kinase inhibitor: An overview. 
JIPBS 5(1): 51-59. doi or PMID: 2349-2759 
601 Tsutsumi R, Ran H & Neel BG (2018). Off-target inhibition by active site-targeting SHP2 
inhibitors. FEBS Open Bio 8(9): 1405-1411. doi or PMID: 10.1002/2211-5463.12493 
602 Wickramasinghe D & Kong-Beltran M (2005). Met activation and receptor dimerization in 
cancer: a role for the Sema domain. Cell Cycle 4(5): 683-685. doi or PMID: 
10.4161/cc.4.5.1688 
603 Hu ZQ, Li J, Gao Q et al. (2017). SHP2 overexpression enhances the invasion and metastasis of 
ovarian cancer in vitro and in vivo. Onco Targets Ther 10: 3881-3891. doi or PMID: 
10.2147/OTT.S138833 
604 Zhou X, Coad J, Ducatman B et al. (2008). SHP2 is Overexpressed in Breast Cancer Cells and in 
Infiltrating Ductal Carcinoma of the Breast, Implying its Involvement in Breast Cancer 
Development. Histopathology 53(4): 389-402. doi or PMID: 10.1111/j.1365-
2559.2008.03103.x 
605 Giubellino A, Burke TR & Bottaro DP (2008). Grb2 Signaling in Cell Motility and Cancer. Expert 
Opin Ther Targets 12(8): 1021-1033. doi or PMID: 10.1517/14728222.12.8.1021 
606 Melvin VS, Feng W, Hernandez-Lagunas L et al. (2013). A morpholino-based screen to identify 
novel genes involved in craniofacial morphogenesis. Dev Dyn 242(7): 817-831. doi or PMID: 
10.1002/dvdy.23969 
607 Walrath JC, Hawes JJ, Van Dyke T et al. (2010). Genetically engineered mouse models in 
cancer research. Adv Cancer Res 106: 113-164. doi or PMID: 10.1016/S0065-230X(10)06004-
5 
608 Hall B, Cho A, Limaye A et al. (2018). Genome Editing in Mice Using CRISPR/Cas9 Technology. 
Curr Protoc Cell Biol 81(1): e57. doi or PMID: 10.1002/cpcb.57 
609 Thompson PD, Panza G, Zaleski A et al. (2016). Statin-Associated Side Effects. J Am Coll 
Cardiol 67(20): 2395-2410. doi or PMID: 10.1016/j.jacc.2016.02.071 
610 Bayat Mokhtari R, Homayouni TS, Baluch N et al. (2017). Combination therapy in combating 
cancer. Oncotarget 8(23): 38022-38043. doi or PMID: 10.18632/oncotarget.16723 
611 Pandyra A, Mullen PJ, Kalkat M et al. (2014). Immediate Utility of Two Approved Agents to 
Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop. Cancer 
Res 74(17): 4772-4782. doi or PMID: 10.1158/0008-5472.can-14-0130 
612 Di Fiore PP & von Zastrow M (2014). Endocytosis, signaling, and beyond. Cold Spring Harb 
Perspect Biol 6(8): a016865. doi or PMID: 10.1101/cshperspect.a016865 
613 Villaseñor R, Kalaidzidis Y & Zerial M (2016). Signal processing by the endosomal system. Curr 
Opin Cell Biol 39: 53-60. doi or PMID: 10.1016/j.ceb.2016.02.002 
614 Schiefermeier N, Teis D & Huber LA (2011). Endosomal signaling and cell migration. Curr Opin 
Cell Biol 23(5): 615-620. doi or PMID: 10.1016/j.ceb.2011.04.001 
137 
 
615 Mosessian S, Avliyakulov NK, Mulholland DJ et al. (2009). Analysis of PTEN complex assembly 
and identification of heterogeneous nuclear ribonucleoprotein C as a component of the 
PTEN-associated complex. J Biol Chem 284(44): 30159-30166. doi or PMID: 
10.1074/jbc.M109.027995 
616 Takada R, Mii Y, Krayukhina E et al. (2018). Assembly of protein complexes restricts diffusion 
of Wnt3a proteins. Commun Biol 1: 165. doi or PMID: 10.1038/s42003-018-0172-x 
617 Willert K, Brown JD, Danenberg E et al. (2003). Wnt proteins are lipid-modified and can act as 
stem cell growth factors. Nature 423(6938): 448-452. doi or PMID: 10.1038/nature01611 
618 Camacho-Carvajal MM, Wollscheid B, Aebersold R et al. (2004). Two-dimensional Blue 
native/SDS gel electrophoresis of multi-protein complexes from whole cellular lysates: a 
proteomics approach. Mol Cell Proteomics 3(2): 176-182. doi or PMID: 
10.1074/mcp.T300010-MCP200 
619 Gerlach JP, Jordens I, Tauriello DVF et al. (2018). TMEM59 potentiates Wnt signaling by 
promoting signalosome formation. Proc Natl Acad Sci U S A 115(17): E3996-E4005. doi or 
PMID: 10.1073/pnas.1721321115 
620 Posor Y, Eichhorn-Gruenig M, Puchkov D et al. (2013). Spatiotemporal control of endocytosis 
by phosphatidylinositol-3,4-bisphosphate. Nature 499(7457): 233-237. doi or PMID: 
10.1038/nature12360 
621 Gay B, Suarez S, Weber C et al. (1999). Effect of potent and selective inhibitors of the Grb2 
SH2 domain on cell motility. J Biol Chem 274(33): 23311-23315. doi or PMID: 
10.1074/jbc.274.33.23311 
622 Atabey N, Gao Y, Yao ZJ et al. (2001). Potent blockade of hepatocyte growth factor-
stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 
Src homology 2 domain interactions. J Biol Chem 276(17): 14308-14314. doi or PMID: 
10.1074/jbc.M010202200 
623 Giubellino A, Gao Y, Lee S et al. (2007). Inhibition of tumor metastasis by a growth factor 
receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res 67(13): 
6012-6016. doi or PMID: 10.1158/0008-5472.CAN-07-0022 
624 Yu Y, Nie Y, Feng Q et al. (2017). Targeted Covalent Inhibition of Grb2-Sos1 Interaction 
through Proximity-Induced Conjugation in Breast Cancer Cells. Mol Pharm 14(5): 1548-1557. 
doi or PMID: 10.1021/acs.molpharmaceut.6b00952 
625 Sapio L, Di Maiolo F, Illiano M et al. (2014). Targeting protein kinase A in cancer therapy: an 
update. EXCLI J 13: 843-855. doi or PMID: 26417307 
626 Yu M, Liu T, Chen Y et al. (2018). Combination therapy with protein kinase inhibitor H89 and 
Tetrandrine elicits enhanced synergistic antitumor efficacy. J Exp Clin Cancer Res 37(1): 114-
114. doi or PMID: 10.1186/s13046-018-0779-2 
627 Ahmed Z, George R, Lin CC et al. (2010). Direct binding of Grb2 SH3 domain to FGFR2 
regulates SHP2 function. Cell Signal 22(1): 23-33. doi or PMID: 10.1016/j.cellsig.2009.08.011 
628 Ahmed Z, Lin CC, Suen KM et al. (2013). Grb2 controls phosphorylation of FGFR2 by inhibiting 
receptor kinase and Shp2 phosphatase activity. J Cell Biol 200(4): 493-504. doi or PMID: 
10.1083/jcb.201204106 
629 Lin CC, Melo FA, Ghosh R et al. (2012). Inhibition of basal FGF receptor signaling by dimeric 
Grb2. Cell 149(7): 1514-1524. doi or PMID: 10.1016/j.cell.2012.04.033 
630 Scott AM, Allison JP & Wolchok JD (2012). Monoclonal antibodies in cancer therapy. Cancer 
Immun 12: 14. doi or PMID: 22896759 
 
